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1 ABSTRACT 
To  date,  no  single,  ideal  strategy  of  vaccination  has  been  identified  that  can 
provide  complete  protection  against  every  form  of  viral,  bacterial  and  parasitic 
disease  encountered  currently  by  man.  This  is  because  every  pathogen  requires 
activation  of  a  unique  immunological  response  to  ensure  effective  clearance  from 
the  body.  Thus,  one  of  the  main  challenges  of  modem  vaccine  development  is  to 
devise  strategies  of  vaccination  that  can  be  tailored  to  ensure  the  rapid  and  effective 
removal  of  a  pathogen  before  it  is  able  to  initiate  infection.  In  addition,  the  concept 
of  therapeutic  vaccines  to  treat  established  disease  has  recently  been  introduced  for 
the  treatment  of  chronic  infections  such  as  Hepatitis  B  virus  (HBV). 
This  thesis  describes  work  undertaken  to  consider  how  strategies  of 
vaccination  can  be  manipulated  to  generate  specific  types  and  magnitude  of  immune 
response  to  prevent  infection  or  treat  established  infection.  In  particular,  the 
project  considered  the  combined  use  of  naked  DNA  vaccination  with  a  second 
form  of  vaccination  to  maximise  the  specific  immune  response  generated. 
The  vaccination  strategies  employed  were  based  on  the  initial  delivery  of 
DNA  vaccine  through  intramuscular  injection  or  ballistic  delivery  using  a  gene  gun, 
followed  by  heterologous  boosts,  based  on  the  same  antigen  delivered  using  an 
alternative  route.  These  boost  strategies  included  a)  intramuscular  delivery  of 
purified  recombinant  HBcAg,  b)  mucosal  delivery  of  HBcAg  expressed  by  an 
attenuated  strain  of  Salmonella  typhimurium,  and  c)  intranasal  delivery  of  the  protein 
accompanied  by  a  mucosal  adjuvant. 
Following  each  vaccination  regime  tested  a  number  of  specific  immune 
responses,  including  serum  and  mucosal  antibody  production,  CD4+  T  helper 
2 proliferation  in  spleens  and  lymph  nodes,  CD8+  T  cell  activation  and  killing  were 
measured.  These  experiments  revealed  that  the  character  of  the  immune  responses 
primed  in  response  to  DNA  vaccination  differed  according  to  route  of 
immunisation,  with  intramuscular  vaccination  inducing  a  rapid  CTL  response. 
CD4+  T  cells  generated  appeared  to  be  of  the  Thl  phenotype  and  showed  the 
strongest  localisation  in  the  spleen.  In  contrast,  following  vaccination  with  the  gene 
gun,  CD4+  cells  of  a  Th2  phenotype  were  generated  with  responses  being  found  to 
be  stronger  in  the  local  draining  lymph  nodes  than  the  spleen. 
Combining  DNA  delivered  using  the  intramuscular  route  with  recombinant 
purified  protein  delivered  by  the  same  route  was  effective  at  boosting  systemic 
antibody  titres,  as  was  boosting  using  attenuated  Salmonella  expressing  the  same 
antigen  when  delivered  to  the  mucosal  surface  of  the  gut.  In  contrast,  boosting  of 
DNA  primed  animals  with  purified  protein,  even  in  the  presence  of  an  appropriate 
mucosal  adjuvant,  was  not  successful  at  increasing  titres  of  systemic  antibodies. 
Interestingly,  specific  mucosal  immune  responses  were  absent  when  either  of  the 
heterologous  vaccination  strategies  used  a  mucosal  boosting  approach.  The 
implications  of  the  characterisation  of  the  immune  responses  to  the  various 
prime/boost  protocols  employed  are  discussed  and  their  potential  use  for  the 
development  of  new  prophylactic  and  therapeutic  vaccine  design  considered. 
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13 1  INTRODUCTION 
1.1  Aims  of  vaccination 
The  aim  of  vaccination  is  to  provide  a  human  or  animal  with  immunity  to  a 
specific  disease.  Traditionally  this  has  been  achieved  by  exposing  the  immune 
system  to  non-pathogenic  components  (antigens)  of  a  disease-causing  organism,  or 
to  an  avirulent  form  of  the  entire  pathogen.  This  exploits  the  immune  system's 
capacity  to  effect  a  more  rapid  and  potent  memory  response  to  foreign  antigens  on 
subsequent  re-exposure  to  the  antigens  during  an  actual  infection.  An  effective 
vaccine  should  provide  long  lasting,  protective  immunity  against  the  disease  and 
where  possible  reduce  the  capacity  of  the  organism  to  spread  to  other  susceptible 
hosts. 
1.2  History  of  Vaccination 
1.2.1  Development  of  Vaccination 
The  idea  of  deliberate  exposure  of  an  individual  to  a  relatively  harmless 
form  of  disease  in  order  to  protect  against  the  full  virulence  of  a  natural  infection  is 
not  new.  The  process  of  variolation,  a  term  given  to  the  practice  of  scoring  the  skin 
and  deliberately  exposing  it  to  material  from  the  pustules  on  the  skin  of  a  smallpox 
victim,  was  reported  to  have  been  used  as  far  back  as  the  17th  century  (Bazin  2003). 
Variolation  provoked  a  very  mild  form  of  the  smallpox  and  protected  the  recipient 
when  exposed  to  the  fully  virulent  form  of  the  disease.  In  1796  Edward  Jenner 
took  the  process  a  step  further,  by  testing  the  commonly  held  idea  that  infection 
14 with  cowpox  provided  protection  from  smallpox.  This  was  confirmed  when  he 
deliberately  inoculated  a  young  boy  with  material  from  the  pustules  on  the  skin  of 
an  infected  cow.  In  order  to  confirm  the  protective  effects  of  the  treatment  the  boy 
was  later  exposed  to  an  attenuated  strain  of  smallpox.  The  boy  did  not  display  any 
disease  symptoms,  and  the  process  of  vaccination  (from  Vaccinia,  the  virus  that 
causes  cowpox)  was  born  (Baxby  2002;  Bazin  2003).  Jenner's  vaccination  had  the 
great  advantage  of  providing  lasting  protection  without  risk  of  the  vaccine  recipient 
becoming  the  source  of  a  smallpox  outbreak. 
1.2.2  The  Requirement  for  New  Vaccines 
As  a  result  of  this  early  work,  vaccine  development  against  a  variety  of 
diseases  has  continued  for  more  than  200  years.  Over  this  period  of  time  there  has 
been  a  dramatic  increase  in  the  level  of  understanding  of  both  pathogenesis  and  the 
nature  of  the  immune  system  as  well  as  improvements  in  public  hygiene  and 
successful  treatment  of  disease  by  chemotherapy.  Despite  these  advances,  there 
remain  many  infections  for  which  there  are  no  effective  vaccines.  These  include 
malaria,  HIV,  hepatitis  C  virus,  anthrax,  and  many  others. 
In  many  older  vaccine  formulations,  protection  is  mediated  largely  by  the 
induction  of  strong  antibody  (humoral)  responses.  Without  denying  the  undoubted 
success  of  such  vaccines,  humoral  responses  alone  are  not  always  sufficient  to  offer 
protection.  Observations  in  human  patients  and  animal  models  of  disease  show 
that  other  processes  including  responses  mediated  by  specific  cells  of  the  body  are 
also  required.  Thus  much  current  vaccine  research  focuses  on  the  generation  of 
broad  and  effective  immune  responses  (Plotkin  2003). 
15 In  addition  to  diseases  that  have  been  present  in  human  populations  for  a 
long  period  of  time,  there  are  also  newly  emerging  infections  such  as  HIV  and 
SARS,  which  provide  an  ongoing  challenge  to  vaccinologists.  These  pathogens  are 
often  highly  virulent  and  reinforce  the  need  for  continued  research  to  identify 
vaccine  strategies  that  provide  wider  application. 
Immunity  to  a  disease  often  involves  the  activation  of  a  combination  of 
different  effector  mechanisms.  The  protective  mechanisms  required  may  be  largely 
dependent  on  the  pathogen  in  question  and  the  causes  of  its  pathogenesis  and  its 
lifestyle.  The  way  in  which  these  mechanisms  are  activated  and  how  they  function 
to  protect  against  disease  are  described  below. 
1.3  Innate  Immunity 
The  immune  system  can  be  split  into  two  separate  but  linked  entities;  the 
innate  and  the  specific  (or  adaptive)  immune  systems.  Innate  immunity  is  based 
upon  activation  of  responses  following  tissue  damage  or  recognition  of  types  of 
molecules  particularly  associated  with  pathogens.  The  defence  mechanisms  that 
make  up  innate  immunity  are  able  to  act  immediately,  because  unlike  specific 
immunity  they  do  not  rely  on  the  clonal  expansion  of  cells. 
The  innate  defence  mechanisms  include  mechanical  systems,  the  action  of 
cells  such  as  phagocytes  and  the  complement  system.  The  innate  immune  system 
has  no  memory  mechanism  of  its  own,  however,  it  can  still  have  relevance  in 
vaccine  development.  Although  the  innate  and  specific  systems  are  in  many  ways 
separate  and  are  induced  by  different  mechanisms,  each  can  enhance  the  other  to 
provide  maximum  effectiveness  (Medzhitov  and  Janeway  Jr.  1998).  For  example, 
cytokines  secreted  by  innate  cells  (e.  g.  macrophages)  and  specific  cells  (such  as 
16 lymphocytes)  can  increase  the  efficacy  of  both  cell  types  (Biron  1998).  Also, 
molecules  found  associated  with  the  invading  pathogen  itself  can  have  a  significant 
impact  on  non-specific  activation  of  the  immune  system.  A  number  of  these 
pathogen-associated  molecular  patterns,  or  PAMPs  have  been  recently  identified 
and  play  an  important  role  in  the  activation  of  naive  lymphocytes  (see  section  1.4.1, 
Antigen  Processing  and  Lymphocyte  Activation). 
Physically,  the  body  is  protected  from  infection  by  the  epithelial  barriers  of 
the  skin  and  mucosal  surfaces  of  the  intestines,  lungs  and  urogenital  tracts. 
Pathogens  can  initiate  an  infection  only  when  these  surfaces  are  colonised  or 
crossed.  In  particular,  the  normal  fauna  of  the  skin  and  mucosal  surfaces  can 
provide  a  considerable  defence  by  competing  for  space  and  nutrients  with  potential 
pathogens.  Secretion  of  mucus  is  also  important,  coating  micro-organisms  and 
preventing  them  from  adhering  to  the  surface  and  when  combined  with  the  co- 
ordinated  beating  of  cilia  on  the  surface  of  epithelial  cells  in  the  lungs,  allows 
expulsion  of  microbes  from  these  surfaces. 
In  addition  to  mechanical  barriers  at  the  epithelia,  there  are  also  chemical 
products  and  degradative  proteins  that  can  kill  or  inhibit  the  growth  of  bacteria. 
These  include  lysozyme,  present  in  saliva  and  tears,  which  can  cause  the  lysis  of 
bacteria,  acid  pH  in  the  stomach  and  digestive  enzymes  that  destroy  the  majority  of 
pathogens  prior  to  their  arrival  in  the  gut. 
1.3.1  Non-specific  Activation  of  Immune  Cells 
A  range  of  phagocytic  cells  that  are  able  to  recognise,  ingest  and  kill  many 
pathogens  that  do  penetrate  the  epithelia  include  macrophages,  which  are  found  in 
many  tissues  of  the  body  and  are  highly  efficient  phagocytes,  and  neutrophils  that 
17 are  present  in  the  blood.  These  can  quickly  penetrate  tissues  hosting  an  incipient 
infection  and  phagocytose  the  organisms  present. 
A  number  of  these  cells  have  been  shown  to  be  activated  by  PAMPs,  which 
stimulate  Toll-like  receptors  (TLRs)  found  on  the  surface  of  some  immune  system 
cells.  This  leads  to  the  activation  of  signalling  pathways  that  result  in  the 
production  of  antimicrobial  products  and  inflammatory  cytokines  by  these  cells.  In 
addition,  stimulation  of  TLRs  triggers  dendritic  cell  (DC)  maturation  and  results  in 
the  induction  of  co-stimulatory  molecules  and  increased  antigen-presenting  capacity 
(Krug  et  al.  2001).  Thus,  microbial  recognition  by  TLRs  helps  to  directly  activate 
innate  immune  responses  for  immediate  killing  of  pathogens  and  indirectly  stimulate 
adaptive  responses  Qaneway  and  Medzhitov  2002). 
Stimulation  of  TLRs  via  PAMPs  provides  an  early  warning  signal  to  the 
immune  system  that  pathogens  are  present,  thus  allowing  the  rapid  deployment  of 
innate  defence  mechanisms  based  on  a  general  molecular  pattern,  rather  than 
specific  antigen  recognition  Qaneway  and  Medzhitov  2002). 
To  date,  several  PAMPS  have  been  identified.  Two  of  these;  bacterial 
lipopolysaccharide  (LPS)  and  unmethylated  Cytidine-phosphate-guanisine 
dinucleotides  (CpG  motifs)  in  DNA  (Brown  and  Corral  2002;  Janeway  and 
Medzhitov  2002;  Royle  et  al.  2003),  have  direct  relevance  to  this  project. 
Gram  negative  bacteria  such  as  E.  coli  and  Salmonella  carry  endotoxin,  or  LPS 
as  an  integral  part  of  their  outer  membrane.  The  structure  of  LPS,  as  shown  in 
Figure  1-1,  consists  of  highly  conserved  lipid  A,  which  anchors  the  structure  into 
the  cell  wall,  the  core  polysaccharide  and  the  hyper-variable  0-polysaccharide.  This 
antigen  is  highly  immunogenic  and  is  readily  recognised  by  antibodies.  It  is  the 
variation  in  the  recognition  of  this  region  by  antibodies  that  results  in  the  many 
different  serotypes  of  Salmonella  (Ewing  1972).  It  can  also  have  a  significant  effect 
18 on  the  biology  of  the  organism;  Salmonella  can  alter  the  nature  of  the  LPS  molecule 
it  expresses  under  different  conditions.  This  ability  allows  the  bacteria  to  change  its 
surface  characteristics  to  suit  the  environment  of  gut  epithelial  cells  or  protect  itself 
against  the  intracellular  killing  mechanisms  within  the  phagosomes  of  macrophages 
(Ernst  et  ah  1999;  Freudenberg  et  al.  2001). 
However,  LPS  can  also  interact  with  the  innate  immune  system,  directly 
through  'MR  -4  found  on  the  surface  of  DCs  and  macrophages  (Royle  et  al.  2003). 
Stimulation  through  TLR-4  signalling  by  LPS  causes  upregulation  of  macrophage 
killing  mechanisms,  increased  cytokine  production  and  higher  levels  of  co- 
stimulatory  molecules  on  the  surface  of  APCs.  The  presence  of  these  molecules, 
along  with  the  microbial  antigens  presented  by  macrophages  and  DCs,  helps 
activate  CD4+  Th  cells  leading  to  a  co-ordinated  adaptive  immune  response  (Ernst 
et  aL  2001;  Royle  et  aL  2003). 
The  CpG  motifs  found  in  bacterial  DNA  are  another  example  of  a  PAMP. 
These  unmethylated  CpG  motifs  found  in  a  particular  nucleotide  context  in 
bacterial  but  not  eukaryotic  DNA  activate  the  immune  system  via  TLR-9.  They  are 
discussed  in  more  detail  in  the  section  on  DNA  vaccination  below  (section  1.5.4.3). 
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Figure  1-1:  Composition  of  bacterial  LPS 
Lipid  A,  the  mitogenic  region  of  the  LPS  molecule,  is  made  up  of  a  variable  number 
and  chain  lengths  of  fatty  acid.  These  are  linked  to  the  core  region  of  LPS  by 
phosphorylated  diglucosamine  (G1uN)  and  2-keto-3-deoxymanno-octonic  acid 
(KDO).  The  O-side  chain  polysaccharide  or  O-antigen  consists  of  repeating 
oligosaccharide  units.  These  also  vary  between  strains  and  species;  the  086  antigen 
of  E.  coli  is  shown  here.  This  variation  can  have  a  large  impact  on  phenotype  and 
pathogenicity,  for  example  bacteria  with  complete  0  antigen  form  smooth  colonies 
whereas  bacteria  which  cannot  synthesise  the  antigen  form  rough  colonies.  Figure 
adapted  from  `Immunological  aspects  of  bacterial  virulence'  (Patrick  and  Larkin 
1995). 
20 1.3.2  Chemokines  and  Inflammation 
Once  activated  via  the  TLRs,  cells  such  as  macrophages  are  stimulated  to 
secrete  several  cytokines  including  inflammatory  mediators.  These  include  two  sub- 
families  of  chemokines,  a  and  (3,  which  can  cause  an  influx  of  cells.  The  a- 
chemokines,  such  as  interleukin-8  (IL-8),  attract  neutrophils,  whereas  the  (3- 
chemokines  attract  macrophages  (Herbert  et  aL  1995).  These  molecules  help  target 
neutrophils  and  macrophages  to  the  site  of  infection  by  up-regulating  expression  of 
leukocyte  adhesion  molecules  in  the  endothelial  cells  of  nearby  blood  vessels.  As 
well  as  monocytes  and  neutrophils,  specific  immune  cells  such  as  lymphocytes 
migrate  to  the  site  of  inflammation.  The  inflammatory  response  can  therefore 
speed  the  genesis  of  a  specific  immune  response  (Biron  1998). 
1.3.3  Complement 
Complement  is  another  molecular  component  of  the  innate  immune  system. 
This  system  is  made  up  of  a  large  number  of  proteins  present  in  the  plasma  that 
respond  to  the  presence  of  microbes  by  the  binding  of  certain  proteins  to  the 
pathogen  surface.  Following  activation,  they  can  function  in  a  number  of  ways, 
including  opsonisation  of  pathogens  which  enhances  the  efficiency  with  which 
phagocytes  such  as  macrophages  are  able  to  internalise  them.  Complement  is 
regarded  as  part  of  the  innate  immune  system,  however,  the  ability  to  induce  an 
inflammatory  response  is  also  an  example  of  how  the  innate  and  specific  immune 
systems  can  communicate.  Complement  can  also  act  as  an  effector  arm  of  specific 
immunity,  as  it  can  additionally  be  activated  by  the  formation  of  antibody-antigen 
complexes  (Barrington  et  a1.2001). 
21 1.4  Antigen-Specific  Immunity 
1.4.1  Antigen  Processing  and  Lymphocyte  Activation 
Specific  or  adaptive  immunity  is  based  on  the  precise  recognition  by 
lymphocytes  of  antigen-fragments  containing  specific  epitopes.  The  antigens  of  a 
micro-organism  are  processed  by  cells  and  the  resulting  peptide  fragments  are 
presented  on  the  cell  surface  in  the  context  of  Major  Histocompatibility  (MHC) 
molecules.  These  peptides  are  subject  to  surveillance  by  T  lymphocytes.  If  the  T 
cell  receptor  (TCR)  specifically  recognises  the  epitope  contained  in  the  fragments 
displayed  on  the  surface  of  antigen  presenting  cells  (APCs),  along  with  an 
appropriate  secondary  signal,  the  T  cells  are  activated.  They  then  proliferate  and 
differentiate  into  effector  cells  with  a  range  of  functions  including  the  enhancement 
of  antibody  production  by  B  cells,  phagocytosis  by  macrophages  and  activation  of 
cytotoxicity. 
1.4.1.1  Endogenous  Antigen  Processing  and  CD8`  T  cell  activation 
Antigens  expressed  within  most  body  cells  can  be  processed  through  the 
endogenous  pathway,  illustrated  in  Figure  1-2.  Although  this  pathway  is  utilised  by 
both  professional  and  non-professional  APCs,  it  can  be  modulated  in  professional 
APCs  (such  as  DCs)  by  an  increased  expression  of  co-stimulatory  molecules.  The 
antigens  processed  through  this  pathway  are  largely  drawn  from  defective  ribosomal 
products  (Lehner  and  Cresswell  2004).  The  pathway  is  therefore  open  to  any 
protein  expressed  in  the  cytosol,  including  self-antigen,  virus  antigen  and  DNA 
vaccine  antigens.  However,  proteins  from  sources  other  than  the  cytosol  are  also 
able  to  enter  the  pathway,  as  discussed  below  in  section  1.4.1.3,  Cross  Presentation. 
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Figure  1-2:  The  endogenous  antigen  presentation  pathway 
Recently  synthesised  ribosomal  products  are  degraded  by  proteasomes  (1)  and 
peptidases.  The  resulting  peptidases  are  transported  into  the  ER  by  TAP  molecules 
(2).  In  the  ER  peptides  are  able  to  bind  to  MHC  class  I  molecules.  The  MHC- 
peptide  complex  is  then  able  to  migrate  to  the  cell  surface  (3). 
23 The  antigens  are  broken  down  by  proteasomes  into  8-  10  amino  acid 
peptide  fragments,  which  enter  the  endoplasmic  reticulum  (ER)  via  the  transporter 
associated  with  antigen-processing  (TAP)  molecule.  Associated  with  TAP  are  MHC 
class  I  molecules  to  which  some  of  the  peptides  will  be  able  to  bind.  On  binding, 
the  three-dimensional  structure  of  MHC  I  is  altered  resulting  in  the  release  of  the 
peptide-MHC  complex  from  associated  ER  proteins.  The  complex  then  migrates  to 
the  cell  surface  via  the  Golgi  apparatus  where  it  is  exposed  to  CD8  T  cell 
surveillance  (Heemels  and  Ploegh  1995;  Williams  et  aL  1996;  Lehner  and  Cresswell 
2004). 
The  process  of  activation  of  CD8+  T  cells  is  shown  in  Figure  1-3.  Naive 
lymphocytes,  whether  CD4+  T  cells,  CD8+  T  cells  or  B  cells,  require  similar  signals 
for  activation.  In  T  cells,  the  first  signal  comes  from  an  antigen-specific  interaction 
between  the  cell  surface  TCR  and  the  MHC  class  I-peptide  complex.  This  requires 
specific  recognition  of  the  peptide  by  the  TCR.  The  specificity  of  the  TCR  is 
conferred  by  somatic  recombination  of  the  genes  encoding  the  TCR  proteins  during 
development  of  the  T  cell  in  the  thymus.  The  vast  array  of  different  possible 
recombinations  that  can  occur  by  chance  (approximately  1018  variations)  mean  that 
every  T  cell  effectively  has  a  unique  specificity  (Goldrath  and  Bevan  1999;  Nemazee 
2000).  This  variation  is  key  to  the  T  cell  population  and  provides  the  capacity  to 
respond  specifically  to  a  huge  range  of  different  antigens  (Correia-Neves  et  aL  2001). 
Such  wide  variety  ensures  that  some  cells  will  be  generated  bearing  TCRs  that  are 
specific  for  self-antigens.  Usually,  cells  that  bind  to  self-antigens  during 
development  undergo  apoptosis,  preventing  autoimmunity  (Davis  and  Bjorkman 
1988;  Oltz  2001).  As  well  as  direct  TCR-peptide  interactions  between  the  T  cell  and 
the  APC,  the  CD8+  molecule  binds  to  invariant  regions  of  MHC  I  in  an  antigen- 
independent  fashion  (Garboczi  et  aL  1996). 
24 The  TCR-peptide  specific  interaction  along  with  CD8+-MHC  binding  is 
sufficient  to  trigger  previously  activated  CD8+  T  cells.  However,  naive  lymphocytes 
require  an  additional,  secondary,  signal  in  order  to  initiate  proliferation  and 
differentiation  into  effector  cells.  This  is  provided  by  a  second  cognate  interaction 
between  a  co-stimulatory  molecule  on  the  APC  and  its  co-receptor  on  the  naive  T 
cell.  The  level  of  expression  of  APC  co-stimulatory  molecules  varies  depending  on 
the  activation  status  of  these  cells  and  whether  the  APC  is  a  `professional'  presenter. 
For  example,  a  DC  is  a  professional  APC  and  is  characterised  by  constitutive 
expression  of  co-stimulatory  molecules  such  as  the  B7  family  members  CD80  and 
CD86  (which  bind  to  CD28  on  the  T  cell),  or  CD40  (which  binds  to  CD40  ligand). 
Expression  is  increased  even  further  on  activation  of  the  cell.  However,  many  other 
cells  expressing  MHC  class  I  need  to  upregulate  the  surface  expression  of  these 
molecules  whilst  processing  exogenous  antigens.  Expression  of  co-stimulatory 
molecules  is  tightly  regulated  by  signalling  events  associated  with  the  recognition  of 
molecules  associated  with  tissue  damage  or  with  certain  pathogens  (PAMPs)  by 
receptors  including  the  TLRs  (Harding  et  al.  1992;  Gonzalo  et  al.  2001;  Shedlock  and 
Shen  2003). 
The  co-stimulatory  requirement  for  activation  of  naive  CD8+  T  cells  are 
higher  than  that  required  for  naive  CD4'  cells.  This  ensures  that  the  potentially 
devastating  cytotoxic  response  is  not  induced  inappropriately.  To  activate  a  naive 
CD8+  cell  requires  either  antigen  presentation  by  a  DC,  which  naturally  express  high 
level  of  co-stimulatory  molecules,  or  the  action  of  Ih  cells  with  the  same  antigen- 
specificity,  that  can  upregulate  co-stimulatory  molecule  expression  in  other  types  of 
APC. 
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Figure  1-3:  CD8+  T  cell  antigen  recognition  and  activation 
Peptides  in  the  context  of  MHC  I  are  specifically  recognised  by  the  TCR  and  CD8+ 
binds  to  MHC  I.  This  is  sufficient  for  activation  of  effector  CD8+  T  cells.  An 
additional  signal  is  required  for  activation  of  naive  cells,  to  initiate  proliferation  and 
differentiation.  This  comes  from  co-stimulatory  molecules  expressed  by  the  APCs 
such  as  B7,  which  binds  to  CD28  on  the  T  cell,  providing  the  secondary  signal. 
26 The  requirement  for  a  secondary  signal  provides  an  additional  level  of 
regulation  in  the  development  of  a  primary  immune  response,  and  helps  to  ensure 
that  responses  only  develop  against  pathogens  or  antigens  associated  with  tissue 
pathology,  what  is  referred  to  as  a  `danger'  signal.  A  successful  vaccine  therefore 
needs  to  include  the  specific  antigens  for  lymphocytes  to  recognise,  and  must  also 
provide  the  secondary  signal  necessary  for  activation,  differentiation  and 
proliferation  of  the  lymphocytes. 
1.4.1.2  Exogenous  Antigen  Processing  and  CD  4'  T  Cell  Activation 
Although  APCs  can  process  antigen  through  the  endogenous  pathway  and 
present  peptides  in  the  context  of  MHC  class  I,  as  described  above,  internalised  or 
exogenous  proteins  are  present  in  a  separate  cellular  compartment  and  are 
processed  and  presented  by  a  distinct  pathway  (with  some  exceptions;  see  Cross 
Presentation  below).  They  are  bound  to  MHC  class  II  molecules,  unique  to 
professional  APCs,  and  are  presented  to  CD4+  T  helper  cells. 
Following  internalisation,  exogenous  antigen  is  processed  in  vesicles  that 
become  increasingly  acidic  with  time.  As  the  pH  lowers,  proteases  within  the 
endosome  are  activated,  breaking  down  proteins  into  peptides  (Brodsky  and 
Guagliardi  1991;  Watts  2004). 
MHC  class  II  molecules  are  present  in  the  ER,  but  are  prevented  from 
binding  protein  from  the  cytosol  that  has  been  taken  up  by  TAP  (as  MHC  class  I 
molecules  do),  by  an  associated  molecule;  the  invariant  chain.  This  molecule 
physically  blocks  the  peptide-binding  site  of  MHC  class  II  and  targets  it  to  migrate 
to  endosomes.  When  the  invariant  chain-MHC  class  II  complex  reaches  a  late-stage 
endosome,  limited  proteolysis  of  the  invariant  chain  occurs,  leaving  a  smaller 
peptide  called  CLIP.  This  molecule  is  then  exchanged  for  antigenic  peptides.  The 
27 MHC  class  II-peptide  complex  then  migrates  to  the  cell  surface  where  the  antigen  is 
presented  to  CD4+  T  cell  surveillance  (Brodsky  and  Guagliardi  1991;  Pieters  1997). 
This  process  is  illustrated  in  Figures  1-4  (Processing  of  exogenous  antigen)  and  1-5 
(MHC  class  II  presentation). 
Activation  of  CD4+  cells  is  a  similar  process  to  the  activation  of  CD8+  cells 
described  above.  The  TCR  specifically  recognises  the  peptide  in  the  context  of  the 
MHC  class  II  molecule  and  CD4+  binds  to  invariant  regions  of  MHC  class  II.  Co- 
stimulatory  signals  are  also  required  to  activate  naive  CD4+  cells;  these  are  the  same 
as  the  secondary  signals  involved  in  CD8+  activation. 
It  has  been  suggested  that  antigen  is  initially  presented  to  naive  CD4+  T  cells 
exclusively  by  DCs  within  the  T  cell  areas  of  secondary  lymphoid  tissues  (lymph 
nodes,  spleen  and  the  Peyer's  Patches  in  the  intestinal  wall)  (Jenkins  et  al.  2001; 
Bajenoff  and  Guerder  2003).  Other  potential  APCs  such  as  macrophages  and  B 
cells  are  not  found  in  the  T  cell  areas  of  this  tissue,  and  free  antigen  does  not  easily 
enter  the  IN.  However,  B  cells  are  able  to  interact  with  T  cells  at  the  interface  of 
the  B  and  T  cell  compartments  of  the  lymphoid  tissues  following  encounter  with 
specifically  recognised  antigen,  and  may  be  important  in  presenting  blood-borne 
antigen  to  CD4+  T  cells  (Baumgarth  2000;  Mills  and  Cambier  2003).  DCs  are 
thought  to  acquire  antigen  by  pinocytosis  at  the  site  where  it  entered  the  body  or 
was  expressed,  rather  than  in  the  lymphoid  tissue  itself.  Danger  signals  such  as 
PAMP  recognition  and  inflammation  enhance  CD4+  T  cell  activation  by  stimulating 
DCs  to  migrate  to  T  cell  areas  and  upregulate  their  expression  of  MHC  and  co- 
stimulatory  molecules. 
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Although  MHC  class  II  molecules  are  present  in  the  ER,  they  cannot  bind  to 
peptides  in  the  ER  due  to  the  presence  of  the  invariant  chain  (1).  Extracellular 
material  (exogenous  antigen)  is  internalised  and  degraded  by  proteases  and  the 
progressively  acidic  conditions  in  endosomes  (2).  MHC  class  II  molecules  migrate 
to  endosomes,  where  the  invariant  chain  is  partially  cleaved  by  proteases.  This 
allows  binding  of  the  degraded  exogenous  antigen.  The  MHC  II  -  peptide  complex 
is  transported  to  the  cell  surface  (3). 
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Figure  1-5:  CD4+  T  cell  antigen  recognition  and  activation 
This  process  is  similar  in  many  ways  to  the  presentation  of  antigen  and  activation  of 
CD8+  T  cells,  the  main  differences  being  the  peptide  is  presented  by  MHC  class  II 
molecules  and  the  TCR  is  associated  with  CD4+  on  the  T  cell. 
30 1.4.1.3  Cross  Presentation  -  Crossover  Between  the  Endogenous  and 
Exogenous  Pathways 
It  is  worth  noting  that  there  are  exceptions  to  the  two  main  processing 
pathways  outlined  above:  endogenous  antigen  can  be  presented  in  the  context  of 
the  MHC  class  II  molecule  and  exogenous  antigen  in  that  of  MHC  class  I. 
Although  molecules  found  in  the  cytosol  are  rarely  processed  and  presented 
in  complex  with  MHC  class  II  in  professional  APCs,  other  cellular  proteins  can  be 
processed  in  this  way.  Fragments  of  proteins  associated  with  cell  membrane,  ER 
and  Golgi  apparatus  proteins  can  be  presented  in  this  manner  (Robinson  and  Delvig 
2002).  Thus  endogenous  antigen  can  still  trigger  CD4+  T  helper  responses. 
Conversely,  exogenous  antigen  can  be  presented  by  MHC  class  I  molecules, 
by  at  least  one  of  several  mechanisms.  In  macrophages  and  DCs  fusion  of  ER  and 
phagosome  membranes  has  been  shown  to  occur.  This  could  allow  interaction 
between  antigen  internalised  by  phagocytosis  and  MHC  class  I  molecules 
(Ackerman  and  Cresswell  2004);  (Kumaraguru  et  ah  2000;  Maecker  et  ah  2001). 
Another  mechanism  that  has  been  described  is  peptide  exchange.  In  this  model 
MHC  class  I-  endogenous  peptide  complexes  are  already  present  on  the  surface  of 
a  phagocytic  cell,  as  in  normal  endogenous  antigen  presentation.  As  exogenous 
material  is  phagocytosed,  MHC  class  I-  peptide  complexes  on  the  cell  surface  may 
be  simultaneously  internalised.  The  conditions  in  the  lysosome  degrade  the 
exogenous  antigen  to  peptides  able  to  bind  to  MHC  class  I  molecule,  which  can 
then  be  exchanged  for  the  already  bound  endogenous  peptides.  This  second 
mechanism  is  considered  as  being  less  likely  to  occur  in  vivo,  since  the  proteolytic 
environment  of  the  endocytic  pathway  is  unlikely  to  reproducibly  generate  the  same 
peptides  as  produced  by  the  proteasomes  that  normally  produce  MHC  class  I 
epitopes  (Lehner  and  Cresswell  2004). 
31 While  the  mechanism(s)  behind  cross-priming  are  not  fully  understood,  it  is 
a  phenomenon  that  has  been  observed  repeatedly.  One  example  particularly 
relevant  to  this  project  is  the  processing  of  particulate  exogenous  antigen  by  DCs 
and  subsequent  efficient  presentation  to  CD8+  T  cells  (Stober  et  at  2002).  It  is 
therefore  possible  for  exogenous  antigen  to  stimulate  activation  of  CTLs. 
1.4.1.4  B  Lymphocyte  Antigen  Recognition  and  Activation 
B  cell  specificity  is  defined  by  a  process  of  somatic  recombination  (similar  to 
that  of  T  cells)  within  the  genes  of  immunoglobulin,  which  code  for  the  B  cell 
receptor  (BCR).  This  occurs  during  development  of  the  lymphocyte  in  the  bone 
marrow,  and  is  limited  only  to  exclude  specificities  for  self-antigens.  Previously 
activated  memory  B  cells  can  be  triggered  by  antigen  specific  recognition  alone 
(Hebeis  et  al.  2004),  in  the  same  way  as  memory  T  lymphocytes. 
However,  recognition  of  antigen  alone  is  usually  insufficient  for  activation 
of  naive  B  cells.  As  with  T  cells,  a  secondary  signal  is  required,  often  in  the  form  of 
antigen-specific  interactions  between  an  activated  Th  cell  and  the  naive  B  cell  which 
is  presenting  the  antigen.  This  standard  model  of  B  lymphocyte  activation  was  first 
proposed  over  30  years  ago  (Bretscher  and  Cohn  1970).  According  to  the  current 
version  of  this  model,  B  cells  internalise  and  process  antigen  through  the  BCR, 
providing  the  first  activation  signal  necessary.  However,  as  with  T  lymphocytes, 
signal  one  is  not  sufficient  to  initiate  clonal  expansion  and  differentiation  of  naive  B 
cells. 
Segregation  of  B  and  lb  cells  in  secondary  lymph  nodes  is  maintained  by 
chemokine  gradients  to  which  the  naive  lymphocytes  respond  differentially.  Within 
hours  of  encountering  antigen,  B  cells  increase  chemokine  receptor  CCR7 
expression,  enhancing  responsiveness  to  T  cell  chemokines.  Likewise,  activated  T 
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cells  express  receptors  for  follicular  zone  chemokines.  Thus  B  cells  that  have 
encountered  antigen  and  activated  T  cells  are  able  to  migrate  to  the  boundaries  of 
cortical  T  and  follicular  B  cell  zones  (Mills  and  Cambier  2003).  When  these  cells 
come  into  contact,  then  antigen  specific  TCR/MHC-peptide  interaction  can  induce 
the  expression  of  secondary  signal  molecules  in  the  B  cell.  These  include  CD40 
ligand  and  IL-4,  -5  and  -6,  initiating  proliferation  of  the  B  cell  and  differentiation 
into  an  antibody  secreting  plasma  cell  (Baumgarth  2000;  Mills  and  Cambier  2003). 
However,  T  cell-independent  B  cell  activation  mechanisms  also  exist.  These 
require  T  cell-independent  antigens,  or  antigens  plus  secondary  signals  from  a 
source  other  than  Th  cells,  and  can  induce  a  full  B  cell  response.  These  alternative 
means  of  activation  potentially  provide  a  more  rapid  humoral  response,  since  they 
can  be  initiated  without  the  prior  clonal  amplification  of  Th  cells,  a  process  that 
takes  several  days  (Baumgarth  2000).  Some  multivalent,  polymeric  antigens,  such  as 
the  hepatitis  B  core  antigen  (see  below),  are  able  to  simultaneously  bind 
simultaneously  to  several  BCR  molecules.  This  extensive  cross-linking  of  the 
receptor  molecules  can  be  sufficient  to  initiate  activation  of  the  B  cell  without  T  cell 
help  (Milich  and  McLachlan  1986).  B  cell  mitogens,  for  example  LPS,  can  also 
activate  B  cells  regardless  of  their  antigen  specificity. 
1.4.2  T  Cell  Effector  Functions 
All  T  cell  functions  are  dependent  on  interaction  between  an  activated  T  cell 
and  a  target  antigen-specific  presenting  cell.  The  functions  performed  by  T  cells 
depend  upon  the  array  of  effector  molecules  that  they  secrete  in  response  to  being 
triggered.  These  include  tightly  regulated  cytotoxins,  such  as  those  released  by 
CTLs  to  kill  virally  infected  cells,  and  cytokines  that  can  act  locally  or  at  a  distance 
33 by  binding  to  cell  receptors.  This  results  in  a  change  in  the  behaviour  or  properties 
of  the  target  cell. 
1.4.2.1  C'''S'  T  Cell  Eiiector  Responses 
While  humoral  responses,  supported  by  CD4+  T  cell  help,  provide 
protection  in  the  extracellular  spaces  in  the  body,  activated  CD8+  T  cells,  or  CTLs, 
combat  intracellular  pathogens  by  effector  cytokine  secretion  and  killing  of  cells 
presenting  foreign  antigens. 
An  activated  CTL  that  encounters  a  recognised  peptide-MHC  class  I 
molecule  will  be  triggered  to  kill  the  presenting  cell.  The  principal  way  in  which  this 
occurs  is  through  the  calcium  dependent  release  of  specialised  lysosomes  following 
recognition.  These  contain  perform,  a  molecule  that  enters  the  membrane  of  the 
target  cell  and  polymerises  to  form  a  transmembrane  pore.  The  presence  of  this 
pore  disrupts  the  integrity  of  the  membrane  and  allows  free  flow  of  water  and  salts 
in  and  out  of  the  cell.  In  addition,  proteases  known  as  granzymes  are  released  from 
the  same  lysosomes  as  perform.  On  formation  of  the  transmembrane  pore,  the 
granzymes  are  able  to  enter  the  target  cell.  Granzymes  activate  caspase  enzymes, 
triggering  a  chain  of  events  that  ends  with  degradation  of  DNA  and  the  induction 
of  apoptosis  (Barry  and  Bleackley  2002).  CTLs  also  express  Fas  ligand.  When  the 
T  cell  and  target  cell  bound  together  in  an  antigen-specific  reaction,  Fas  ligand  can 
bind  to  Fas  receptors  (`death  receptors)  in  the  target  cell  membrane.  Ligation  of 
Fas  also  activates  caspase  molecules.  Fas  activated  apoptosis  is  believed  to  be  an 
important  mechanism  in  regulating  peripheral  immune  responses;  once  antigen  is  no 
longer  present,  the  majority  of  antigen-specific  lymphocytes  are  killed  via  this 
mechanism  (Seid  et  aL  2002;  Dockrell  2003). 
34 Apoptosis  is  an  induced  form  of  cell  death,  regulated  by  carefully  controlled 
cellular  pathways.  Unlike  necrosis,  it  results  in  the  release  of  fragments  of  cellular 
material  in  vesicles  or  `blebs',  which  are  taken  up  by  phagocytic  cells.  Chromosomal 
and  cytosolic  DNA  are  degraded  into  small  fragments,  and  proteases  are  activated. 
These  mechanisms  ensure  the  destruction  of  intracellular  pathogens  and  uptake  of 
dying  cell  by  macrophages  but  importantly  does  not  encourage  an  inflammatory 
response.  In  contrast,  necrotic  cell  death  allows  the  escape  of  intracellular 
pathogens  and  the  release  of  molecules  that  induce  an  inflammatory  response.  The 
two  forms  of  cell  death  therefore  have  very  different  immunological  outcomes,  and 
apoptosis  results  in  significantly  less  immunopathology  than  necrosis. 
As  well  as  directly  killing  cells,  activated  CI  Ls  secrete  cytokines  such  as 
tumour  necrosis  factors  (TNF)  -a  and  -ß  and  IFN-y.  These  molecules  act  non- 
specifically  and  do  not  cause  cell  death.  Instead  they  contribute  to  host  defence  in 
various  different  ways.  TNFs  and  IFNs  upregulate  Natural  Killer  cell  activity  and 
IFN-y  directly  inhibits  viral  replication  and  increases  expression  of  proteins 
involved  in  the  expression  of  antigen,  such  as  MHC  class  I,  in  infected  cells.  IFN-'y 
also  activates  macrophages  in  conjunction  with  another  signal  such  as  the  presence 
of  LPS.  It  reduces  intracellular  tryptophan  concentrations,  which  can  inhibit  the 
growth  of  intracellular  pathogens  by  effectively  starving  them,  and  increases  the 
efficacy  of  Fas-and  perforin-mediated  cytotoxicity  by  CTLs  (Roth  and  Pitcher 
2004).  TNF-cc  and  TNF-ß  also  activate  macrophages,  acting  synergistically  with 
IFN-y,  and  can  induce  killing  in  some  target  cells  through  TNF  receptor  I. 
35 1.4.2.2  CD4`  T  Cell  Responses 
CD4+  Ih  cells  aid  in  the  activation,  enhance  the  activity  and  encourage 
proliferation  of  other  immune  cells.  They  can  activate  macrophages  to  kill 
intracellular  bacteria,  induce  proliferation  and  class  switching  in  B  cells  and  help 
activate  naive  CD8+  T  cells  (see  above).  Like  CD8  T  cells,  their  effects  are 
mediated  by  direct  cellular  interactions  and  cytokine  secretion  following  antigen 
specific  recognition. 
Physical  detection  of  antigen-specific  CD4+  T  cells  has  revealed  features  of 
the  in  vivo  immune  response  that  were  not  appreciated  from  previous  in  vitro  studies. 
In  vivo,  antigen  is  initially  presented  to  naive  CD4+  T  cells  mainly  by  DCs  within  the 
T  cell  areas  of  secondary  lymphoid  tissues.  Anatomical  constraints  make  it  likely 
that  these  DCs  acquire  the  antigen  at  the  site  where  it  enters  the  body. 
Inflammation  enhances  T  cell  activation  by  stimulating  DCs  to  migrate  to  the  T  cell 
areas  and  upregulate  MHC  and  co-stimulatory  molecule  expression.  Inflammatory 
signals  induce  chemokine  receptors  on  activated  T  cells  that  direct  their  migration 
toward  B  cell  follicles  to  interact  with  antigen-specific  B  cells  (Jenkins  et  aL  2001). 
T  helper  cells  have  been  shown  to  be  important  in  the  development  of  a 
strong  memory  response.  Proliferation  of  memory  CD8+  T  lymphocytes  and  the 
level  of  cytokine  production  they  display  are  dependent  on  the  presence  of  CD4+  T 
cells  during  an  initial  recognition  of  antigen  (Shedlock  and  Shen  2003;  Sun  and 
Bevan  2003). 
The  cytokine  environment  generated  at  the  time  of  priming  is  also 
important  in  the  differentiation  of  the  T  cell.  This  can  come  from  previously 
activated  helper  cells  or  from  the  APC  itself  and  directs  the  T  helper  bias  of  the 
ensuing  clonal  population.  CD4+  Th  cells  fall  into  two  main  categories;  Ill  cells 
and  112  cells,  depending  on  the  pattern  of  cytokines  they  generate  following 
36 activation.  Broadly  speaking,  Thl  cells  promote  inflammatory  responses  and 
activate  macrophages  by  the  production  of  IL-2,  IFN-y,  IL-6  and  IL-12,  and  Th2 
cells  support  the  expansion  of  activated  B  cells  through  the  generation  of  IL-4,  IL-5 
and  IL-10  (Mosmann  and  Sad  1996). 
Successful  protection  against  some  diseases,  such  as  tuberculosis,  can  be 
significantly  affected  by  the  expansion  of  particular  subsets  of  Th  cells  (Tanghe, 
D'Souza  et  al  2001). 
Th1  CD4+  Responses 
Thl  cells  co-ordinate  the  immune  response  against  intracellular 
microorganisms.  Central  to  this  is  the  antigen-specific  activation  of  macrophages. 
Some  bacteria  such  as  Salmonella  and  mycobacteria  are  able  to  survive  and  grow  in 
the  phagolysosomes  of  macrophages  after  phagocytosis.  In  this  environment  they 
are  protected  from  CTLs  and  antibodies.  They  survive  by  specifically  inhibiting  the 
normal  killing  process  of  acidification  of  the  phagosome,  proteolysis  and  fusion 
with  lysosomes  used  by  macrophages.  However,  activation  of  macrophage  by  a 
Thl  cell  following  antigen  recognition  can  eliminate  such  intracellular  pathogens  by 
enhancing  the  killing  mechanisms  within  the  cell.  Two  signals  are  required  for 
macrophage  Activation:  IFN-y  and  one  of  several  other  potential  signals,  such  as 
CD40L,  TNF-a  or  TNF-ß  binding.  These  signals  can  be  simultaneously  be 
provided  by  an  activated  CD4+  Th1  cell  secreting  appropriate  inflammatory 
cytokines. 
The  Thl  cytokine  IFN-y  also  induces  B  cells  to  switch  the  class  of 
immunoglobulin  subtype  they  produce,  usually  in  mice  from  IgM  to  IgG2a.  This 
37 subtype  of  antibodies  has  been  correlated  with  strong  opsonisation  activity  (see 
section  1.4.3  Humoral  Immune  Responses). 
Th2  CD4+  Responses 
Th2  cells  on  the  other  hand  activate  naive  B  cells  to  proliferate  and  produce 
IgM.  The  cytokines  they  secrete  also  drive  class-switching  to  production  and 
secretion  of  other  types  of  antibody,  including  IgG1,  IgA  and  IRE.  These 
antibodies  are  more  important  in  the  control  of  extracellular  pathogens,  and  are 
efficient  at  neutralisation  and  opsonisation  of  pathogens.  Also  IgA  in  its  secretory 
form  has  the  capacity  to  translocate  the  mucosal  epithelium,  neutralising  microbes 
at  the  mucosal  surfaces.  Details  of  the  effector  functions  of  antibodies  are  given 
below  (section  1.4.3) 
Factors  Affecting  the  Development  of  a  Th1  or  Th2  Outcome 
The  differentiation  of  a  naive  CD4+  T  into  a  Th1  or  Th2  type  of  cell  appears 
to  be  heavily  dependent  upon  the  microenvironment  surrounding  the  cell  when  it  is 
activated.  There  are  several  factors  that  appear  to  influence  this  environment, 
including  the  local  production  of  cytokines.  These  can  have  a  major  influence  on 
Th1/Th2  outcome  and  their  presence  is  largely  dependent  on  the  type  of  cells  that 
are  present  and  activated.  Macrophages  and  NK  cells  secrete  pro-Thi  cytokines 
such  as  TNF-CL  and  IL-12.  Mast  cells  and  B  cells  secrete  the  pro-Th2  cytokines  IL- 
4  and  IL-10.  As  well  as  the  cytokines  present,  the  concentration  of  activating 
antigen  can  affect  the  outcome,  with  higher  concentration  of  antigen  resulting  in  a 
tendency  toward  Thi  cell  development.  In  addition,  in  mice  there  appears  to  be  a 
balance  between  these  types  of  responses.  IFN-y  inhibits  Th2  cell  growth  and  IL- 
10  inhibits  Thl  cell  growth.  This  action  can  lead  to  strong  polarisation  of  response. 
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B  cells  develop  in  the  bone  marrow  and  in  their  naive  state  traffic  through 
the  B  cell  follicles  of  secondary  lymphoid  tissues.  On  activation,  they  proliferate  in 
germinal  centres,  begin  to  secrete  antibody  and  undergo  somatic  hypermutation  (to 
generate  increased  diversity  of  antibody  specificity).  During  this  stage  of 
differentiation,  the  B  cell  population  undergoes  affinity  maturation;  cells  compete  to 
bind  antigen  and  those  with  poor  affinity  are  selected  out.  Class  switching  of 
antibody  production  can  be  influenced  by  cytoltines  secreted  by  T  helper  cells,  for 
example,  in  order  to  produce  antibody  with  different  effector  functions. 
Antibodies  protect  extracellular  spaces  within  the  body  and  mucosal 
surfaces  at  the  interface  between  the  body  and  the  external  environment.  They 
function  by  binding  to  molecules  or  microbes  in  an  antigen-specific  manner.  They 
are  structurally  similar  to  the  BCR  and  their  specificity  is  determined  by  the  same 
somatically  recombined  genes,  therefore  the  antibody  produced  by  a  plasma  cell  will 
bind  to  the  same  antigen  that  was  initially  bound  by  the  BCR.  Figure  1-6  shows  a 
schematic  diagram  of  an  antibody  showing  the  variable  antigen-binding  and  the 
constant  regions. 
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Figure  1-6:  Schematic  IgG  antibody  molecule 
This  diagram  shows  the  functional  and  structural  domains  of  immunoglobulin  G. 
The  molecule  is  made  up  of  light  (,  )  and  heavy  (})  chains  with  variable  (V)  and 
constant  (C)  domains.  The  molecule  is  bivalent,  with  a  pair  of  light  and  heavy 
variable  domains  making  up  each  antigen  binding  site.  The  entire  antibody  can  be 
divided  into  two  fragments:  an  antigen-binding  fragment  (Fab)  and  a  crystallisable 
fragment  (Fc)  the  latter  of  which  can  bind  to  Fc  receptors  on  the  surface  of  B  cells 
and  other  APCs. 
40 1.4.3.1  Antibody  Classes  and  Subtypes 
Different  classes  of  antibody  are  produced  by  different  plasma  cells  and 
each  has  the  capacity  to  induce  the  mechanisms  outlined  above  to  a  different  degree 
(Corbeil  2002). 
The  different  classes  of  antibody  are  determined  by  the  gene  from  which  the 
heavy  chain  is  transcribed.  The  different  classes  of  antibody  include 
Immunoglobulin  (Ig)  M  and  IgD  (expressed  by  naive  B  cells),  IgG  (the  main  class 
found  in  serum  during  infection)  and  IgA  (a  form  of  which  can  cross  mucosal 
surfaces).  The  class  produced  by  aB  cell  depends  on  the  cytokines  present  in  the 
microenvironment,  often  due  to  T  cell  help.  For  example,  a  Th  cell  might  secrete 
IFN-y  during  activation  of  aB  cell,  which  can  induce  the  production  of  IgG2a. 
Alternatively,  the  main  cytokine  secreted  might  be  IL-4,  which  would  cause  IgGl 
production  (Stavnezer  1996;  Nambu  et  al.  2003).  Table  1-1  shows  the  influence  of 
different  cytokines  on  immunoglobulin  class  and  subtype  expression. 
1.4.3.2  Antibody  Functions 
Antibodies  have  several  main  protective  functions.  First  is  the  neutralisation 
of  pathogens  and  their  toxins.  Antibodies  can  physically  block  the  active  sites  of 
toxin  molecules,  for  example,  inhibiting  their  enzymatic  function  or  attach 
themselves  to  ligands  on  the  bacterial  surface,  prevent  them  from  binding  to 
receptors  on  host  cells.  Any  functionally  important  molecule  that  is  exposed  to 
antibody  binding  can  thus  be  a  target  of  neutralisation. 
41 IgM  IgGi  IgG2a  IgG2b  IgA 
IL-4  Inhibits  Induces  Inhibits  -- 
IL-5  ----  Augments 
IFN-y  Inhibits  Inhibits  Induces  -- 
TGF-ß  Inhibits  --  Induces  Induces 
Table  1-1:  Role  of  cytokines  in  regulating  immunoglobulin  expression 
Adapted  from  Qaneway  et  al.  2001),  (Tokuyama  and  Tokuyama  1999)  and 
(Michaelsen  et  al.  2004). 
42 The  second  function  is  opsonisation;  the  promotion  of  phagocytosis. 
Certain  immune  effector  cells  such  as  macrophages  are  able  to  bind  to  antibodies 
via  the  Fc  region  (see  Figure  1-6)  once  the  antibody  is  bound  to  its  target,  facilitating 
phagocytosis. 
Antibodies  can  trigger  the  complement  cascade,  which  is  itself  able  to 
enhance  opsonisation  and  induce  lysis  of  some  bacteria  (see  section  1.3,  Innate 
Immunity;  (Ehrenstein  et  ah  1998). 
Antibodies  can  also  bind  to  viral  proteins  expressed  on  the  surface  of 
infected  self-cells  and  allow  the  binding  of  NK  cells  that  can  kill  the  infected  cell. 
This  process  is  known  as  antibody-dependent  cell-mediated  cytotoxicity  (Moretta  et 
aL  2003). 
The  constant  region  of  the  immunoglobulin  molecule  determines  its 
antibody  class  and  influences  the  functional  activity  of  the  molecule.  The  Fc  region 
of  different  immunoglobulin  classes  are  recognised  by  Fc  receptors  on  the  surfaces 
of  different  immune  effector  cells,  allowing  each  antibody  class  to  interact  with 
distinct  subsets  of  immune  cells.  For  example  IgGl  Fc  is  recognised  by 
macrophage  and  neutrophil  receptors,  enhancing  the  phagocytosis  of  pathogens 
coated  with  this  immunoglobulin  subtype  (Barrington  et  aL  2001). 
The  Fc  portion  of  an  antibody-antigen  complex  can  bind  to  the  Clq 
molecule  of  complement,  enhancing  the  uptake  of  immune  complexes  by 
phagocytes  and  activating  the  complement  cascade  (Brekke  et  at  1995). 
IgM  can  strongly  activate  complement,  thus  providing  an  alternative 
protective  mechanism  early  in  infection,  when  high  levels  of  IgNI  are  present  but 
specific  cellular  responses  have  not  reached  their  maximum.  IgM  is  also  believed  to 
have  a  role  in  the  development  of  a  strong  IgG  response  (Ehrenstein  et  al.  1998). 
43 The  Fc  region  enables  the  active  transport  of  antibody  to  areas  where  it 
would  not  otherwise  be  present,  for  example  the  mucosal  surfaces.  This  is 
accomplished  by  binding  of  the  Fc  to  receptors  allowing  the  translocation  of  the 
molecule  through  epithelial  barriers.  This  is  an  important  protective  measure, 
bringing  the  protective  mechanisms  of  antibodies  to  these  areas.  Most  types  of 
antibody  cannot  cross  the  epithelia,  but  secretory  IgA  (sIgA)  is  able  to  do  so,  as  is 
IgM  to  a  lesser  extent.  SIgA  is  produced  by  plasma  cells  residing  in  the  lamina 
propria,  adjacent  to  the  basal  membrane  of  the  epithelial  surfaces.  The  sIgA 
molecule  is  a  dimer  consisting  of  two  individual  IgA  molecules  joined  by  aJ  chain. 
Poly-immunoglobulin  receptors  on  the  basal  surface  of  epithelial  cells  bind  sIgA. 
Binding  is  followed  by  internalisation,  active  transport  across  the  cell  and  release 
into  e.  g.  the  bronchial  or  intestinal  lumen  (Rojas  and  Apodaca  2002).  This  form  of 
IgA  is  able  to  neutralise  pathogens  and  toxins  at  the  epithelial  surfaces.  Thus  sIgA 
provides  antigen-specific  defence  at  the  mucosal  surfaces  in  addition  to  innate 
mechanisms. 
In  contrast,  IgG  acts  to  protect  the  extracellular  spaces  of  the  internal 
tissues.  It  has  a  relatively  long  half-life  and  like  IgA  can  neutralise  pathogens  and 
toxins.  In  addition  it  can  activate  complement  and  opsonise  pathogens.  t  It  is  the 
main  class  of  immunoglobulin  found  in  the  serum  during  infection.  IgG2a  is 
effective  at  opsonising  material  for  phagocytosis  and  activating  complement  (Clark 
1997;  Michaelsen  et  al.  2004).  The  main  functions  of  1gM  are  efficient  neutralisation 
(due  to  its  pentameric  structure)  and  activation  of  complement. 
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Lymphocyte  action  and  immune  responses  as  a  whole  can  be  restricted  to 
certain  body  compartments.  This  provides  an  immune  response  where  necessary, 
enabling  the  efficient  clearance  of  pathogens  whilst  limiting  the  potential  for 
widespread  immunopathogenesis.  The  tropism  of  lymphocytes  is  regulated  by  the 
expression  of  surface  adhesion  molecules,  such  as  integrins.  Naive  lymphocytes 
display  a  lymph  node-specific  tropism,  causing  them  to  reside  in  areas  where  they 
are  likely  to  encounter  APCs.  Expression  of  different  adhesion  molecules  might, 
for  example,  direct  activated  cells  to  migrate  to  a  site  of  inflammation  (Sallusto  et  al. 
1999).  A  consequence  of  this  is  that  different  routes  of  vaccination  may  or  may  not 
synergise  to  provide  stronger  overall  response,  depending  on  which  immunological 
compartment  the  individual  responses  occur  in,  and  the  flow  of  antigen,  APCs  and 
lymphocytes  between  the  compartments. 
1.4.5  Generation  of  Memory  T  and  B  Lymphocytes 
Immunologic  memory  gives  the  immune  system  the  ability  to  respond  more 
rapidly  and  effectively  to  pathogens  that  have  been  previously  encountered. 
Activated  lymphocytes  develop  either  into  the  effector  cells  that  provide  the 
functions  described  above,  or  into  memory  cells.  Whilst  effector  cells  are 
responsible  for  conferring  immediate  defence  against  pathogens,  memory  cells  are 
important  for  providing  immunity  against  re-infection,  or  in  the  case  of  a  response 
stimulated  by  vaccination,  long-term  defence  against  a  natural  infection. 
When  an  infection  has  been  cleared,  or  vaccine  antigen  is  removed  by  the 
immune  system,  the  ongoing  signals  that  stimulate  an  effector  response  are 
removed.  In  the  absence  of  these  signals,  the  majority  of  effector  cells  die  through 
45 apoptosis  (Masopust  et  al.  2001).  Memory  T  and  B  cells  are  a  distinct  subset  of  the 
clonally  expanded  lymphocyte  population  that  has  undergone  affinity  selection  for 
the  antigens  presented  during  immunisation.  Unlike  effector  cells,  they  can  persist 
without  residual  antigen.  The  generation  of  such  a  population  is  believed  to  be 
proportionate  to  the  number  of  effector  cells  activated,  thus  measurement  of  strong 
immune  responses  based  on  the  initial  effector  population  is  predictive  of  the 
development  of  strong  secondary  responses  on  subsequent  challenge.  Th  cells  are 
important  in  the  development  of  the  memory  response.  Proliferation  of  memory 
lymphocytes  is  dependent  on  the  presence  of  CD4+  T  cells  during  an  initial 
vaccination  (Sun  and  Bevan  2003). 
A  secondary  or  subsequent  humoral  response  to  a  pathogen  is  characterised 
by  a  much  higher  level  of  IgG  production.  IgM  is  still  present  in  the  secondary 
response,  at  similar  levels  to  those  measured  during  the  primary  response.  IgA  and 
IgE  are  also  present  to  a  greater  degree  during  memory  responses.  Individual 
antibody  molecules  exhibit  a  higher  affinity  for  antigen,  due  to  somatic 
hypermutation  in  the  V  regions  of  immunoglobulin  genes  and  antigen-binding 
dependent  selection  in  the  lymph  nodes.  The  affinity  continues  to  increase  during 
secondary  and  subsequent  immune  responses,  therefore  it  can  be  advantageous  to 
deliver  multiple  doses  of  a  vaccine  over  a  period  of  time.  The  increased  affinity  of 
surface  antibody  as  well  as  greater  expression  of  MHC  class  II  molecules  facilitate 
antigen  uptake  and  presentation,  giving  a  greater  sensitivity  to  low  antigen 
concentrations.  Memory  B  cells  persist  in  the  germinal  centres  of  the  secondary 
lymphoid  organs  (Ochsenbein  et  al.  2000). 
Memory  T  cells,  on  the  other  hand,  can  traffic  to  various  tissues  depending 
on  which  surface  adhesion  molecules  are  expressed,  by  which  they  can  be 
distinguished  from  effector  T  cells.  Like  memory  B  cells,  such  T  cells  are  long  lived 
46 and  can  be  observed  at  elevated  numbers  following  the  resolution  of  an  infection. 
There  are  two  subsets  of  memory  T  cells:  effector  memory  T  cells  and  central 
memory  T  cells.  The  effector  cells  circulate  in  the  periphery  and  can  be  activated 
much  more  rapidly  than  central  memory  cells,  which  persist  in  the  lymphoid  tissues 
and  may  possess  greater  longevity.  The  two  populations  of  memory  cells  are 
thought  to  provide  two  different  functions  in  the  event  of  re-exposure  to  antigen. 
The  peripheral  cells  are  able  to  provide  a  rapid  effector  response  whilst  the  central 
cells  promote  secondary  proliferative  responses  (Masopust  et  al.  2001;  Sallusto  et  ah 
2004). 
1.5  Types  of  Vaccine 
The  goal  of  a  vaccine  is  to  stimulate  the  immune  cells  described  above  to 
confer  protection  against  a  particular  pathogen  and  to  maintain  this  protection  over 
a  long  period  of  time.  Outlined  below  are  some  conventional  types  of  vaccines 
including  those  examined  in  this  thesis. 
1.5.1  Killed  Whole-Cell  Vaccines 
Killed  whole  cell  vaccines  are  composed  of  entire  pathogen  preparations, 
whose  viability  has  been  destroyed  by  chemical  and/or  heat  treatment.  These  types 
of  vaccine  are  considered  safer  than  live,  attenuated  vaccines  as  there  is  no  danger 
of  reversion  to  a  virulent  phenotype.  However,  they  are  generally  less  immunogenic 
and  often  require  multiple  doses  to  be  effective.  Examples  of  chemically  inactivated 
vaccines  are  those  protecting  against  rabies  virus,  Bordetella  pertusrir  (the  causative 
agent  of  whooping  cough,  although  an  acellular  vaccine  has  recently  been 
47 introduced  in  the  UK),  and  the  Salk  polio  vaccine.  'T'his  vaccine,  in  which  wild-type 
virus  is  inactivated  by  treatment  with  formalin,  is  more  expensive  to  produce  than 
the  attenuated  vaccine,  and  is  less  immunogenic,  but  its  improved  safety  may  render 
it  a  more  appropriate  choice  in  regions  were  there  are  few  natural  cases  of  polio 
(Imam  1981).  Despite  the  high  efficacy  of  killed  vaccines,  side  effects  are  not 
uncommon,  and  such  vaccines  are  used  in  humans  only  when  safer  alternatives  are 
not  available.  In  animals,  however,  safety  concerns  are  often  less  stringent,  and 
whole-cell  killed  vaccines  are  in  common  use  (Cobo  et  aL  2002;  Armijos  et  aL  2004). 
1.5.2  Subunit  Vaccines 
Acellular  or  subunit  vaccines  consist  of  the  purified  components  of 
pathogens.  They  are  believed  to  be  safer  than  either  killed  whole-organism  or  live, 
attenuated  vaccines,  since  a  vaccine  based  on  a  whole  organism  can  contain  toxic 
components,  even  if  the  microbe  itself  is  non-viable.  Subunit  vaccines  contain  a 
few  or  even  a  single  purified  antigen  from  the  original  pathogen.  Recombinant 
subunit  vaccines  are  precisely  defined  and  are  usually  safe  and  well  tolerated. 
Examples  of  successful  subunit  vaccines  include  Hepatitis  B  surface  antigen  and  the 
acellular  Bordetella  pertuscis  vaccine.  The  drawback  to  producing  such  vaccines  is  that 
many  purified  antigens  do  not  elicit  a  strong  immune  response.  This  can  be  because 
too  few  antigens  are  included  in  the  formulation  or  the  removal  of  inflammatory 
molecules  and  PAMPs  from  the  whole  cell  formulation  reduces  the  potential  to 
activate  the  immune  system.  Without  these  triggers,  many  antigens  are  not 
immunogenic  and  must  be  administered  with  an  adjuvant  -a  substance  that 
increases  the  immune  response  to  co-administered  molecules.  To  date  the  type  of 
adjuvants  that  have  been  licensed  for  use  in  humans  remain  limited  to  aluminium 
48 salts  (alum),  which  has  been  in  use  for  decades,  or,  more  recently,  detoxified 
bacterial  molecules  (e.  g.  monophosphoryl  lipid  A  (Baldrick  et  aL  2002)).  A 
consequence  of  using  alum  is  that  subsequent  immunity  tends  to  be  biased  strongly 
towards  a  Th2  response;  high  antibody  production  but  little  cell-mediated  immunity, 
whereas  bacterial  derivatives  can  induce  Thl  responses  (Lodmell  et  aL  2000). 
1.5.3  Live-Attenuated  Vaccines 
Live,  attenuated  vaccines  are  generally  powerful  vaccines,  reproducing  many 
of  the  features  of  a  natural  infection  including  some  degree  of  replication  and 
survival  of  the  organism  in  the  body.  This  characteristic  makes  attenuated  vaccines 
potentially  more  likely  to  generate  protective  immunity  than  killed  organisms  or 
subunit  vaccines.  However,  attenuated  vaccine  strains  can  potentially  revert  to  a 
virulent  state  resulting  in  disease.  This  has  been  observed  with  the  Sabin  oral  polio 
vaccine,  where  reversion  to  virulence  occurs  in  about  one  vaccinee  per  million  and 
can  result  in  poliomyelitis  (Wood  and  Thorley  2003).  Therefore  the  utility  of  this 
vaccine  depends  on  the  conditions  in  which  it  is  employed.  As  a  cheap,  easily 
administered  and  highly  effective  vaccine,  for  treatment  in  endemic  regions,  this 
type  of  vaccine  is  invaluable.  However,  in  a  population  from  which  the  virus  has 
been  largely  eliminated,  the  use  of  this  vaccine  can  be  the  cause  of  the  majority  of 
cases  of  poliomyelitis  (Plotkin  2003;  Yang  et  al.  2003).  In  these  circumstances  it  may 
become  appropriate  to  use  an  inactivated  vaccine  that  is  less  immunogenic  but 
shows  a  greater  safety  profile  (Wood  and  Thorley  2003). 
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The  single  greatest  advantage  of  mucosal  vaccination  is  its  potential  to 
invoke  immunity  at  the  mucosal  surface  as  well  as  systemically.  Since  the  majority 
of  pathogens  invade  the  body  through  the  mucosal  surfaces,  the  mucosal  immune 
response  can  prevent  the  initial  entry  of  the  organism  into  the  host  and  thus  prevent 
systemic  disease.  This  effectively  provides  an  earlier  line  of  defence  against 
infection  and  can  additionally  protect  against  infectious  organisms  that  cause 
damage  to  these  surfaces  by  the  production  of  toxins.  Protection  is  partially 
mediated  by  secretory  IgA,  which  is  not  induced  by  parenteral  vaccination  (Johnson 
et  al.  1995).  Similarly,  systemic  vaccination  fails  to  induce  cell-mediated  immunity  at 
mucosal  membranes,  whilst  delivery  of  a  vaccine  directly  to  the  mucosal  surfaces 
can  induce  such  responses  (Gallichan  and  Rosenthal  1996;  Kanellos  et  aL  2000).  In 
addition,  it  is  believed  that  trafficking  of  lymphocytes  between  mucosal  surfaces  is 
linked  and  that  a  vaccine  delivered  to  one  part  of  the  mucosal  immune  system  can 
induce  immunity  at  some  distal  mucosal  sites.  For  example,  oral  immunisation  can 
confer  an  immune  response  in  the  upper  respiratory  tract  as  well  as  in  the  intestinal 
mucosa.  This  is  generally  known  as  the  common  mucosal  immune  response  and 
makes  mucosal  immunisation  particularly  attractive  (Chen  2000). 
Mucosal  immunisation  also  offers  practical  advantages  for  vaccine  delivery. 
Since  there  is  no  hypodermic  administration  of  the  vaccine,  blood-borne  diseases 
such  as  HIV  and  hepatitis  cannot  be  passed  from  one  recipient  to  another  by  re-use 
of  contaminated  needles.  Not  are  medical  staff  at  risk  of  infection  due  to  accidental 
needlestick  injuries,  currently  a  frequent  occurrence  (Elmiyeh  et  aL  2004).  Painless, 
simple  and  non-invasive,  mucosal  administration  can  also  lead  to  increased  uptake 
in  a  population. 
50 A  potential  problem  with  mucosal  vaccination  is  the  difficulty  of  generating 
mucosal  immune  responses.  The  normal  response  to  mucosal  antigens  is  anergy  or 
tolerance,  since  an  inappropriate  response  against  innocuous  airborne  molecules  or 
proteins  in  food,  for  example,  could  be  harmful  (Dougan  et  al.  2000).  Secondary 
signals  must  be  provided  for  the  activation  of  naive  lymphocytes.  These  signals  can 
be  triggered  by  bacterial  toxins  such  as  E.  codi  LT  or  Cholera  toxin  (Rappuoli  et  ah 
1999),  which  can  be  detoxified  and  yet  remain  effective  as  mucosal  adjuvants  (Pizza 
et  al.  2001). 
1.5.3.2  Use  ofAttenuated  Vectors 
Despite  the  advantages  outlined  above,  there  are  few  mucosal  vaccines  in 
use.  This  is  mainly  because  of  the  difficulty  of  generating  mucosal  responses. 
However,  live  organisms,  even  though  attenuated,  can  overcome  mucosal  tolerance 
through  the  activation  of  innate  immunity  (Dougan  et  al.  2000;  Huang  et  ah  2001; 
Woo  et  ah  2001). 
The  ability  to  replicate,  even  at  a  reduced  rate,  confers  increased  longevity  of 
antigen  expression  and  stimulation  of  the  immune  system  (compared  to  a  non-living 
vaccination  system).  Also,  immunisation  with  attenuated  vectors  can  generate 
immune  responses  to  the  vector,  which  can  induce  protective  responses  against 
related  pathogens,  as  has  been  shown  with  Salmonella  (Salerno-Goncalves  et  aL 
2003),  as  well  as  to  any  heterologous  antigens  that  are  expressed  by  this  organism. 
This  can  be  achieved  by  genetic  manipulation  of  the  attenuated  vaccine  to  allow 
expression  of  a  heterologous  antigen  (Medina  and  Guzman  2001).  Therefore  this 
strategy  has  the  potential  to  simultaneously  vaccinate  against  more  than  one 
pathogen. 
51 One  problem  associated  with  the  use  of  attenuated  vector  vaccines  is  pre- 
existing  immunity  to  the  vaccine  organism  in  geographical  regions  where  the  wild- 
type  organism  is  endemic.  This  might  result  in  early  clearance  of  the  vector  and 
reduced  exposure  to  the  vaccine  antigens,  giving  dramatically  reduced  immune 
responses  (Medina  and  Guzman  2001).  To  overcome  this,  higher  doses  of  bacteria 
can  be  used,  but  not  without  introducing  the  danger  of  giving  too  high  a  dose  to 
non-immune  individuals.  Conversely,  the  calculated  dose  might  be  too  high  in  non- 
endemic  areas  if  vaccine  is  originally  tested  in  endemic  infection  area  (Attridge  et  al. 
1997).  However,  this  theoretical  risk  may  not  be  important,  since  it  has  been  shown 
that  prior  immunologic  experience  of  a  Salmonella  vaccine  carrier  strain  (or  similar 
strains  of  Salmonella)  can  potentiate  a  stronger  humoral  immune  response  than  is 
seen  without  prior  exposure  (Bao  and  Clements  1991). 
A  wide  range  of  different  bacteria  and  attenuation  mutants  are  being 
evaluated  for  vaccine  delivery,  but  Salmonella  is  one  of  the  most  studied  genera,  with 
several  examples  of  human  clinical  trials  (Medina  and  Guzman  2001).  Such  studies 
have  considered  their  use  in  human  typhoid  fever  vaccines  (Salerno-Goncalves  et  al. 
2003),  for  use  as  carriers  to  deliver  DNA  vaccines  to  host  cells  (Woo  et  al.  2001),  or 
to  deliver  vaccine  antigens  of  other  pathogens  in  humans  (Bumann  et  aL  2000)  and 
mice  (Foynes  et  al.  2003). 
1.5.3.3  Use  of  Salmonella  typhimurlum  as  a  live  attenuated  delivery  strain 
Salmonella  enterica,  serovar  tyßhimurium,  is  referred  to  as  S.  typbimurium 
throughout  this  thesis.  It  is  a  Gram  negative  bacterium  which  when  used  to  infect 
mice  causes  a  systemic  disease  with  many  of  the  features  associated  with  human 
typhoid  fever. 
52 Salmonella  can  enter  the  body  through  gut  epithelial  cells  or  M  cells,  specialist 
antigen  sampling  cells  on  the  surface  of  the  Peyer's  patches  in  the  intestinal 
epithelium.  From  here  they  are  able  to  invade  macrophages  and  DCs  and  can 
survive  in  the  phagolysosomes  of  these  cells.  This  is  despite  the  intracellular  killing 
mechanisms  that  exist  within  macrophages  to  eliminate  intracellular  pathogens 
(Carrol  et  al  1979).  Migration  of  such  infected  cells  can  lead  to  systemic  infection, 
with  dissemination  to  the  spleen,  liver  and  lymph  nodes.  The  presence  of  the 
bacteria  at  different  sites  enables  the  activation  of  responses  both  systemically  and  at 
mucosal  surfaces  (Medina  and  Guzman  2000). 
The  presence  of  highly  immunogenic  components  of  the  bacteria  including 
LPS  and  flagellin  and  the  invasion  of  immune  cells  such  macrophages  activate 
mechanisms  which  can  enhance  specific  immune  responses.  This  is  mediated 
through  the  release  of  pro-inflammatory  cytokines,  such  as  IL-1  and  TNF-a, 
resulting  in  an  influx  of  neutrophils,  DCs  and  T  lymphocytes  to  regions  with 
bacteria-carrying  cells  and  upregulating  APC  co-stimulatory  signals  via  TLRs 
(Takeda  and  Akira  2001). 
Control  of  infection  is  mainly  by  acquired  T  cell  responses:  including 
enhancement  of  macrophage  killing  mechanisms  by  Thl  cells  and  direct  killing  of 
infected  cells  by  CTLs  (Mastroeni  and  Sheppard  2004).  This  occurs  more  rapidly 
with  attenuated  vaccine  strains,  but  does  not  prevent  the  presentation  of  antigens 
encoded  by  the  bacteria,  or  the  dissemination  of  the  bacteria  around  the  body. 
1.5.3.4  Attenuation  of  S.  typhimurium  B.  RD  509 
Live  bacteria  used  to  deliver  vaccines  must  be  attenuated  to  the  extent  that 
they  cannot  cause  disease  in  the  vaccine  recipient.  Salmonella  is  a  much  studied 
organism,  and  its  virulence  factors  have  been  well  characterised  (Hensel  et  aL  1995; 
53 Marcus  et  aL  2000).  This  has  facilitated  the  creation  of  mutants  lacking  various 
virulence  factors  (O'Callaghan  et  a!  1988).  One  effective  vaccine  candidate  is  S. 
typhimw  um  BRD509.  The  strain  is  attenuated  by  deletion  of  two  genes;  arvA  and 
aroD,  encoding  enzymes  in  the  biosynthetic  pathways  involved  in  the  generation  of 
the  aromatic  amino  acids  (Strugnell  et  al.  1992).  The  bacteria  are  therefore 
auxotrophic,  ie.  dependent  on  external  supply  of  these  amino  acids.  The  am  genes 
were  selected  for  mutation  because  aromatic  metabolites  are  not  usually  present  in 
human  tissues,  therefore  mutants  should  be  unable  to  replicate  at  these  sites.  Their 
diminished  ability  to  replicate  in  vivo  results  in  a  self-limiting,  sub-clinical  infection, 
but  they  remain  able  to  express  and  present  vaccine  antigen  (Chatfield  et  a!  1993). 
Administration  of  this  strain  expressing  antigens  from  other  pathogens  has  been 
shown  to  result  in  mucosal  responses  offering  partial  protection  against  a  mucosal 
pathogen  (Strugnell  et  al.  1992).  Systemic  antibody  production  against  the  antigens 
of  the  secondary  vaccine  candidate  has  also  been  observed  (Roberts  et  al.  2000), 
although  T  helper  cell  responses  were  limited  to  Salmonella  antigens  (Londono  et  a! 
1996). 
1.5.3.5  Antigen  Expression 
The  production  and  presence  of  a  heterologous  antigen  lays  a  considerable 
metabolic  burden  on  recombinant  bacteria.  This  can  result  in  reduced  growth  and 
decreased  plasmid  stability.  Attempts  to  reduce  the  impact  of  antigen  expression  on 
plasmid  stability  have  included  the  use  of  inducible  promoters  as  an  alternative  to 
constitutive  antigen  expression.  One  commonly  described  promoter  is  nirB,  which 
is  activated  under  anaerobic  conditions  such  as  the  interior  of  eukaryotic  cells  (Bell 
et  aL  1990).  This  allows  growth  in  vitro  where  oxygenation  of  the  culture  is  high, 
whilst  allowing  antigen  expression  on  vaccination  in  the  tissue  when  the  oxygen 
54 tension  is  low.  There  have  been  several  comparisons  between  strains  expressing 
antigens  under  the  control  of  different  promoters.  Two  groups  have  demonstrated 
greater  plasmid  stability  both  in  vitro  and  in  vivo  with  the  use  of  nirB  than  equivalent 
plasmids  from  which  an  antigen  is  constitutively  expressed  (Oxer  et  aL  1991; 
Chatfield  et  al.  1992).  The  nirB  promoter  has  also  been  shown  to  drive  higher  levels 
of  expression  in  S.  typhimurium  amA  mutants  than  pagC  under  conditions  in  which 
both  promoters  were  induced.  In  this  case,  plasmids  expressing  the  same  antigen 
under  the  control  of  these  promoters  were  shown  to  have  similar  levels  of  stability 
in  vitro.  However,  stability  of  both  plasmids  was  reduced  in  vivo,  although  nirB  was 
maintained  at  a  higher  level  (Foynes  et  aL  2003).  Other  work  has  shown  that  the 
copy  number  of  the  plasmid  carried  by  an  S.  yphimurium  am  mutant  is  inversely 
proportional  to  the  ability  of  the  bacteria  to  colonise  mice,  presumably  due  to  the 
metabolic  burden  of  maintaining  a  high  copy  number  plasmid  (Bell  et  aL  1990). 
1.5.4  DNA  Vaccines 
1.5.4.1  Background  and  Development 
A  relatively  novel  approach  to  inducing  immune  responses  involves  the 
administration  of  naked  DNA  that  encodes  the  vaccine  antigens  of  interest,  rather 
than  of  the  antigens  themselves.  This  system  relies  on  the  use  of  a  eukaryotic 
promoter  to  drive  expression  of  the  DNA  encoded  antigen  within  the  transfected 
host  cell.  First  described  in  1990  (Wolff  et  al.  1990),  its  application  to  vaccine  design 
resulted  from  the  observation  that  specific  antibodies  could  be  generated  to  the 
antigen  encoded  by  the  DNA  following  intramuscular  administration  (Tang  et  al. 
1992).  These  findings  were  mirrored  by  later  work  (Williams  et  al.  1992),  which 
used  an  alternative  method  of  vaccination;  ballistic  delivery  of  DNA  into  the  dermis 
55 using  a  gene  gun  (see  below).  These  initial  studies  have  led  to  a  massive  expansion 
of  research  in  this  area.  Work  to  date  has  investigated  the  possibilities  of  using 
DNA  to  act  as  a  vaccine  in  humans  and  animals  against  a  variety  of  diseases.  Many 
approaches  have  been  considered  and  a  number  of  human  clinical  trials  have  been 
completed.  However,  these  have  demonstrated  that  DNA  vaccines  need  to  be  used 
in  combination  with  other  vaccine  strategies  to  generate  immunity.  Examples 
include  vaccines  for  malaria  (Epstein  et  al.  2004;  Moorthy  et  ah  2004),  HIV-1  (Mwau 
et  ah  2004),  and  various  cancers  (Tagawa  et  ah  2003). 
DNA  vaccines  require  a  similar  investment,  in  terms  of  development  of  the 
technology,  to  other  forms  of  vaccines.  However,  production  of  the  vaccine  itself  is 
much  simpler  and  therefore  potentially  cheaper;  there  is  no  requirement  for  a 
complex  purification  of  recombinant  protein  from  bacteria  (thus  ensuring  there  is 
no  potential  for  residual  toxicity  due  to  co-purified  contaminants).  DNA  is  easily 
isolated  in  a  highly  pure  form,  and  can  be  dried  out  for  storage.  Transport  of 
lyophilised  DNA  is  simple;  it  requires  no  refrigeration  and  is  stable  for  long  periods 
of  time,  unlike  protein  vaccines,  which  commonly  require  refrigeration. 
1.5.4.2  Generation  oflmmune  Responses  to  DNA  Vaccines 
A  summary  of  the  generation  of  immune  responses  following  DNA 
vaccination  is  shown  in  Figure  1-7.  DNA  vaccination  has  been  shown  to  elicit 
CD4+  T  cell,  CD8+  T  cell  and  B  cell  responses.  However,  the  precise  mechanisms 
by  which  these  responses  are  generated  are  not  clear,  probably  depending  on  which 
transfected  cells  are  involved  in  the  expression  of  antigen  and  acting  as  professional 
APCs  to  CD4+  T  helper  cells. 
Initially,  DNA  is  taken  up  into  the  cells  of  the  vaccine  recipient  and 
translocated  into  the  nucleus  by  as  yet  undefined  mechanisms.  From  there,  the 
56 DNA  is  transcribed  into  mRNA  and  translated  into  protein  by  exactly  the  same 
process  that  cellular  proteins  are  manufactured.  Translation  is  followed  by  protein 
modification.  Such  proteins  can  then  be  processed  and  presented  on  the  surface  of 
the  cell  in  the  context  of  MHC  class  I  molecules.  This  can  lead  to  the  activation  of 
CD8+  T  cells.  In  addition,  specialist  APCs  can  present  vaccine  antigen  (either 
following  direct  transfection  of  the  APC,  or  internalisation  of  antigen  expressed  and 
released  following  death  of  by  other  transfected  cells).  Antigen  presentation  by 
APCs  can  be  in  the  context  of  MHC  class  I  as  above,  or  class  II,  potentiating  the 
activation,  of  CD4+  T  cells.  Finally,  B  cells  can  also  be  activated  following  an 
encounter  with  vaccine  antigen,  although  given  the  typically  low  humoral  responses 
to  DNA  vaccines  administered  alone,  this  is  thought  to  occur  at  a  low  level. 
Currently  the  precise  mechanism  by  which  professional  APCs  could  acquire 
DNA-expressed  antigens  is  unknown.  It  is  possible  that  transfected  muscle  cells  or 
keratinocytes  could  produce  antigen  that  is  picked-up  by  APCs.  Alternatively,  cells 
at  the  site  of  vaccination  (e.  g.,  Langerhans  cells  -  LCs  -  in  the  dermis)  could 
undergo  direct  transfection,  or  be  transfected  by  DNA  that  moved  from  the  target 
site  through  the  blood  vessels  or  lymphatics.  Since  neither  muscle  cells  nor 
keratinocytes  constitutively  express  MHC  class  II  or  the  co-stimulatory  molecules 
required  to  activate  T-helper  (ii)  cells,  their  role  in  antigen  processing  and 
presentation  may  not  be  as  APCs,  but  they  may  still  have  a  significant  role  in  the 
expression  of  the  encoded  antigen. 
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Figure  1-7:  The  development  of  immune  responses  following  DNA 
vaccination 
Following  vaccination,  DNA  is  taken  up  into  the  nucleus  (1).  DNA  is  translated 
into  mRNA  and  the  encoded  antigens  are  then  expressed  in  the  cytoplasm  by  the 
normal  cellular  mechanism  (2).  Following  expression,  the  antigens  will  be  processed 
and  presented  on  the  cell  surface  in  the  context  of  MHC  class  I  molecule  , 
(endogenous  pathway).  The  MHC-antigen  complex  may  then  be  recognised  by 
specific  CD8+  T  cell  (3),  which  is  then  activated  and  matures,  resulting  in 
proliferation  and  cytokine  secretion  (4).  Activated  CTLs  will  initiate  apoptosis  in 
any  cells  subsequently  encountered  presenting  MHC-I-antigen  complexes,  which 
bind  to  the  TCR  in  conjunction  with  a  secondary  signal.  Antigens  from  a  DNA 
vaccine  may  be  encountered  by  professional  APCs  (5).  These  can  be  taken  up  into 
the  cell  by  endocytosis  and  processed  through  the  exogenous  pathway,  whereby 
epitopes  are  presented  on  the  cell  surface  bound  to  MHC  class  II  molecules. 
Subsequent  interactions  with  naive  CD4+  Th  cells  will  then  result  in  their  activation, 
characterised  by  proliferation  and  secretion  of  cytokines  in  order  to  co-ordinate  the 
cellular  and  humoral  immune  responses  (6).  If  aB  cell  encounters  an  antigen  to 
which  its  receptors  can  bind,  it  will  begin  to  secrete  antibody.  AT  helper  cell  with 
the  same  specificity  can  induce  aB  cell  to  mature  into  a  plasma  cell,  whilst 
proliferating  and  undergoing  class  switch  from  IgM  production  to  other  classes 
including  IgG  (7). 
58 It  is  known  that  myocytes  can  express  vaccine  antigen  following  transfection 
in  vivo,  and  that  they  constitutively  express  MHC  class  I.  Therefore  it  was  initially 
thought  that  these  cells  were  capable  of  driving  the  CD8+  activation  observed 
(Hohlfeld  and  Engel  1994).  Furthermore,  soluble  proteins,  secreted  by  myocytes  or 
released  following  cell  death,  could  stimulate  B  cells  and  CD4+  T  cells.  However, 
the  importance  of  myocytes  in  any  of  these  processes  is  currently  unclear.  They 
lack  co-stimulatory  molecules,  such  as  B7,  that  are  necessary  for  activating  naive 
CD8+  T  cells,  and  therefore  they  are  unlikely  to  directly  initiate  a  CD8+  T  cell 
response.  Nevertheless,  they  may  be  a  major  source  of  expressed  antigen.  CTL 
activation  is  thought  to  be  more-likely  driven  by  professional  APCs  that  may  be 
directly  transfected  following  immunisation.  On  trafficking  to  regional  lymphoid 
tissues,  these  cells  would  be  able  to  prime  naive  B  cells,  CD4'  T  cells  and  CD8+  T 
cells.  This  poses  no  theoretical  problem  when  considering  intradermal  vaccination 
(see  below),  given  the  numbers  of  professional  APCs  such  as  LCs  present  in  the 
dermis.  However,  muscle  tissue  is  not  well  supplied  with  professional  APCs.  An 
alternative  possibility  is  that  the  tissue  damage  caused  by  im.  vaccination  results  in 
the  recruitment  of  APCs  to  the  muscle.  These  cells  could  then  internalise  DNA  and 
express  and  present  antigen  themselves,  or  provide  secondary  signals  for  antigen 
presenting  muscle  cells;  it  is  thought  that  antigen  presentation  and  co-stimulation  do 
not  have  to  be  provided  by  the  same  cell  (Kundig  et  al.  1995). 
Some  of  the  mechanisms  that  may  be  responsible  for  this  process  are 
outlined  above  in  section  1.4.1.3,  Cross  Presentation.  It  is  still  uncertain  precisely 
which  cell  types  are  involved  in  the  generation  of  the  activated  T  cells,  but  there  is 
some  evidence  to  suggest  that  the  immune  response  may  be  modulated  by  altering 
the  cellular  localisation  of  expressed  protein  and  the  immunisation  route  (Morel  et 
al.  2004). 
59 Low  antibody  responses  seen  in  response  to  some  DNA  vaccines  suggest 
that  DNA  vaccines  drive  limited  B  cell  activation.  This  is  probably  due  to  the  low 
levels  of  antigen  expressed  by  transfected  cells  in  comparison  to  the  quantity 
delivered  by  e.  g.  recombinant  protein  vaccination  (Davis  and  McCluskie  1999). 
After  administration,  it  has  been  demonstrated  that  antigen  expression  can 
continue  for  a  significant  time  period  (Wolff  et  aL  1990).  This  low  but  ongoing 
expression  of  antigen  continuously  augments  the  immune  response  and  it  has  been 
conjectured  that  this  similarity  to  natural  infection  enhances  the  response  (Donnelly 
et  a1.1997). 
L5.4.3  Factors  Al  ecting  the  Nature  of  the  Immune  Response  Generated 
Level  of  Antigen  Expression 
There  is  a  direct  correlation  between  the  expression  level  of  secreted 
proteins  encoded  by  DNA  vaccines  and  humoral  responses,  although  there  is  no 
such  correlation  for  intracellular  proteins  (Barry  and  Johnston  1997).  The  level  of 
expression  is  also  thought  to  have  an  effect  on  the  induction  of  CTLs.  However 
whilst  increases  up  to  a  certain  level  gave  an  increased  response,  high  doses  actually 
resulted  in  a  decreased  CTL  response  (Barry  and  Johnston  1997).  It  maybe  that 
higher  levels  of  expression  resulted  in  more  rapid  killing  of  transfected  cells, 
curtailing  the  activation  of  CTLs. 
Nature  of  the  Antigen 
The  post-transcriptional  localisation  of  antigen  expressed  following  DNA 
vaccination  has  a  major  impact  on  the  subsequent  immune  response.  The  effect  of 
localisation  was  dissected  by  immunisation  using  DNA  expressing  cytoplasmic, 
secreted  or  transmembrane  ovalbumin.  Gene  gun  immunisation  with  cytoplasmic 
60 or  transmembrane  protein  led  to  strong  ovalbumin-specific  CTL  responses,  but  not 
following  immunisation  with  secretory  protein.  In  contrast,  im.  immunisation  with 
DNA  expressing  the  secretory  or  transmembrane  protein  led  to  potent  CTL  whilst 
vaccination  with  the  cytoplasmic  form  was  ineffective.  OVA-specific  antibodies 
were  detected  following  gene  gun  immunisation  with  all  three  constructs,  whereas 
only  the  secretory  construct  induced  antibody  production  following  i.  m. 
immunisation  (Morel  et  al.  2004).  These  results  demonstrate  that  the  localisation  of 
the  protein  is  central  to  the  nature  of  the  response  generated  and  indeed  whether 
any  response  is  elicited  and  that  CTL  and  antibody  responses  are  induced  by 
different  mechanisms. 
Vector  and  Promoter  Selection 
The  plasmid  vector  is  responsible  for  directing  transcription  of  the  encoded 
antigen  within  cells  transfected  during  vaccination.  The  backbone  of  the  vector  can 
be  important  due  to  the  presence  of  immunostimulatory  CpG  motifs  (see  below). 
The  other  main  significant  feature  is  the  promoter.  The  human  cytomegalovirus 
(CMV)  immediate  early  promoter  is  the  most  commonly  used  as  it  has  been  shown 
to  drive  high  levels  of  antigen  expression  in  murine  skeletal  muscle  in  vivo,  following 
either  gene  gun  or  im.  vaccination  (Cheng  et  al.  1993;  Manthorpe  et  aL  1993). 
Immunostimulatory  CpG  Motifs 
Bacterial  plasmids  used  in  DNA  vaccination  differ  from  eukaryotic  DNA  in 
several  subtle  but  important  characteristics.  Firstly,  bacterial  CpG  motifs  (cytidine  - 
phosphate  -  guanidine  dinucleotides)  are  unmethylated,  unlike  those  found  in 
eukaryotic  DNA.  Secondly,  these  motifs  are  present  at  the  frequency  predicted  by 
chance  (1  in  16  dinucleotides)  in  bacterial  DNA,  whereas  they  are  far  less  common 
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the  DNA  to  store,  replicate  and  transcribe  genetic  information,  but  can  be  exploited 
by  the  immune  system  to  differentiate  between  mammalian  DNA  and  bacterial 
DNA  (Krieg  2002).  In  particular  these  differences  are  recognised  by  TLR-9  found 
on  the  surface  of  immune  cells  (Brown  and  Corral  2002).  The  stimulatory  activity 
of  the  DNA  motifs  depends  on  the  precise  nucleotide  sequence  surrounding  each 
motif  (Krieg  et  aL  1999). 
Recognition  of  unmethylated  CpGs  is  mainly  mediated  by  DCs,  since  they 
express  high  levels  of  TLR-9.  However,  the  activity  of  B  cells,  macrophages  and 
NK  cells  are  all  directly  affected  to  some  degree.  In  B  cells,  recognition  strongly 
enhances  antigen-specific  activation  by  upregulating  co-stimulatory  molecule 
expression,  and  can  drive  T  cell-independent  class  switching.  Secretion  of  IL-6,  IL- 
10  and  immunoglobulin  are  all  upregulated.  Innate  effector  mechanisms  are 
enhanced,  such  as  phagocytosis  and  the  release  of  antimicrobial  reactive  oxygen 
species  in  macrophages,  and  NK  cytotoxicity  and  IFN-y  secretion  are  increased.  T 
cells  are  not-directly  affected,  but  can  be  more  readily  activated  due  to  the  changes 
in  APCs  (Cowdery  et  al.  1996;  Krieg  et  aL  1999;  Brown  and  Corral  2002). 
Recently,  synthetic  oligodeoxynuleotides,  containing  immunostimulatory 
CpG  motifs,  have  been  used  as  adjuvants  in  various  vaccine  strategies.  They  drive 
Thl  responses  in  mice  and  primates,  probably  due  to  the  induction  of  IL-12  and 
IFN-y  (Krieg  et  al.  1999).  In  DNA  and  protein  vaccines,  CpGs  have  been  shown  to 
be  effective  at  increasing  antibody  production,  both  systemically  and  at  mucosal 
surfaces  (McCluskie  et  al.  2001;  McCluskie  et  aL  2002;  Klinman  2003). 
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DNA  vaccination  offers  a  degree  of  flexibility  in  terms  of  the  quality  of 
immune  response  generated,  depending  on  the  means  of  administration  of  the 
vaccine.  It  has  been  shown  in  many  instances  that  immunisation  by  im.  vaccination 
can  result  in  an  immune  response  dominated  by  CD4+  cells  of  the  Thl  phenotype. 
However,  ballistic  delivery  of  DNA  into  the  dermis  can  elicit  a  Th2  dominated 
response.  Ballistic  delivery  involves  attaching  plasmid  DNA  to  microscopic  gold 
particles,  which  are  fired  into  the  skin  under  pneumatic  pressure,  using  a  device 
known  as  a  `gene  gun'.  The  different  immune  responses  generated  to  im.  and  gene 
gun  DNA  vaccination  have  been  noted  in  several  studies  (Zlei  2002;  Zhu  et  al. 
2004). 
Induction  of  Th1  responses  following  i.  m.  vaccination  has  been  partly 
explained  by  the  presence  of  immunostimulatory  CpG  motifs  on  plasmid  DNA.  In 
fact,  although  gene  gun  vaccination  has  been  shown  to  preferentially  induce  Th2 
immunity  this  bias  can  be  overcome  by  co-administering  the  vaccine  DNA  with 
large  quantities  of  CpG  motifs  (Schirmbeck  and  Reimann  2001;  Zhou  et  at  2003). 
This  potential  to  overcome  Th2  bias  could  be  exploited  in  the  therapeutic 
vaccination  of  chronic  diseases  where  an  ineffective  Th2  immune  response 
dominates. 
The  inhibitory  feedback  between  Thi  and  Th2  cytokines  can  make 
immunomodulation  of  existing  responses  difficult,  since  an  existing  Th2  cytokine 
milieu  around  naive  CD4+  T  cells  will  hinder  their  development  into  Thl  cells. 
Thus  vaccination  strategies  that  induce  strong  Thi  responses  and  specifically  prime 
CD8+  T  cell  responses,  such  as  im.  DNA  vaccines,  may  be  necessary  for  effective 
therapeutic  vaccination  (Zajac  et  al.  1998).  Immunomodulation  is  not  only 
important  in  infectious  disease,  it  can  also  be  used  to  treat  cancers  and 
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apparent  as  in  mouse  models.  Although  human  memory  T  cells  restimulated  in  the 
appropriate  cytokine  milieu  may  be  able  to  switch  Ih  phenotype,  mouse  memory 
cells  do  not  share  this  ability  (Sallusto  et  al.  2004). 
1.5.5  Prime-Boost  Strategies 
Conventional  vaccines  are  often  successful  at  generating  effective  antibody 
responses  that  can  control  or  prevent  a  wide  range  of  infections.  However,  as 
discussed  above  (see  section  1.2.2,  The  Requirement  for  New  Vaccines),  there 
remain  many  diseases  for  which  such  a  response  is  not  sufficiently  protective. 
These  include  tuberculosis,  HIV  and  malaria,  currently  the  three  infectious  diseases 
responsible  for  the  greatest  numbers  of  deaths  world-wide.  All  three  are 
intracellular  pathogens,  and  cannot  be  cleared  by  an  immune  response  lacking  a 
potent  cell  mediated  component.  Homologous  boosting  (delivering  multiple  doses 
of  the  same  vaccine  formulation)  can  often  increase  humoral  responses  to  the  level 
where  they  are  protective,  such  as  with  the  recombinant  HBsAg  of  the  HBV 
vaccine.  However,  the  strategy  of  repeatedly  delivering  the  same  vaccine  is  not 
effective  at  increasing  the  magnitude  of  CD8+  T  cell  responses. 
The  advent  of  DNA  vaccination  was  treated  with  enthusiasm  as  the  ability 
to  induce  strong  cell-mediated  immune  responses  offered  the  tantalising  prospect  of 
effective  vaccination  against  such  intransigent  diseases.  In  reality,  DNA  vaccination 
has  not  yet  lived  up  to  initial  expectations.  A  logical  progression  was  therefore  to 
combine  different  vaccination  strategies  in  heterologous  prime-boost  regimes. 
Sequential  vaccination  with  the  same  antigen  employing  different  strategies  of 
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synergistically  together  (McShane  2002). 
One  of  the  aims  of  this  project  is  to  examine  the  effects  of  boosting  a  DNA 
prime  vaccination  with  different  heterologous  boosts  and  determine  the  extent  to 
which  responses  are  enhanced.  Whilst  many  strategies  are  able  to  prime  cell 
mediated  immunity,  few  have  been  shown  to  boost  cellular  responses  effectively. 
The  response  after  a  primary  vaccination  generally  focuses  on  a  few 
immunodominant  epitopes  of  an  antigen.  It  is  thought  that  boosting  the  response 
with  the  same  antigen  allows  a  preferential  expansion  of  pre-existing  memory  T 
cells  to  these  epitopes.  When  a  different  vector  is  employed,  the  further 
development  of  responses  against  the  first  vector  is  avoided.  This  may  prevent  a 
`dilution'  of  the  response,  instead  allowing  the  immune  system  to  focus  on  the 
vaccine  antigen  itself  (Woodland  2004). 
The  successful  use  of  prime-boost  vaccination  strategies  is  dependent  on  the 
ability  of  the  boost  vaccine  to  enhance  the  primed  immune  response.  For  this  to  be 
achieved  the  boost  needs  to  be  given  proximally  to  that  of  the  prime  to  ensure  that 
memory  T  and  B  cells  residing  in  local  draining  lymph  nodes  are  stimulated.  In  the 
case  of  attenuated  vectors,  an  association  with  immune  cells  (such  as  the  uptake  by 
macrophages  of  Salmonella)  may  be  an  advantage  since  this  could  direct  antigen 
more  efficiently  to  lymphoid  tissues  and  memory  lymphocytes  (Ramshaw  and 
Ramsay  2000). 
There  are  various  examples  of  prime-boost  vaccination  displaying 
synergistically  improved  responses  (Kanellos  et  al.  2000;  Estcourt  et  aL  2002; 
McCluskie  et  al.  2002).  One  in  particular  is  the  increased  efficacy  of  BCG 
vaccination  against  tuberculosis  when  vaccination  with  the  bacteria  was  enhanced  by 
prior  administration  of  a  DNA  vaccine.  The  DNA  vaccine  alone  had  little  effect. 
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BCG  alone  in  an  aerosol  challenge  model  Protection  was  mediated  in  part  by  CTL 
activity  (McShane  2002). 
Application  of  effective  prime  boost  strategies  has  not  only  been  suggested 
for  the  development  of  new  prophylactic  vaccines  but  also  in  the  development  of 
therapeutic  vaccines.  This  type  of  vaccine  would  be  used  in  the  treatment  of  a 
chronic  infection  such  as  Hepatitis  B  in  which  activation  of  a  specific  arm  of  the 
immune  system  may  serve  to  clear  the  disease. 
1.6  Hepatitis  B  Virus 
HBV  is  an  enveloped  virus  with  an  icosahedral  core  and  double-stranded 
circular  DNA  genome.  The  virus  invades  and  replicates  within  the  liver  cells  of  the 
human  host.  Following  replication,  assembled  virus  particles  bud  from  the  cell 
surface  (Ganemn  and  Schneider  2001). 
The  virus  can  be  passed  on  through  sexual  contact  and  body  fluids  such  as 
blood,  including  untreated  blood  products.  The  high  viral  load  in  the  blood  of 
those  infected  renders  it  highly  infectious  through  contaminated  needles.  Acutely 
infected  adults  can  normally  clear  the  virus.  However,  chronic  infection  is  a 
problem  with  recent  estimates  of  350  million  people  infected  world-wide  (WHO 
1996).  As  about  25%  of  chronic  carriers  (1  million  people  each  year)  will  die  of 
chronic  active  hepatitis,  cirrhosis  or  primary  liver  cancer  there  is  an  obvious  need 
for  new  treatments  to  be  developed. 
Although,  a  useful  prophylactic  vaccine  exists,  based  on  parenteral  delivery 
of  recombinant  surface  antigen  expressed  in  yeast,  it  is  not  effective  as  a  therapeutic 
vaccine  in  chronically  infected  patients  (WHO  1996). 
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One  area  of  much  interest  over  the  last  5  years  is  the  potential  to  modulate 
the  immune  response  to  HBV  to  encourage  clearance  of  the  virus  as  persistence  is 
believed  to  be  due,  at  least  in  part,  to  modulation  of  the  immune  response  by  viral 
antigens.  Patients  who  suffer  from  a  self  limiting  disease  usually  display  evidence  of 
a  strong,  broad  Thl  response  (Chisari  and  Ferrari  1995;  Guidotti  et  al.  1996).  In 
contrast,  chronically  infected  patients  display  a  strong  humoral  response  to  the  virus 
but  usually  have  weak  CTL  activity  against  only  a  few  viral  epitopes.  This  does  not 
imply  that  the  T12  response  is  ineffectual  as  there  is  clinical  evidence  that  significant 
levels  of  circulating  antibody  are  also  necessary  for  clearance  and  to  protect  against 
re-infection  (Milich  and  McLachlan  1986;  Milich  et  at  1995).  However,  these 
humoral  responses  alone  are  not  sufficient  for  clearance  of  an  established  infection. 
Interestingly,  there  is  evidence  that  the  virus  itself  plays  a  role  in  modulating 
the  immune  response  to  prevent  effective  clearance  through  the  core  antigen.  The 
gene  for  this  protein  contains  two  in-phase  start  codons,  one  of  which  leads  to  the 
transcription  of  HBcAg,  the  other  a  protein  that  is  processed  in  the  ER  and  secreted 
from  the  cell  as  the  HBeAg.  This  antigen,  although  largely  identical  to  core  in 
sequence,  is  a  soluble  protein,  which  unlike  the  HBcAg  does  not  self  assemble  to 
form  particles.  It  has  been  demonstrated  that  this  non-particulate  form  of  the 
antigen,  is  effective  at  stimulating  a  Th2  response  which  is  less  effective  at  clearing 
the  virus  than  the  Thl  response  induced  by  the  particulate  antigen  (Nilich  et  aL 
1997).  The  high  level  of  the  HBeAg  observed  in  the  blood  stream  of  chronic 
patients  effectively  swamps  the  immune  system  with  antigen  (Milich  et  aL  1998). 
This  may  result  in  the  lack  of  a  broad  CTL  response,  which  has  been  proposed  as 
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evolutionary  strategy,  on  the  part  of  the  virus,  to  enable  chronic  carriage  and 
therefore  increase  the  likelihood  of  dissemination  to  other  hosts. 
1.6.2  Therapeutic  Vaccination  and  HBV  Infection 
A  possible  hypothesis  for  the  successful  clearance  of  HBV  infection  is  that 
hepatocytes  infected  with  the  virus  present  viral  antigens  to  CrL  which  then  trigger 
apoptosis  in  these  cells.  On  activation,  however,  the  CIL  begin  to  secrete  Thi 
cytokines  such  as  IL-12  and  IFN-y  (Rossol  et  at  1997).  The  latter  cytokine  induces 
an  antiviral  state  in  hepatocytes,  resulting  in  degradation  of  viral  RNA,  abrogation 
of  virus  assembly  and  preventing  future  infection  of  cells  (Guidotti  et  al.  1999).  As 
the  Th1  response  brings  the  population  of  infected  hepatocytes  under  control,  B 
cells  produce  neutralising  antibody  that  mops  up  circulating  virus,  preventing  re- 
infection.  Conversely,  it  may  be  that  the  poor  activation  of  CTLs  and  'M-like 
immune  response  in  chronic  carriers  prevents  them  from  clearing  the  virus  (Chisari 
and  Ferrari  1995;  Guidotti  et  aL  1996). 
If  this  hypothesis  is  correct,  it  seems  plausible  that  efforts  aimed  at  curing 
chronically  infected  patients  should  induce  a  Th1  response.  Indeed,  current 
moderately  effective  treatments,  such  as  interferon  (IFN)  and  ribavirin  therapy,  are 
effective  at  raising  Thl  responses  (Hultgren  et  al.  1998;  Michel  et  al.  2001). 
Attempts  have  been  made  to  use  DNA  vaccination  in  human  patients  to 
modulate  immune  responses  to  chronic  HBV  infection.  They  have  been  partially 
effective;  inducing  CTL  responses  and  reducing  viral  replication  (Michel  et  al..  2001), 
but  not  leading  to  full  clearance.  It  is  possible  that  these  results  could  be  improved 
using  combined  vaccination/antiviral  therapy  or  by  employing  a  heterologous 
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immunity  through  vaccination  has  been  the  historical  lack  of  safe,  effective  Th1 
adjuvants  (Moingeon  et  aL  2001).  However,  DNA  vaccines  contain 
immunostimulatory  CpG  motifs  (described  above)  that  strongly  drive  Thl 
responses.  It  is  therefore  possible  that  DNA  vaccination  will  become  central  to 
therapeutic  vaccination  strategies. 
1.6.3  Structure  and  Immunogenicity  of  the  Core  Antigen 
The  model  antigen  used  for  the  purposes  of  this  project  was  the  hepatitis  B 
core  antigen  (HBcAg),  the  capsid  protein  of  the  hepatitis  B  virus.  This  monomeric 
protein  of  approximately  21kDa  in  size  (as  shown  in  Figure  1-8)  is  capable  of  self- 
assembly  into  large  particles  when  present  in  sufficient  concentrations.  The 
assembled  particle  is  shown  in  Figure  1-9.  The  antigen  was  selected  as  a  model 
because  it  is  highly  immunogenic  and  it  provides  a  unique  opportunity  to  consider 
the  impact  of  prime  boost  strategies  on  particulate  rather  than  soluble  antigens,  as 
described  previously  in  this  laboratory  (Zlei  2002).  The  reason  for  this  comparison 
is  the  different  nature  of  particulate  and  soluble  antigen  processing  (see  section 
1.4.1).  Particulate  antigens  are  presented  with  an  efficiency  three  to  four  orders 
magnitude  greater  than  that  of  soluble  antigen  (Kovacsovics-Bankowski  et  aL  1993; 
Harding  and  Song  1994). 
The  particle  itself  is  made  up  of  many  dimers  of  the  core  protein.  During 
natural  infection,  it  forms  the  capsid  in  which  viral  DNA  and  a  DNA  polymerase 
enzyme  are  packaged.  Although  the  protein  consists  of  183  amino  acids,  only  the 
N-terminal  140  amino  acids  are  required  for  generation  of  the  particulate  structure, 
although  particle  stability  is  increased  by  inclusion  of  a  cysteine  at  position  183 
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the  nucleic  acid  binding  region  required  for  encapsulation  of  the  viral  genome.  The 
capsid  particles  can  consist  of  either  180  or  240  subunits,  forming  particles  of  320 
and  360  Angstrom  in  width,  respectively  (Wynne  et  aL  1999). 
The  polymers  are  made  up  of  many  pairs  of  individual  polypeptides.  These 
dimers  are  highly  stable  and  resistant  to  full  denaturation.  This  is  believed  to  be  due 
to  interactions  between  the  a-helices  of  the  cl  loop  (see  below)  (Bottcher  et  al. 
1997),  and  the  extensive  hydrophobic  core  of  the  protein.  A  cysteine-cysteine 
disulphide  bridge  is  formed  between  the  cc-helices  in  dimers,  but  is  not  necessary  for 
dimer  or  capsid  formation  (Wynne  et  ah  1999). 
The  major  structural  and  immunological  feature  of  the  capsid  is  a  surface 
spike.  In  the  monomer,  two  consecutive  cc-helices,  from  amino  acid  50-73  and  79- 
110,  form  a  hairpin  structure  known  as  the  cl  loop  (Wynne  et  al..  1999).  These 
associate  in  the  dimer  to  form  a  4-helix  bundle,  which  protrudes  from  the  surface  of 
the  capsid  by  about  25  Angstrom  (Conway  et  ah  1997). 
HBcAg  contains  several  highly  immunogenic  T  and  B  cell  epitopes  against 
which  strong  immune  responses  can  be  raised  (Milich  et  al.  1995).  It  can  function  as 
aT  cell-independent  antigen,  because  of  its  ability  to  activate  naive  B  cells  directly 
by  the  cross  linking  of  multiple  BCRs,  resulting  in  the  induction  of  B7  co- 
stimulatory  molecules  (Milich  et  aL  1997).  This  does  not,  however,  prevent  the 
HBcAg  from  promoting  T  helper  responses,  therefore  it  is  both  aT  cell-dependent 
and  T  cell-independent  antigen  (Milich  and  McLachlan  1986).  The  principle 
antigenic  site  of  the  protein  is  found  at  amino  acids  78  to  82  and  coincides  with  the 
tip  of  the  surface  spike  (Bottcher  et  al.  1997)  (see  Figure  1-8). 
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Figure  1-8:  Three-dimensional  layout  of  the  truncated  core  protein  monomer 
The  numbers  represent  the  amino  acid  positions  of  principles  features,  i.  e.  (:  and  N 
terminal  residues,  start  and  end  of  a  helix  regions  and  cysteine  residues  (Bottcher  ei 
al.  1997). 
71 Figure  1-9:  Assembled  HBcAg  polymer 
The  assembled  H  Bci\g  particle,  determined  at  a  resolution  of  9  Angstroms  from 
cryo-electron  micrographs  (Conway  et  al.  1997). 
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This  project  was  designed  to  fulfil  two  main  objectives. 
"  The  first  was  to  characterise  and  compare  the  immune  responses 
developed  following  intra-muscular  (i.  m)  and  gene  gun  delivery  of  a 
DNA  vaccine  consisting  of  a  plasmid  expressing  HBcAg. 
"  The  second  was  to  determine  the  effect  of  boosting  the  primary 
response  to  DNA  vaccination  through  the  use  of  heterologous  boost 
strategies. 
The  boosting  strategies  examined  included  im.  administration  of  the 
recombinant  purified  HBcAg  alone,  infra-nasal  (i.  n.  )  administration  of  the  purified 
antigen  in  combination  with  mucosal  adjuvant  LT  and  intra-gastric  (i.  g.  ) 
administration  of  an  attenuated  bacterial  vector  (S.  typhimurium  BRD  509)  that 
expresses  the  HBcAg  in  vivo. 
In  order  to  complete  this  work,  a  plasmid  capable  of  expressing  the  HBcAg 
in  eukaryotic  cells,  pcDNA3.1/core,  was  constructed  and  the  Salmonella  strain  was 
transformed  with  a  plasmid  that  would  express  HBcAg  following  invasion  of 
mammalian  cells. 
To  characterise  the  humoral  and  cell-mediated  immune  responses  induced 
by  the  different  vaccination  strategies,  assays  were  developed  which  allowed 
measurement  of  HBcAg  specific  serum  and  mucosal  antibody  production,  CD4+  T 
cell  proliferation  and  CD8+  T  cell  activation  and  killing  capacity. 
73 2  MATERIALS  AND  METHODS 
2.1  Microbiology 
2.1.1  Bacterial  Stocks 
Master  stocks  of  bacteria  were  maintained  on  microbank  beads  at  -80°C. 
Working  stocks  were  kept  in  50%  glycerol/Luria  Bertani  (LB)  broth  at  -80°C. 
Bacteria  were  streaked  out  onto  LB  agar  plates  containing  the  appropriate 
antibiotics  and  grown  at  37°C  to  confirm  resistance  and  colony  morphology  before 
use. 
2.1.2  Transformation  of  Competent  Escherichia  coil  by  Heat 
Shock 
E.  coli  XL10  Gold®  competent  bacteria  (Stratagene)  were  taken  from 
storage  at  -80°C  and  thawed  on  ice.  4p1  of  1.42M  (3-mercapto-ethanol  was  added  to 
bacteria,  which  were  incubated  on  ice  with  occasional  gentle  mixing  for  10  minutes. 
To  transform  the  bacteria,  between  0.1  and  50ng  of  experimental  DNA  was  added, 
mixed  gently  and  incubated  on  ice  for  30  minutes.  The  bacteria  were  heat  pulsed 
for  thirty  seconds  in  a  water  bath  at  42°C,  then  incubated  on  ice  for  two  minutes. 
0.9m1  of  preheated  (37°C)  LB  broth  was  added  to  each  tube  and  the  tubes 
incubated  for  1  hour  at  37°C  in  a  rotary  shaker  (-200rpm).  The  bacteria  were  then 
plated  onto  agar  plates  in  the  presence  or  absence  of  the  appropriate  antibiotics  and 
incubated  overnight  at  37°C. 
74 The  ratio  of  colonies  on  antibiotic  and  antibiotic  free  plates  gave  an  estimate 
of  transformation  efficiency.  Colonies  were  screened  by  PCR  or  by  restriction 
analysis  (see  below)  to  determine  if  the  transformation  was  successful. 
2.1.3  Making  Competent  Salmonella  typhimurium 
A  5m1  overnight  starter  culture  of  S.  tphimurium  LB5010  (galE)  was  used  to 
inoculate  a  500m1  flask  of  media.  The  culture  was  grown  to  mid  logarithmic  phase 
(OD6,  O  of  -0.5)  and  then  the  bacteria  concentrated  by  centrifugation  at  4°C,  at 
10,000g.  The  resultant  pellet  was  resuspended  in  200m1  TFB1  (30mM  sodium 
acetate,  100mM  RbCl,  10mM  CaCl2,50mM  MnCI2,15%  glycerol  in  distilled  water) 
and  incubated  on  ice  for  5  minutes.  The  bacteria  were  then  pelleted  as  described 
previously  and  finally  resuspended  in  20m1  of  TFB2  (10mM  RbCl,  75mM  CaCl2, 
10mM  MES,  15%  glycerol  in  distilled  water).  The  competent  cells  were  then 
aliquoted  into  microfuge  tubes  and  stored  at  -80°C.  When  required,  these  bacteria 
were  transformed  with  plasmid  as  described  above. 
2.1.4  Creation  of  Recombinant  Bacteriophage  P22/pGA-1 
D-galactose  was  added,  at  a  final  concentration  of  0.04%,  to  an  overnight 
culture  of  S.  1yphimurium  LB5010,  which  had  been  previously  transformed  with  the 
plasmid  pGA-1  using  the  method  described  above.  The  culture  was  then  incubated 
for  a  further  45  minutes  to  allow  uptake  of  D-galactose  and  synthesis  of  smooth 
LPS,  making  the  bacteria  susceptible  to  bacteriophage  P22  infection. 
During  this  time,  buffer  T2  (66mM  KH2PH4,69mM  NaCl,  29mM  K2SO4, 
17mM  Na2HPO4,1mM  MgSO4,55µM  CaC1.6H2O,  0.01%  gelatin  in  1L  distilled  H20) 
75 was  used  to  dilute  the  P22  stock  into  10-fold  serial  dilutions.  100µl  of  bacterial 
culture  was  added  to  tubes  containing  10µl  of  virus  for  each  dilution.  The  tubes 
were  incubated  for  1  hour  statically  at  37°C  to  allow  the  phage  to  infect  the  bacteria. 
Following  infection,  previously  melted  top  agar  (lg  tryptone,  0.8g  agar, 
140mM  NaCl  in  100m1  distilled  H20)  was  cooled  to  48°C  and  3.5m1  was  added  to 
each  bijou.  The  contents  were  poured  evenly  over  an  agar  plate.  Plates  were 
incubated  for  5-6  hours  at  37°C  until  plaques  were  visible.  A  sterile  microscope 
slide  was  used  to  scrape  off  the  top  agar  layer.  The  virus  was  then  recovered  from 
this  top  agar  by  addition  of  3m1  T2  buffer  and  200µ1  chloroform  to  the  agar  (to  kill 
any  remaining  live  bacteria)  to  the  agar.  The  tubes  were  incubated  for  30  minutes  at 
37°C  to  release  the  bacteriophage  and  then  centrifuged  for  5  minutes  at  1000g.  The 
supernatant,  containing  the  recombinant  phages,  was  recovered  and  stored  in  a  glass 
bijou,  with  5O1i1  fresh  chloroform,  at  4°C. 
2.1.5  Transduction  of  S.  typhimurium  BRD509  with 
Bacteriophage  P22 
The  recombinant  virus  was  then  used  to  transform  the  vaccine  strain  (S. 
tyßhimurium  BRD509,  attenuated  by  deletion  of  two  Am  genes  (Strugnell  et  al.  1992), 
see  Introduction  section  1.5.3.4.  Overnight  cultures  of  this  strain  were  aliquoted 
into  microfuge  tubes  to  which  different  volumes  of  the  supernatant  containing  the 
phage  were  added.  These  were  incubated  at  37°C  for  30  minutes  to  allow  infection 
and  then  spread  onto  LB  plates  containing  ampicillin/5mM  EGTA.  The  presence 
of  EGTA  in  the  media  prevents  the  virus  completing  its  life  cycle,  so  the  infected 
bacteria  are  not  lysed  by  replicating  phage. 
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EGTA  after  overnight  growth,  to  ensure  only  those  bacteria  into  which  the 
bacteriophage  had  successfully  passed  the  plasmid  of  interest  would  survive. 
2.1.6  Salmonella  Viable  Counts 
Viable  counts  of  Salmonella  were  made  to  accurately  determine  the 
relationship  between  OD  and  concentration  of  bacteria  for  the  purposes  of 
vaccination  and  also  to  determine  the  numbers  of  bacteria  recovered  from  tissue  of 
previously  inoculated  mice.  These  were  performed  by  making  10-fold  serial 
dilutions  of  the  bacterial  suspension  and  plating  10ul  volumes,  in  triplicate,  onto 
quadrants  of  agar  plates.  The  plates  were  incubated  overnight  at  37°C.  The  plates 
containing  the  highest  concentration  of  colonies  that  could  be  distinguished 
separately  were  counted  and  the  colony  numbers  recorded. 
2.2  DNA  Manipulation  and  Preparation 
2.2.1  Plasmids 
22.1.1  pGA-1 
This  plasmid,  kindly  provided  by  Medevapharma  PLC,  was  created  from 
pPV404.  The  plasmid  encodes  the  HBcAg,  under  the  control  of  the  tac  promoter. 
In  pGA-1  the  tac  promoter  is  replaced  by  the  anaerobically  activated  nirB  promoter, 
which  induces  translation  under  low  oxygen  concentration. 
77 2.2.1.2  ptr%ore 
The  plasmid  ptrc/core  was  also  received  from  Medevapharma  PLC.  The 
core  sequence  was  cloned  from  pGA-1  into  a  new  plasmid,  pKK233-2,  in  which 
expression  is  controlled  by  the  trc  promoter  which  is  activated  by  addition  of  1mM 
Isopropyl  ß-D-1-thiogalactopyranoside  (IPTG)  to  the  media. 
221.3  pcDNA3.1+ 
This  plasmid  was  obtained  from  Invitrogen.  It  has  a  eukaryotic  (CMV) 
promoter  and  carries  an  ampicillin  resistance  gene.  The  plasmid  is  shown  in  Figure 
2-1. 
2.2.2  Small-Scale  Preparation  of  Plasmid  DNA 
Small  scale  preparation  of  plasmid  DNA  from  bacteria  was  carried  out  using 
the  Qiagen  miniprep  kit.  The  protocol  for  this  kit  can  be  found  at 
http:  //wwwl 
.  giagen.  com/literature/protocols/QIAprepMiniprep.  aspx. 
The  DNA  was  eluted  in  distilled  H2O  (pre-heated  to  60°C  to  increase 
elution  efficiency).  DNA  was  stored  at  -20°C  for  subsequent  analysis  and  reactions. 
2.2.3  Polymerase  Chain  Reaction 
The  reagents  for  use  in  the  polymerase  chain  reaction  (PCR)  were  combined 
as  described  in  Table  2-1  -  PCR  master  mix. 
Template  was  acquired  from  plasmid  DNA  from  a  small-scale  preparation 
of  purified  DNA  (miniprep)  or  from  bacterial  lysates,  prepared  as  follows.  A 
freshly  grown  colony  was  picked  from  an  agar  plate  using  a  sterile  toothpick  and  the 
78 bacteria  added  to  100µ1  of  MB  grade  H20.  The  suspension  was  heated  at  90°C  for 
10  minutes  and  then  centrifuged  for  one  minute  to  pellet  the  lysed  bacteria.  10µ1  of 
the  supernatant  was  added  to  the  PCR  mix  for  each  reaction. 
The  PCR  mix  was  aliquoted  into  individual  sterile  2O0µ1  PCR  tubes  and  the 
reaction  was  carried  out  using  a  Hybaid  Genesprint  PCR  machine  under  the 
conditions  described  in  Table  2-2  -  PCR  reaction  parameters. 
2.2.4  PCR  Primers 
The  primers  used  in  this  project  are  outline  in  Table  2-3:  Cloning  and 
sequencing  primers.  All  primers  were  synthesised  by  Invitrogen. 
2.2.5  Nucleic  Acid  Endonuclease  Restriction  Digestion 
The  DNA  to  be  digested  was  added  to  the  reaction  mix  as  described  in 
Table  2-4.  The  total  volume  of  the  reaction  mixture  was  then  made  to  a  final 
volume  of  2O11  with  distilled  HZO.  The  reaction  mixture  was  incubated  for  1  hour 
at  37°C  in  a  water  bath  and  then  the  enzymes  were  inactivated  by  raising  the 
temperature  to  55°C  for  5  minutes. 
2.2.6  DNA  Purification 
Cleaning  of  DNA  (isolating  DNA  from  enzyme  reaction  mixtures  and 
resuspending  in  H2O)  was  carried  out  using  the  Qiagen  PCR  purification  protocol. 
The  method  for  this  protocol  can  be  found  at:  http:  //wwwl.  qiagen.  com/literature/ 
protocols/QlAquickSpin.  aspx 
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Figure  2-1:  Schematic  representation  of  the  plasmid  pcDNA3.1` 
This  diagram,  obtained  from  www.  inxVitrogcn.  com,  shows  the  main  features  of  the 
plasmid  including  promoter  (P(,,  ),  antibiotic  resistance  markers  (:  1mpicillin  and 
Neomycin)  origin  of  replication  (ori)  and  the  restriction  sites  in  the  multiple  cloning 
site. 
80 Reagent  Final  concentration 
lOx  DNA  polymerase  buffer  (Promega)  lx 
MgC12  1.5mM 
dNTPs  200µM 
primers  (Invitrogen)  400nM 
Tag  DNA  polymerase  (Promega)  2  units 
Table  2-1  -  PCR  master  mix 
These  reagents  were  made  up  to  a  total  volume  of  25µl  distilled  H2O  per  reaction, 
including  the  template  DNA. 
81 Stage  Cycles  Temperature  Duration 
(°C) 
11  94  60s 
2  15-30  94  20s 
55  *  30s 
72  60s 
31  72  5min 
4-4  hold 
Table  2-2  -  PCR  reaction  parameters 
*-  the  annealing  step  was  modified  depending  on  the  predicted  annealing 
temperatures  of  the  primers. 
82 Name  Function  Sense  Restriction 
sites 
Sequence 
underlined 
(start/stop 
) 
codons 
BJS  1  cloning  sense  Hind  III  TTG  GGT  GGA  AGC  TTA  CCA  TGG 
ACA  TTG  ACC  C 
BJS  2  cloning  anti  BamH  I  GCT  TGG  GGA  TCC  CTA  ACA  TTG 
sense  AGA  TTC  CCT  AG 
BJS  4  sequencing  sense  -  GCC  TTC  TGA  CTT  CTT  TCC  TTC 
(internal  core)  C 
BJS  5  sequencing  anti  -  TCG  GTC  CCG  TCG  TCT  AA 
('internal  core)  sense 
BJS  11  sequencing  sense  -  CGC  AAA  TGG  GCG  GTA  GGC  GTG 
(CMV 
promoter) 
BJS  22  sequencing  anti  -  TCT  AGC  AT  TAG  GTG  ACA  CTA 
(pcDNA3.1  sense  TAG 
post  MCS) 
Table  2-3:  Cloning  and  sequencing  primers 
83 2.2.7  Agarose  Gel  Electrophoresis 
Molecular  biology-certified  agarose  (Bio-Rad)  was  mixed  with  TBE  (9On  M 
tris,  90mM  borate,  2.5mM  EDTA)  at  2%  (w/v)  for  separation  of  PCR  products  or 
digestion  fragments  <1000bp  in  size,  or  1%  for  plasmids/fragments  >1000bp.  The 
agarose  was  melted,  allowed  to  cool  and  then  poured  into  a  gel  cast  with  l0µl  of 
1mg/ml  ethidium  bromide.  Once  the  gel  was  set,  DNA  was  mixed  with  DNA 
loading  buffer  (Sambrook  et  aL  1989)  to  give  between  50  and  500ng  DNA  per  well, 
in  a  volume  of  up  to  25µl.  1Kb  DNA  ladder  (Gibco)  was  run  alongside  the  DNA 
samples  at  1µg  per  lane,  providing  individual  marker  bands  for  accurate  sizing  of 
approximately  100ng.  Gels  were  then  run  at  80V  for  at  least  80  minutes  (depending 
on  the  size  of  the  fragments)  and  finally  visualised  under  UV  light. 
2.2.8  Ethanol  Precipitation  of  DNA 
To  precipitate  DNA  samples,  two  volumes  of  MB  grade  ethanol  were  added 
to  an  aqueous  sample  of  DNA  in  a  microfuge  tube.  0.1  volumes  of  3M  pH5.2 
sodium  acetate  was  added.  The  mixture  was  frozen  at  -80°C  for  30  minutes  and 
then  centrifuged  at  10,000g  for  30  minutes  at  4°C.  The  tube  was  washed  with  1ml 
70%  v/v  ethanol,  frozen  and  centrifuged  again.  The  DNA  could  then  be 
resuspended  in  the  appropriate  volume  and  medium. 
84 Reaction  component  Final  concentration 
DNA  200ng  -  1µg  per  reaction 
lOx  enzyme  buffer  lx  (composition  varies  with 
enzyme  and  manufacturer) 
Acetylated  BSA  2µg 
Enzyme  1µl  (10units) 
Table  2-4:  Restriction  digest  reaction  mixture  composition 
85 2.2.9  Ligation  of  DNA  Fragments 
Pre-digested  DNA  fragments  to  be  ligated  together  were  added  to  the  same 
microfuge  tube,  at  the  desired  ratio  (usually  3:  1,  insert  :  vector).  The  DNA  was 
then  ethanol  precipitated  and  resuspended  in  the  ligation  mix  (O.  51i1  T4  DNA  ligase, 
O.  5µ1  lOx  ligase  buffer,  4µl  distilled  H2O)  and  incubated  overnight  at  4°C.  The 
ligated  DNA  was  transformed  into  competent  bacteria,  which  were  screened  for  the 
recombined  DNA  by  PCR. 
2.2.10  DNA  Quantification  by  UV  Spectrophotometry 
DNA  was  diluted  in  molecular  biology  grade  water  and  measured  in  a 
spectrophotometer  (Amersham  Pharmacia  biotech  Genequant  Pro  RNA/DNA 
calculator)  at  wavelengths  of  260  and  280nm.  The  concentration  of  double 
stranded  DNA  was  calculated  as  fifty  times  the  OD2,0.  OD280gives  a  measure  of  the 
purity  of  the  sample  (Sambrook  et  al.  1989). 
2.2.11  Large  Scale  Preparation  of  DNA  for  Vaccination 
Large  scale  (-1mg)  preparation  of  plasmid  DNA  from  bacteria  was  carried 
out  using  the  Qiagen  megaprep  kit.  The  protocol  for  use  of  this  kit  can  be  found  at 
http:  //wwwl.  qiagen.  com/literature/protocols/QIAGENPlasmidPurification.  aspx. 
The  DNA  was  resuspended  in  LPS-free  Phosphate-buffered  saline  (PBS, 
0.15M  NaCI,  2.5mM  KCI,  0.15M  KH2PO4,10mM  Na2HPO4,  pH7.3)  for 
quantification  and  use  in  vaccinations. 
86 2.2.12  Preparation  of  Gene  Gun  Cartridges  for  DNA  Vaccination 
22.12.1  Precipitation  ofDNA  onto  Gold  Particles 
Gene  gun  DNA  cartridges  were  made  with  2µg  DNA  and  500µg  of  1µm 
diameter  gold  particles  per  cartridge.  Due  to  losses  during  washing  and  binding  the 
DNA,  the  final  concentration  is  approximately  1µg  DNA  per  cartridge.  100µg  of 
DNA  and  25mg  of  gold  particles  were  added  to  200µ1  0.05M  spermidine  solution. 
100µl  of  1M  calcium  chloride  was  added  slowly.  The  mixture  was  allowed  to 
precipitate  at  room  temperature  for  10  minutes  and  then  centrifuged  briefly  to  pellet 
the  gold.  The  supernatant  was  discarded  and  the  pellet  washed  three  times  in  lml 
MB  grade  100%  ethanoL 
After  the  final  wash,  the  pellet  was  resuspended  in  3.3m1  0.05mg/ml  poly 
vinyl  pyrrolidone  (PVP)/ethanol  solution. 
22.12.2  Loading  DNA-Gold  Suspension  onto  Gene  Gun  Cartridge  Tubing 
A  30  inch  section  of  gene  gun  tubing  was  connected  to  the  tubing  prep 
station,  and  nitrogen  allowed  to  flow  through  in  order  to  clear  the  tubing.  The 
DNA/gold  suspension  was  vortexed  thoroughly  and  aspirated  into  the  tubing.  The 
gold  was  allowed  to  settle  out  and  the  ethanol  withdrawn  slowly  to  give  the  tube  an 
even  coating  of  DNA/gold. 
The  tubing  was  then  left  to  rotate  whilst  drying  in  nitrogen  (0.4L  per 
minute)  for  30  minutes.  The  tube  was  then  removed  from  the  station  and  sectioned 
into  cartridges  of  0.5  inches. 
87 22.12.3  Assessment  ofDNA  Loaded  onto  Cartridges 
To  quantify  the  amount  of  DNA  on  each  cartridge,  every  10th  cartridge 
down  the  tube  length  was  removed  and  the  following  analysis  completed. 
Using  a  sharp,  large  bore  hypodermic  needle,  holes  were  punched  in  the 
base  of  O.  5µ1  microfuge  tubes.  These  were  then  placed  inside  1.5  ml  microfuge 
tubes.  One  cartridge  was  placed  into  each  of  the  small  tubes.  50µ1  of  10mM  tris 
HCl  pH8.5  was  slowly  pipetted  into  the  cartridge.  The  cartridges  were  left  at  room 
temperature  for  -3  hours  and  then  vortexed,  the  liquid  spun  out  and  collected,  and 
the  procedure  repeated  overnight  at  4°C. 
The  two  samples  for  each  cartridge  were  pooled  and  the  DNA  quantified  by 
UV  spectrophotometry  (see  above). 
2.2.13  Quantification  of  Lipopolysaccharide  in  DNA 
The  limulus  amaebocyte  lysate  (LAL)  assay  allows  the  quantification  of  LPS 
in  a  sample  in  a  kinetic  assay  by  comparison  against  a  standard  curve.  Reagents  are 
from  the  QCL  endotoxin  kit  (BioWhittiker,  Cambrex).  LPS-free  pipette  tips  and 
tubes  were  used  throughout. 
The  LPS  standard  was  reconstituted  in  LPS-free  water  and  vortexed  for  10 
minutes.  Four  tenfold,  lml  serial  dilutions  were  made  from  this  stock,  from 
50IU/ml  to  0.05IU/ml,  vortexing  each  sample  thoroughly  between  dilutions. 
Appropriate  serial  dilutions  of  samples  were  made  in  the  same  way.  Standards  were 
added  in  duplicate  to  a  96  well  plate  (Costar  3590).  Samples  were  added  to  four 
wells  for  each  dilution  to  be  tested.  Two  wells  of  each  sample  were  then  inoculated 
with  spikes  of  51U  from  the  standard  samples.  This  ensures  that  no  contamination 
88 in  the  sample  could  interfere  with  the  assay.  Blanks  were  added  to  two  wells  and 
the  plate  incubated  at  37°C  for  ten  minutes. 
When  the  samples  were  up  to  temperature,  l00µ1  of  alkaline  phosphatase 
conjugated  limulus  lysate  was  added  to  each  well  of  the  assay  plate  and  the  OD,  a5 
measured  every  2.5  minutes  over  a  period  of  90  minutes.  The  results  were  analysed 
using  the  program  Kineticalc  4  (Bio-tek  instruments). 
2.3  Protein  Analysis 
2.3.1  Antigen  and  Peptides 
HBcAg  expressed  by  Picbia  pactoris  was  purchased  from  AMS  biotec  (Cat. 
No.  R3B601). 
All  peptides  were  synthesised  by  Sigma  Genosys,  to  a  purity  of  >95%,  based 
on  epitopes  identified  by  the  references  described  in  Table  2-5,  and  modified  to 
reflect  the  sequence  of  the  HBcAg  used  in  this  thesis. 
2.3.2  Polyacrylamide  Gel  Electrophoresis  (PAGE) 
23.21  Preparation  and  Running  ofPolyacrylarnide  Gels 
All  gels  were  prepared  using  the  Bio-Rad  miniprotein  II  PAGE  apparatus. 
The  lower  12.5%  resolving  gel  was  prepared  as  described  in  Table  2-6. 
89 Peptide  Epitope  Sequence  Reference 
HBcAg  H-2b/H-2  VSFGVWIRTPPAYRPPNAP  (Milich  et  aL 
p120-140  CD4+  IL  1987) 
HBcAg  H-2b  CD8+  MGLKIRQL  (Kuhrober  et  ah 
93-100  1997) 
HBcAg  H-2d  CD8+  SYVNTNMGL  (Kuhroher  et  ah 
87-95  1997) 
Table  2-5:  HBcAg  oligopeptide  sequences 
The  sequences  of  oligopeptides  synthesised  by  Sigma-Genosis  and  used  in  ex  vivo 
restimulation  assays. 
90 Component  Composition  Volume  added 
(sufficient  for  10ml  total 
or  2  gels) 
Distilled  water  -  3.35m1 
Separating  buffer  1.5M  Tris,  0.014M  SDS,  pH  2.4m1 
8.8  with  HC1 
30%  Acrylamide  Acrylamide/bis  acrylamide  4.15m1 
29:  1 
10%  ammonium  persulphate  0.44M  60µ1 
(APS) 
Tetra  methyl  ethylene  -  5t 
diamine  (IEMED 
Table  2-6:  Composition  of  separating  gel  for  PAGE 
91 After  polymerisation,  a  4.5%  stacking  gel  was  added  and  combs  inserted 
prior  to  polymerisation  to  create  appropriately  sized  wells  (Table  2-7). 
After  polymerisation  of  this  layer,  the  comb  was  removed  and  the  gel,  still 
between  the  glass  plates,  removed  from  the  casting  rig  and  placed  in  the  PAGE  gel 
running  apparatus.  The  gel  was  submerged  in  PAGE  running  buffer  (25µM  tris, 
192µM  glycine,  3.5µM  SDS)  and  the  wells  washed  out  by  pipetting. 
Samples  were  prepared  by  mixing  with  equal  volume  of  2x  protein  sample 
buffer  (0.125M  Tris,  10%  ß-mercaptoethanol,  20%  glycerol,  4%  SDS,  0.1% 
bromophenol  blue)  and  boiled  for  5-10  minutes.  They  were  centrifuged  for 
approximately  5  seconds  to  remove  insoluble  protein/particulate  debris  and  then 
loaded  into  the  wells.  10µl  Seeblue  ladder  (Invitrogen)  was  added  to  one  well  to 
provide  size  markers.  Electrophoresis  of  the  samples  was  then  carried  out  at  200V 
for  50  minutes. 
23.22  Staining  ofPolyacrylamide  Gels 
Once  full  protein  separation  had  been  completed,  gels  were  carefully 
removed  from  glass  plates  and  immersed  in  -  50ml  Coomassie  blue  stain  (1% 
Coomassie  brilliant  blue,  45%  methanol,  10%  glacial  acetic  acid)  and  left  shaking 
gently  overnight  at  room  temperature.  To  remove  the  stain,  the  gel  was  washed 
several  times  in  destain  solution  (45%  methanol,  10%  glacial  acetic  acid)  until  the 
background  was  colourless.  For  long  term  storage,  gels  were  dried  between 
cellophane  layers  using  Gel-Dri  solution  (Novex). 
92 Component  Composition  Volume  added 
(sufficient  for  4m1/2  gels) 
Distilled  water  -  2.4m1 
Stacking  buffer  0.5M  Tris,  0.014M  SDS,  lml 
pH  6.8  with  HCl 
30%  Acrylamide  Acrylamide/bis  acrylamide  0.6ml 
29:  1 
10%  APS  0.44M  24µl 
TEMED  -  gµi 
Table  2-7:  Composition  of  stacking  gel  for  PAGE 
93 2.3.3  Western  Blotting 
23.3.1  Transfer  of  Protein  from  Polyacrylamide  Gel  onto  Nitrocellulose 
Membrane 
To  transfer  proteins  from  SDS  PAGE  gels  onto  the  surface  of  nitrocellulose 
membranes  for  analysis  by  Western  blotting,  the  following  materials  were  pre- 
soaked  in  transfer  buffer  (25mM  tris,  192mM  glycine,  20%  methanol).  These  were 
placed  in  order,  in  a  gel  holder  cassette:  a  fibre  pad,  2  pieces  of  blotting  paper,  the 
polyacrylamide  gel,  a  4x9cm  piece  of  Amersham  Hybond  C  nitrocellulose,  two  more 
filter  papers  and  the  second  fibre  pad. 
The  cassette  was  placed  in  a  miniprotein  II  Western  blot  apparatus  (Bio- 
Rad),  which  was  filled  with  transfer  buffer.  Transfer  was  then  carried  out  at  95V  for 
75  minutes  or  overnight  at  30V. 
23.3.2  Detection  of  Protein  with  Antibodies 
After  the  transfer,  the  nitrocellulose  membrane  was  washed  for  5  minutes  in 
PBS  containing  0.05%  Tween  20  (polyoxyethylene  sorbitan  monolaurate  Sigma  P- 
5927).  Non-specific  binding  on  the  filter  was  prevented  by  addition  of  3%  Marvel 
skimmed  milk  in  PBST  for  at  least  30  minutes.  The  filter  was  then  washed  twice  in 
PBST  for  5  minutes  before  incubation  with  the  primary  antibody,  diluted  typically 
to  1:  1000  concentration,  in  3%  skimmed  milk  in  PBST  for  45  minutes.  The 
nitrocellulose  was  again  washed  twice  in  PBST  then  incubated  with  an  appropriate 
secondary  antibody,  typically  at  1:  5000,  for  45  minutes.  Two  more  PBST  washes 
were  followed  by  a  final  5  minute  wash  in  PBS  without  tween.  Substrate  solution 
(30mg  4-chloro-l-napthol  tablet  (Sigma),  10m1  methanol  +  3Oµ1  H202,  in  50  ml 
PBS,  mixed  together  immediately  before  use)  was  added  and  incubated  at  RT  until 
94 bands  had  developed  to  sufficient  brightness.  The  reaction  was  then  stopped  by 
removal  of  the  substrate  by  washing  the  nitrocellulose  in  distilled  water. 
2.3.4  Detection  of  Low  Concentration  Proteins  by  Chemi- 
Luminescent  Signalling 
When  attempting  to  detect  protein  expression  in  eukaryotic  cells  driven  by 
the  DNA  constructs,  it  proved  necessary  to  add  the  solution  containing  the  protein 
sample  directly  onto  the  nitrocellulose  membrane  in  a  volume  of  no  more  than  1Oµ1 
per  sample.  This  allowed  production  of  a  concentrated  spot  of  sample.  Once  the 
samples  had  dried,  the  membrane  was  blocked  in  a  solution  of  1%  bovine  serum 
albumin  (BSA)  in  PBS  for  60  minutes  at  RT.  Antibodies  were  added  and  incubated 
and  washes  were  carried  out  as  described  for  the  normal  Western  blotting  technique 
except  that  lower  concentrations  of  antibodies  were  used,  6  washes  were  carried  out 
at  each  stage  and  3%  milk  PBST  was  replaced  in  all  cases  with  1%  BSA  PBST. 
To  enhance  the  signal  generated  a  chemiluminescent  substrate  was  added  to 
the  blot.  This  substrate  was  prepared  by  combining  equal  volumes  of  the 
luminol/enhancer  solution  and  the  stable  peroxide  solution  (Pierce),  and  was  added 
to  the  membrane  in  a  plastic  cover  for  5  minutes.  To  detect  the  released  light,  the 
developed  blot  was  then  placed  against  a  piece  of  photographic  film  (Amersham) 
and  exposed  for  60  seconds  before  developing  as  normal. 
2.3.5  Electron  Microscopy  of  HBcAg  Samples 
Samples  of  commercial  HBcAg  (Biodesign  International,  R3B601)  at  a 
concentration  of  1µg/ml  were  negatively  stained  and  examined  by  transmission 
95 electron  microscopy  with  the  technical  assistance  of  the  University  of  Glasgow 
Integrated  Microscopy  Facility. 
2.4  Tissue  Culture  Protocols 
All  centrifugation  steps  carried  out  with  eukaryotic  cells  were  at  450g  for  5 
minutes  unless  otherwise  stated.  All  incubations  were  at  37°C  with  5%CO2  in  a 
humidified  incubator. 
2.4.1  Passage  of  COS-7  Cell  Line 
COS-7  cells  are  an  African  green  monkey  kidney  epithelial  cell  line.  This  cell 
line  expresses  large  quantities  of  recombinant  antigens  from  transfected  plasmid 
DNA. 
Adherent  cells  were  grown  in  complete  DMEM  media  (cDMEM:  DMEM; 
Gibco  41965-039,10%  FCS  Harlan  Serolabs  10108-165,  L-glutamine  Gibco  25030- 
032,  penicillin-streptomycin  Gibco  15070-022),  in  25  or  75cm2  vented  tissue  culture 
flasks  (Costar).  Cells  were  split  when  -80%  confluent,  as  follows.  The  media  was 
poured  off  and  discarded.  The  cells  were  washed  in  Hanks  balanced  salt  solution 
(Sigma  H9394)  to  remove  any  residual  media  or  dead  cells  and  then  treated  with 
5m1  of  IN  trypsin  EDTA  solution  (Gibco)  made  up  in  Hanks  solution.  The  flask 
was  incubated  at  37°C  for  no  more  than  5  minutes  after  which  the  cells  could  be 
dislodged.  The  trypsin  was  inactivated  by  adding  45m1  cDMEM  and  mixing  gently. 
The  cell  suspension  was  then  centrifuged  and  the  cell  pellet  resuspended  in 
cDMEM.  To  maintain  the  cell  line,  typically,  10%  of  this  volume  was  added  to  a 
96 new  75cm2  flask,  the  final  volume  of  which  was  made  up  to  20m1  cDMEM  and  then 
re-incubated  at  37°C,  5%C02. 
2.4.2  Passage  of  Non-Adherent  Cell  Lines 
P815/c  and  RBL5/c  cells  were  used  in  CIL  assays.  Both  cell  lines  were 
kindly  provided  by  Reinhold  Schirmbeck,  Institute  of  Medical  Microbiology  and 
Immunology,  University  of  Ulm. 
Both  cell  lines  had  been  transfected  with  HBcAg  CD8+  epitopes:  P815,  an 
H-2d  mastocytoma  cell  line  expressed  an  H-2ý  epitope,  while  the  Rauscher  virus- 
transformed  T  lymphoma  line  RBL5  expressed  an  H-2b  epitope  (Kuhrober  et  aL 
1996);  (Kuhrober  et  al.  1997). 
These  lines  were  cultured  in  complete  RPMI  (cRPMI:  RPMI  1640,  Sigma 
R8055,10%FCS,  L-glutamine,  penicillin/streptomycin,  0.05mM  (3-mercapto- 
ethanol)  in  75cm2  vented  tissue  culture  flasks.  Cells  were  passaged  by  taking 
typically  10%  of  the  cell  culture,  adding  these  cells  to  a  new  flask  and  making  it  up 
to  the  previous  volume  with  fresh  cRPMI. 
2.4.3  Lipofectamine  Transfection  of  COS-7  Cells 
COS-7  cells  were  seeded  into  a  24  well  plate  at  1-5x105  cells/well,  in  1ml 
cDMEM  per  well.  The  plates  were  incubated  for  24  hours  at  37°C,  and  5%CO2. 
The  cRPMI  was  removed  from  the  wells  and  replaced,  following  a  wash  with  lml 
Hanks  solution,  with  lml  cDMEM  minus  antibiotics. 
DNA  was  added  to  lipofectamine  at  a  ratio  to  ensure  that  for  each  2p1  of 
lipofectamine  delivered  per  well,  the  complexes  contained  up  to  19g  DNA.  These 
97 complexes  were  prepared  by  admixing  50µl  of  the  DNA,  resuspended  in 
incomplete  RPMI,  with  5Oµ1  of  lipofectamine  solution.  The  mixture  was  then 
incubated  for  20  minutes  to  allow  DNA/lipofectamine  complexes  to  form.  To 
transfect  the  cells,  the  media  above  the  cells  was  removed  and  replaced  with  1O0µ1 
of  DNA/lipofectamine  mixture  per  well.  After  4  hours  at  37°C,  an  additional  900µl 
of  cDMEM  was  added  to  each  well  and  the  plates  returned  to  the  incubator  for  up 
to  72  hours. 
To  measure  the  level  of  protein  produced  from  the  DNA  vaccine,  cells  were 
recovered  from  the  wells  using  trypsin  72  hours  after  transfection.  The  cells  were 
then  lysed  using  high  speed  centrifugation  (14krpm  for  10  minutes)  and  the 
resultant  material  was  concentrated  at  least  5  fold  by  allowing  evaporation  of  the 
water.  Samples  were  then  assayed  for  the  presence  of  the  protein  by  dot-blot  as 
described  earlier. 
2.4.4  Salmonella  Invasion  Assays 
Adherent,  confluent  monolayers  of  J774  mouse  macrophages  were  prepared 
in  24-well  plates  by  seeding  at  1x105  cells/well  24  hours  before  starting  an  infection 
assay.  To  ensure  antibiotics  used  in  the  media  during  routine  passage  of  the  cells 
did  not  affect  bacterial  viability,  cells  were  washed  with  incomplete  RPMI  1  hour 
prior  to  the  start  of  the  experiment. 
10µ1  of  Salmonella  from  an  overnight  culture  were  added  per  well  (the  precise 
number  of  bacteria  was  subsequently  determined  by  preparation  of  viable  counts), 
giving  an  initial  dose  of  approximately  1x10'  bacteria  per  well.  To  bring  the  bacteria 
into  close  proximity  to  the  cell  monolayer,  the  plates  were  centrifuged  at  450g  for  5 
minutes.  Bacteria  were  then  allowed  to  interact  with  the  cells  for  2  hours  before 
98 free  bacteria  were  removed  by  washing  with  sterile  PBS.  Extracellular  bacteria  were 
killed  by  the  addition  of  incomplete  RPMI  containing  100µg/ml  gentamycin  for  a 
minimum  of  1  hour.  At  various  time  points  following  this  treatment,  monolayers 
were  washed  and  cells  lysed  with  1%  triton  X  100.  Serial  dilutions  of  the  contents 
of  each  well  were  prepared  and  plated  out  to  quantify  the  number  of  viable 
intracellular  bacteria.  These  are  expressed  as  colony  forming  units  (CFU)/ml. 
2.5  In  Vitro  Immunoassays 
2.5.1  Enzyme  Linked  ImmunoSorbent  Assays  (ELISAs) 
2.5.1.1  ELISA  to  Determine  Serum  Antibody  Levels 
Sera  were  prepared  from  blood  samples  taken  from  mice  by  hypodermic 
needle  from  the  tail  vein  or  from  cardiac  bleeds.  Serum  was  routinely  separated 
from  the  red  blood  cell  component  by  centrifugation  at  14,000rpm  for  5  minutes. 
96  well  ELISA  plates  (Corning  Costar  96  well  ELISA  plates  3590)  were 
coated  with  the  appropriate  antigen  (e.  g.  HBcAg;  Biodesign  international  R3B601, 
at  0.5µg/4  in  sodium  carbonate  coating  buffer  (O.  1M  Na2HCO3  in  distilled  water 
at  pH  8.2)  in  a  final  volume  of  50µ1/well.  The  plates  were  then  incubated  for  a 
minimum  of  2  hours  at  37°C  before  being  washed  with  PBST.  Wells  were  then 
blocked  with  150µ1/well  10%  newborn  calf  serum  (NCS;  Gibco  16010-159)  in  PBS 
and  incubated  for  another  hour  at  37°C.  Plates  were  washed  as  before  and  dilutions 
of  mouse  sera  prepared  in  10%  newborn  calf  sera.  Samples  were  tested  from  1:  50 
for  sera  (neat  for  mucosal  washes)  in  the  top  well  and  serially  diluted  by  5  fold 
increments.  This  gave  a  range  of  dilutions  from  1/50  to  '1/3.9x106.  In  addition, 
on  each  plate,  a  standard  positive  and  negative  control  sera  was  added  at  the  same 
99 dilutions.  This  allowed  direct  comparison  of  data  from  different  samples  tested  on 
the  same  day  or  samples  tested  on  different  days. 
Following  addition  of  the  sera,  plates  were  returned  to  the  incubator  for  a 
minimum  of  1  hour.  Following  careful  washing  of  the  plates  (using  PBST)  50µl 
detecting  antibody  was  added  (e.  g.  rabbit  anti-mouse  HRP  conjugated  antibody; 
Dako  P0260,  diluted  to  1:  1000  in  10%  NCS/PBS'1)  to  each  well.  The  plates  were 
again  incubated  for  a  minimum  of  1  hour  before  being  washed  and  developed  using 
50µ1  of  substrate  solution  (0.051  citric  acid,  0.125M  Na2HPO4,0.006%  H2021  1 
tablet  O-phenyldiamine-dichloride  (OPD;  Sigma  P-8287)  per  50m1).  Once  the 
maximum  colour  change  had  been  completed  (5-15  minutes),  the  reaction  was 
stopped  by  the  addition  of  50µ1  of  3M  HC1  per  well,  which  inactivates  the  enzyme. 
The  colour  change  in  the  wells  was  then  measured  and  the  absorbance  recorded. 
Plates  were  read  on  an  Elx  808  Ultramicroplate  reader  (Bio-tek  instruments 
inc.  )  at  a  wavelength  of  490nm.  The  data  were  analysed  using  the  program 
Kineticalc  4  (Bio-tek  instruments)  and  Microsoft  Excel.  Endpoint  titres  were 
calculated  as  the  reciprocal  of  the  highest  dilution,  which  gave  an  absorbance  of 
0.3U  above  the  background  absorbance  observed  in  the  negative  control  wells.  All 
titres  were  standardised  against  the  same  positive  control  sera. 
25.1.2  ELISA  to  Measure  Immunoglobulin  A  at  Mucosal  Surfaces 
These  ELISAs  were  carried  out  in  a  similar  manner  to  those  for  serum 
antibody  with  the  following  exceptions.  Firstly,  mucosal  washes  were  added  neat  to 
the  top  row  of  the  ELISA  plate  (and  then  diluted  using  5  fold  serial  dilutions  down 
the  plate,  as  with  serum  samples).  Secondly,  the  detection  antibody  used  in  these 
assays  was  an  a-chain  specific  goat  anti-mouse  biotinylated  antibody  (Sigma  B- 
100 2766)  diluted  at  1:  500.  Binding  of  this  antibody  was  subsequently  detected  using 
streptavidin-horse  radish  peroxidase  conjugate  (Dako  P0397)  added  to  the  wells  at  a 
concentration  of  1:  1000. 
2.5.1.3  ELISA  to  Determine  Lip  opolysaccharide-SpecifcAntibodyLenels 
The  coating  antigen  used  in  these  ELISAs  was  S.  typhimurium  LPS  (Sigma  L- 
6511).  This  was  prepared  by  dissolving  500µg  of  LPS  in  1m1  5x  Reggiardo's  buffer 
(0.25M  glycine,  0.5M  NaCl,  0.005M  EDTA,  0.25M  NaF)  and  then  adding  4m1 
distilled  water,  providing  antigen  sufficient  to  coat  a  single  ELISA  plate  at 
50µ1/well.  The  remainder  of  the  assay  for  detection  of  LPS  specific  antibodies  is 
otherwise  identical  to  that  described  above. 
2.5.2  Preparation  and  Culture  of  Murine  Lymphocytes 
Mice  were  killed  by  cardiac  bleed  under  terminal  anaesthesia  followed  by 
cranial  dislocation.  Spleens  and  lymph  nodes  were  then  recovered  and  stored  in  ice- 
cold  RPMI  media  until  required.  To  generate  single  cell  suspensions,  tissues  were 
placed  in  sterile  petri  dishes  and  were  crushed  using  the  blunt  end  of  a  sterile 
disposable  syringe  with  the  rubber  cap  removed.  Cells  were  then  recovered  in 
approximately  5ml  of  sterile  RPMI.  To  purify  single  cell  suspensions  from  spleen 
tissues,  the  crushed  tissue  was  additionally  subject  to  a  brief  centrifugation  step  (to 
remove  large  masses  of  debris  and  connective  tissue)  and  the  supernatants  were 
decanted  into  fresh  tubes.  The  cells  were  then  pelleted  by  centrifugation  and 
erythrocytes  removed  by  the  addition  of  iml  ACK  red  blood  cell  lysis  buffer 
(160mM  NH3,100mM  KHCO3,100mM  EDTA)  for  2  minutes.  This  reaction 
was  then  stopped  by  addition  of  5  volumes  of  RPMI  and  unlysed  white  cells 
101 recovered  by  centrifugation  at  200g  for  10  minutes.  In  contrast,  cells  from  the 
lymph  nodes  were  passed  through  sterile  100µm  nylon  mesh,  (`nytex'  Cadlish)  to 
remove  any  remaining  debris  and  adipose  tissue,  and  then  cells  pelleted  by 
centrifugation. 
Once  single  cell  suspensions  were  prepared  they  were  counted  using  a 
haemocytometer  before  being  used  in  further  applications. 
2.5.3  Magnetic  Cell  Separation  (MACS) 
In  order  to  isolate  a  particular  cell  type  from  a  population  (either  to  be  used 
as  the  sole  cell  type  in  an  assay  or  to  be  specifically  excluded  from  an  assay)  cells 
were  sorted  using  a  magnetic  cell  separation  system.  To  label  the  cells  with  the 
appropriate  magnetically  tagged  antibody,  cells  were  initially  resuspended  in  MACS 
buffer  (0.5%BSA,  2mM  EDTA  in  sterile  PBS)  at  1x10'  cells  per  9Oµ1  buffer.  l0µ1 
of  MACS  beads  bound  to  antibody  of  the  appropriate  specificity  (Miltenyi  Biotec) 
were  added  to  every  10'  cells.  The  cells  and  beads  were  incubated  together  at  4°C 
for  15  minutes.  The  cells  were  then  washed  to  remove  any  unbound  antibody  and 
the  cells  finally  resuspended  in  lml  MACS  buffer. 
A  washed  magnetic  column  (LS  130-041-306)  was  then  placed  in  the  MACS 
magnet  and  the  labelled  cell  suspension  added.  A  collection  tube  was  placed  under 
the  column  and  the  column  washed  through  with  a  minimum  volume  of  5m1  of 
MACS  buffer.  This  ensured  the  removal  of  any  unbound  cells. 
For  positive  selection,  e.  g.  T  cell  selection,  the  flow  through  was  discarded 
and  the  T  cells  collected  by  removing  the  column  from  the  magnet,  adding  5m1 
more  MACS  buffer  and  expelling  the  cells  into  a  new  collection  tube. 
102 For  positive  deletion,  e.  g.  B  cell  depletion,  the  flow  through  was  retained 
and  the  column,  containing  bound  B  cells,  was  discarded. 
The  selected  cells  were  counted,  washed  and  resuspended  in  cRPMI  for 
further  applications. 
2.5.4  Preparation  of  APCs  for  Proliferation  Assays 
25.4.1  Irradiation  ofAPCs 
Spleen  cells  were  separated  into  a  single  cell-suspension  and  irradiated  with 
2500  rads  from  a  Cobalt-60  source. 
25.4.2  Mitomycin  C  Treatment  ofAPCs 
Cells  were  treated  with  50µg  mitomycin  C  (Sigma)  per  10'  APCs  and 
incubated  for  75  minutes.  The  cells  were  washed  in  a  large  volume  of  culture 
medium  four  times  to  remove  all  traces  of  mitomycin  C  prior  to  use  in  cultures. 
25.4.3  Culture  ofMurine  DCs 
DCs  were  prepared  from  culture  of  bone  marrow  cells  prior  to  the 
proliferation  assay  (Lutz  et  al.  1999).  The  femur  was  removed  from  recently  killed 
mice  of  the  same  strain  to  be  examined  in  the  proliferation  assay.  The  marrow  was 
removed  by  washing  with  sterile  PBS  and  a  single  cell  suspension  prepared.  The 
cells  were  incubated  in  75m1  flasks  in  20m1  of  complete  RPMI  containing  2m1  GM- 
CSF  solution.  The  GM-CSF  was  a  kind  gift  of  Dr.  J.  Brewer  (University  of 
Glasgow)  and  was  obtained  from  transgenic  cell  line  supernatants  (Zal  et  aL  1994). 
Cells  were  incubated  and  fed  with  fresh  media  containing  GM-CSF  (9m1  cRPMI 
103 plus  1ml  GM-CSF)  3  and  6  days  later.  On  the  7'  day  cells  were  harvested  and  used 
as  mature  APCs  in  the  proliferation  assay. 
2.5.5  Proliferation  of  Restimulated  Lymphocytes  Measured  by 
Tritiated  Thymidine  Incorporation 
Following  preparation  of  a  single  cell  suspension  of  the  appropriate 
lymphocyte  population,  cells  were  added  to  the  wells  of  a  round-bottomed  96  well 
plate  (Corning/Costar  L6950)  at  a  concentration  of  105  cells/well  in  a  final  volume 
of  100µL  Cells  from  each  experimental  group  of  mice  were  added  to  12  wells,  to 
give  four  sets  of  triplicate  wells,  which  were  then  tested  using  3  different 
concentrations  of  restimulating  antigen.  Following  addition  of  antigen,  cells  were 
incubated  for  72  hours  and  then  pulsed  with  1  tCi  3H-thymidine  (Amersham)  per 
well.  The  plates  were  incubated  for  a  further  12-16  hours  before  harvesting. 
Cells  were  harvested  onto  a  glass  fibre  filtermat  using  an  automated  MACH 
III  cell  Harvester  (TomTec,  USA).  These  mats  were  then  dried  before  being  placed 
in  a  plastic  sample  bag  with  4m1  scintillant  and  analysed  using  a  Trilux 
MicroBetacounter  (PerkinElmer).  Measured  counts  per  minute  (cpm)  were 
generated  for  each  well  and  mean  data  and  standard  deviations  calculated  using 
Microsoft  Excel. 
2.5.6  Cytotoxic  T  lymphocyte  Killing  Assay 
25.61  SDayRestimulation 
The  appropriate  target  cells  (ie.  RBL5/c  or  P815/c,  see  tissue  culture 
protocols)  were  grown  up  in  bulk  prior  to  recovery  of  CTLs  from  immunised 
104 animals.  The  target  cells  were  centrifuged  and  resuspended  in  an  appropriate 
volume  of  cRPMI.  To  prevent  proliferation  of  these  cells,  50µg  mitomycin  C  was 
added  per  10'  cells.  The  cells  were  incubated  for  75  minutes  (37°C,  5%CO)  and 
then  washed  4  times  in  cRPMI. 
Single  cell  suspensions  of  spleen  cells  were  added  to  the  target  cells  in  25cm2 
tissue  culture  flasks  at  a  final  concentration  of  1.5x106  target  cells  and 
3x107splenocytes.  To  ensure  the  generation  of  sufficient  effector  cells,  4  or  5  flasks 
were  prepared  per  experimental  group  and  amplification  was  allowed  to  proceed  by 
incubation  of  the  two  populations  for  5  days  at  37°C,  5%CO2. 
25.6.2  S'Chtom!  um  Release  Assay 
To  label  the  target  cells,  2x10'  fresh  target  cells  and  the  same  number  of 
control  cells,  were  incubated  separately  with  5MBq  sodium  chromate  (51Cr)  each, 
for  120  minutes. 
Restimulated  cells  from  5-day  incubation  were  washed,  counted  and 
resuspended  at  1x108/ml.  These  cells  were  plated  out  in  four  rows  of  6  wells 
containing  two-fold  dilutions  from  10'  cells/well  to  1.25x106  cells/well.  To  half  of 
these  wells  105  target  cells  were  added  whilst  the  equivalent  numbers  of  control  cells 
were  added  to  the  remaining  wells.  This  gives  effector  :  target  cell  ratios  ranging 
from  100:  1  to  12.5:  1.  As  controls,  six  wells  were  prepared  which  contained  either 
no  antigen  or  effector  cells.  To  allow  estimation  of  the  uptake  of  Cr"  by  the  cells, 
three  of  these  wells  were  treated  with  10%  Triton-X100.  This  completely  lyses  the 
cells  and  releases  the  radioactivity  into  the  surrounding  media. 
The  target  and  effector  cells  were  allowed  to  interact  for  4  hours  before  25µ1 
of  media  from  above  the  cells  was  carefully  removed  and  transferred  to  a  flexiplate 
105 where  it  was  mixed  with  150µl  scintillation  fluid.  The  amount  of  radioactivity 
present  in  each  well  was  analysed  using  a  Trilux  Microbeta  plate  reader.  Percentage 
lysis  was  calculated  as: 
"  2.5.7  Cytotoxic  T  lymphocyte  IFN-y  Secretion  Assay  (ELISPOT) 
T  cells  were  isolated  using  the  pan  T  cell  MACS  beads  as  described 
previously  and  restimulated  with  target  cells  for  5  days. 
To  allow  detection  of  IFN-y  release,  a  96  well  multiscreen  plate  (Millipore) 
was  coated  with  5Oµ1  of  anti  mouse  IFN-y  antibody  (Phamiingen,  UK.  5µg/ml) 
overnight  at  4°C.  The  plates  were  the  washed  and  blocked  for  1  hour  in  cRPMI 
before  addition  of  the  restimulated  cells.  The  isolated  T  cells  were  added  in 
duplicate  wells  to  APCs  that  had  previously  been  treated  with  antigen  or  CD8+ 
peptide  and  the  volume  of  media  in  each  well  made  up  to  2O0µ1  using  cRPMI.  The 
cells  were  then  co-incubated  for  20  hours  before  removal  by  vigorous  washing. 
IFN-y  released  and  captured  was  then  detected  using  a  biotinylated  anti-IFN-y 
antibody  (Pharmingen,  UK;  1µg/4,  which  was  added  in  cRPMI  for  1  hour  at 
37°C. 
To  detect  the  bound  biotinylated  antibody  the  plates  were  treated  with 
100µ1  extravadin  alkaline  phosphatase  at  1:  1000  of  a  1.5mg/ml  solution  and 
incubated  for  1  hour.  The  plate  was  then  washed  and  5Oµ1  of  insoluble  developing 
solution  added  (30mg  tablet  of  BCIP/NBT  in  10ml  distilled  water)  to  each  well. 
Spots  then  developed  on  the  base  of  the  wells  and  were  counted  using  a  low 
106 powered  microscope  at  32x  magnification.  Mean  counts  of  triplicate  wells  were 
calculated. 
Finally,  the  number  of  antigen  specific  IFN-y  producing  cells  was 
determined  by  subtracting  the  number  of  spots  observed  in  wells  containing 
unstimulated  cells  from  those  which  had  been  stimulated  with  peptide  or  protein. 
2.6  In  Vivo  Protocols  -  Vaccinations  and  Acquisition  of 
Samples 
2.6.1  Intra-muscular  (i.  m.  )  Protein  and  DNA  Vaccination 
Mice  were  immunised  in  the  hind  quadricep  by  hypodermic  injection. 
Vaccine  DNA  or  protein  was  delivered  in  a  volume  of  l00µ1  sterile,  LPS-free  PBS, 
50µl  to  each  leg. 
2.6.2  Gene  Gun  DNA  Vaccination 
24  hours  prior  to  vaccination  the  region  of  the  skin  to  be  immunised  was 
shaved.  When  vaccinating,  the  gene  gun  was  positioned  against  the  mouse  skin, 
separated  by  a  2.5cm  spacer,  and  the  coated  gold  particles  driven  into  the  skin  using 
helium  pressurised  to  40psi 
2.6.3  Intra-Gastric  Immunisation  with  Salmonella 
S.  typhimurium  BRD  509  were  grown  statically  overnight  at  37°C.  They  were 
harvested  by  centrifugation  in  a  Sorval  SS34  rotor,  washed  in  LPS-free  PBS  and 
107 resuspended  to  5x101°  bacteria/mL  Bacteria  were  delivered  to  anaesthetised  mice 
using  a  gavage  needle  in  a  final  volume  of  2O0µ1. 
2.6.4  Collection  of  Blood  Samples 
Sample  bleeds  were  taken  from  mice  at  stages  throughout  experiments. 
Hypodermic  needles  were  used  to  extract  approximately  50µ1  of  blood  from  the  tail 
vein  of  restrained  mice.  Samples  were  allowed  to  clot  for  approximately  3  hours  at 
room  temperature  or  overnight  at  4°C.  The  samples  were  then  centrifuged  at 
10,000g  for  5  minutes  and  the  supernatant  collected.  This  serum  was  then  further 
cleaned  by  centrifugation  for  a  further  10  minutes  and  removal  of  the  supernatant 
to  a  fresh  tube.  Samples  were  stored  at  -80°C. 
If  serum  samples  were  required  at  the  end  of  the  experiment,  mice  were 
terminally  anaesthetised  with  halothane  and  exsanguinated  by  cardiac  puncture. 
2.6.5  Collection  of  Mucosal  Washes 
26.5.1  Nasal  and  Pulmonary  Washes 
Following  exsanguination,  the  trachea  of  the  mouse  was  exposed  and 
punctured.  A  sharpened,  fine  tipped  pastette  was  used  to  infiltrate  the  lungs  with 
up  to  1.5m1  of  0.1%  BSA  in  PBS.  Following  3-4  flushings,  as  much  of  the  fluid  as 
possible  was  recovered  and  used  in  subsequent  analysis. 
Nasal  washes  were  obtained  by  separating  the  head  of  the  mouse  from  the 
body  and  removing  the  lower  jaw.  A  fine-tipped  pastette  was  used  to  introduce  1ml 
of  0.1%  BSA  in  PBS  via  the  Eustachian  tube  through  the  nasal  passages  of  the 
108 mouse.  Samples  were  collected  as  this  wash  emerged  from  the  nostrils  of  the 
animal.  Samples  were  stored  at  -20°C  prior  to  analysis. 
2.6.5.2  Intestinal  Washes 
The  upper  intestine  was  dissected  from  the  body  and  separated  into  -5cm 
sections.  Digested  material  was  gently  removed  from  each  section  and  the  tissue 
was  washed  through  twice  with  1.5m1  of  PBS  containing  0.1%  BSA  and  1mM 
Phenyl-methane-sulphonyl-fluoride  (PMSF).  Samples  were  stored  at  -20°C  prior  to 
analysis. 
2.7  Statistics 
Data  were  analysed  with  Student's  two-sample  t  test  using  Microsoft  Excel. 
Differences  in  variation  were  calculated  and  taken  into  account  when  deciding 
whether  to  use  the  test  for  equal  or  unequal  variance.  The  p  values  shown  in  the 
text  indicate  the  probability  of  the  two  samples  analysed  being  different.  Values 
over  0.95  were  considered  significant. 
109 3  RESULTS  -  VACCINE  DEVELOPMENT 
3.1  Chapter  Aims 
The  aim  of  work  described  in  this  chapter  was  to  characterise  the  different 
vaccine  formulations  used  in  the  course  of  this  project.  This  includes  their 
preparation  prior  to  their  testing  in  the. 
3.2  Introduction 
Investigations  carried  out  during  the  course  of  this  project  were  based  on 
the  presentation  of  one  antigen,  HBcAg,  to  the  immune  system  using  different 
vaccination  techniques.  Whilst  some  of  these  vaccines  were  prepared  from 
commercially  available  material,  others  were  synthesised  in  the  laboratory. 
Following  production,  each  vaccine  type  required  characterisation  in  vitm,  to 
demonstrate  the  suitability  of  the  formulation  for  vaccine  delivery. 
3.3  Routes  and  Types  of  Vaccine 
Although  based  on  the  delivery  of  the  same  antigen,  this  study  aimed  to 
consider  the  type  of  immune  response  generated  when  the  antigen  is  delivered  in 
three  very  different  forms: 
"  as  a  purified  recombinant  protein, 
"  encoded  on  purified  plasmid  DNA  vaccine 
"  expressed  from  a  plasmid  DNA  carried  by  an  attenuated  strain  of 
Salmonella. 
110 In  addition,  the  antigens  were  delivered  either  parenterally  or  mucosally. 
The  different  methods  of  vaccination  used  are  described  in  Table  3-1. 
3.4  Vaccine  Formulations 
3.4.1  Purified  HBcAg  Vaccinations 
Purified  HBcAg  obtained  from  a  commercial  source  was  used  for  both 
parenteral  and  mucosal  vaccinations.  This  recombinant  protein,  obtained  from 
Biodesign  International,  (product  number  R3B601),  was  expressed  in  P.  pastoris 
from  an  expression  vector  encoding  the  entire  183  amino  acids  of  the  antigen.  The 
resultant  21kDa  protein  was  described  as  having  purity  of  >95%  and  required  only 
dilution  in  PBS  prior  to  vaccination.  However,  to  ensure  the  protein  was  as 
described  in  the  certificate  of  analysis,  it  was  additionally  analysed  prior  to  use  by 
PAGE,  Western  blot  and  by  electron  microscopy  (conducted  as  described  in 
Materials  and  Methods  sections  2.3.2,2.3.3  and  2.3.5).  Figure  3-1A  shows  that 
under  denaturing  conditions,  the  protein  can  be  seen  as  a  monomer  of 
approximately  21KDa.  Figure  3-1B  shows  that  by  Western  blot  this  protein  reacts 
strongly  with  polyclonal  anti-HBcAg  sera.  In  addition,  the  same  blot  shows  two 
additional  bands  of  approximately  42  and  64KDa.  It  is  believed  that  these  bands 
represent  dimers  and  triiners  of  the  protein.  This  indicates  the  strength  of  binding 
between  monomers,  which  treatment  with  P-mercaptoethanol  failed  to  reduce 
entirely  to  the  monomeric  form. 
111 Route  of  Vaccination  Vaccine  Formulation 
Parenteral  Intra-muscular  DNA  expressing  HBcAg 
Gene  gun  DNA  expressing  HBcAg 
Intra-muscular  Purified  HBcAg  protein 
Mucosal  Intra-nasal  Purified  HBcAg  protein 
Intra-gastric  Attenuated  Salmonella  expressing  HBcAg 
Table  3-1:  Vaccination  strategies  examined  throughout  this  project 
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Figure  3-1:  Characterisation  of  commercial  HBcAg  under  denaturing 
conditions  by  SDS  PAGE  and  Western  blot  analysis 
I,  'igurc  3-1  A  shows  different  quantities  of  I  IBcA  g  visualised  by  Coomassie  blue 
stain.  Lanes  I-5  contain  1).  25µg,  O.  Sµg,  0.75µg,  1.0µg  and  1.5µg  of  protein.  Lane 
M  contains  standard  markers. 
Figure  3-113  shows  the  binding  of  anti-HBcAg  antibody  to  the  protein.  Lanes  1-3 
contain  I.  5µ1;,  1.0µ1;  and  0.5µ1;  of  protein. 
113 To  confirm  that  the  purified  material  was  particulate  in  nature  at  the  time  of 
vaccination,  the  material  was  also  analysed  by  transmission  electron  microscopy.  A 
negatively  stained  sample  of  the  HBcAg  is  shown  in  Figure  3-2.  This  clearly  shows 
assembled  core  particles  of  the  expected  size;  approximately  350  Angstrom  (see 
Introduction  section  1.6.3,  Structure  and  Immunogenicity  of  the  Core  Antigen). 
3.4.2  Generation  of  a  Naked  DNA  Vaccine  Encoding  HBcAg 
A  DNA  vaccine  containing  the  cloned  HBcAg  sequence  under  the  control 
of  the  CMV  promoter  was  generated  using  the  Invitrogen  plasmid  pcDNA3.1+  as 
the  backbone  of  the  construct  (see  Figure  2-1). 
3.4.2.1  Plasmid  Construction 
The  sequence  of  hepatitis  B  virus  core  antigen  (HBcAg)  used  for  cloning 
was  obtained  from  the  plasmid  ptrr/core,  a  kind  gift  from  MedevaPharama  PLC.  In 
this  plasmid,  the  HBcAg  is  expressed  under  the  control  of  a  prokaryotic  promoter, 
which  allows  the  production  of  this  protein  in  bacteria. 
In  order  to  create  a  plasmid  that  could  be  used  in  DNA  vaccination,  the 
sequence  was  cloned  into  the  plasmid  pcDNA3.1  (Invitrogen  P790-20)  using  the 
strategy  outlined  in  Figure  3-3.  In  brief,  primers  were  designed  (BJS  1  and  BJS  2, 
see  Table  2-3)  that  would  amplify  the  HBcAg  DNA  and  introduce  restriction 
enzyme  cutting  sites  close  to  the  5'  (Hind  III)  and  the  3'  (BamH  I)  ends  of  the  PCR 
product.  After  removal  of  the  enzyme  and  buffer  salts  using  the  Qiagen  PCR 
purification  kit,  the  PCR  product  was  subjected  to  digestion  with  Hind  III  and 
BamH  I  (see  Materials  and  Methods  section  2.2.5).  The  digested  DNA  was  then  run 
on  a  0.8%  agarose  gel  and  the  DNA  fragment  cut  and  purified  from  the  gel  (Qiagen 
114 gel  extraction  kit).  Simultaneously,  the  vector  pcDNA3.1  was  digested  with  the 
same  enzymes  and  purified  using  the  same  method.  The  purified  HBcAg  sequence 
and  pcDNA3.1  fragments  were  combined  and  ligated  to  give  a  new  plasmid, 
designated  pcDNA3.1/core,  which  was  transformed  into  competent  E.  coli  XL10. 
Ampicillin  resistant  colonies  were  then  screened  by  PCR  for  the  presence  of  the 
HBcAg  sequence  using  specific  primers  (BJS4  and  5),  see  Figure  3-4.  Insertion  of 
the  HBcAg  sequence  was  additionally  confirmed  by  digest  of  plasmid  isolated  from 
PCR  positive  colonies.  Figure  3-5  shows  single  and  double  digests  of  both  the 
original  plasmid  (pcDNA3.1)  and  the  cloned  plasmid  pcDNA3.1/core.  Whilst  it  is 
difficult  to  observe  a  difference  of  500bp  between  the  plasmids  following 
linearisation  with  a  single  enzyme  (lanes  2  and  5),  a  fragment  of  approximately 
550bp  is  visible  when  pcDNA3.1/core  is digested  with  both  enzymes  (lane  6).  This 
corresponds  to  the  size  of  the  HBcAg  gene.  This  band  is  absent  when  pcDNA3.1 
is  similarly  digested  (lane  3).  To  verify  the  sequence  of  the  cloned  DNA,  the 
isolated  plasmid  was  sequenced.  The  data  in  Table  3-2  confirms  the  expected 
sequence  of  the  inserted  DNA. 
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Figure  3-2:  Electron  micrograph  showing  assembled  HBcAg  particles 
Transmission  electron  microscopy  of  a  negatively  stained  sample  of  commercially 
obtained  I  McAg  expressed  in  P.  pastonc,  viewed  at  8O,  000x  magnification. 
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Figure  3-3:  Schematic  showing  the  cloning  steps  involved  in  the  generation 
of  pcDNA3.1/core 
The  HBV  core  sequence  was  amplified  from  ptrc/core  by  PCR  with  modified 
primers  encoding  the  restriction  enzyme  recognition  sites  Hind  III  and  BamH  I 
flanking  the  HBcAg  reading  frame.  The  PCR  product  was  digested  with  Hind  III 
and  BamH  I  and  ligated  to  the  similarly  digested  plasmid  pcDNA3.1.  The  resulting 
construct,  designated  pcDNA3.1/core,  expresses  the  HBV  core  sequence  under  the 
control  of  a  eukaryotic  promoter. 
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Figure  3-4:  Screening  of  E.  coli  XL-10  bacteria  for  the  presence  of  HBcAg 
DNA  following  transformation  with  pcDNA3.1/core 
Following  the  transformation  of  V.  ro/i  with  the  pcDNA3.1/core  plasmid,  the 
presence  of  the  core  sequence  was  confirmed  by  PCR  using  primers  internal  to  the 
FIBV  core  sequence.  "These  primers  were  expected  to  amplify  a  band  of 
approximately  450hp,  which  was  observed  in  all  ampicillin  resistant  colonies 
screened  (lanes  1-6).  No  such  band  was  present  when  PCR  was  conducted  using 
untransformed,  ampicillin  sensitive  I;.  co/i  (lane  7). 
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Figure  3-5:  Confirmation  of  insertion  of  HBcAg  sequence  by  restriction 
digest  of  pcDNA3.1  and  pcDNA3.1/core  plasmids 
Lanes  1,2  and  3  contain  undigested,  singly  digested  (I  lind  III)  and  doubly  digested 
(Rawl  I  I)  pcl)N;  A3.1  respectively.  Lanes  4-6  contain  the  same  digests  of 
pcl)N  A3.1  /core. 
119 Position  Sequence:  top  row  pcDNA3.1  core 
bottom  row  ptrc/core 
1  ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
51  GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTTCTAGACACCG 
GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTTCTAGACACCG 
101  CCTCAGCTCTGTATCGAGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
CCTCAGCTCTGTATCGAGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
151  CACCATACTGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTGATGAC 
CACCATACTGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTGATGAC 
201  TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCTAGCAGGGATC 
TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCTAGCAGGGATC 
251  TAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAGATCAGGCAACTA 
TAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAGATCAGGCAACTA 
301  TTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGAGAGACTGTACTTGA 
TTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGAGAGACTGTACTTGA 
351  ATATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
ATATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
401  CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
451  CGACGGGGCCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
CGACGGGGCCGAGGCAGGTCCCCTAGAAGAGAACTCCCTCGCCTCGCAAG 
501  ACGCAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTAGGGAATCTC 
ACGCAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTAGGGAATCTC 
551  AATGTTAG 
AATGTTAG 
Table  3-2:  Sequence  analysis  of  cloned  HBcAg  in  pcDNA3.1/core 
This  table  shows  a  comparison  of  the  cloned  sequence  with  that  of  the  known 
sequence  from  the  ptrr/core  plasmid.  The  sequence  shown  in  the  top  row  is  that  of 
pcDNA3.1/core  and  that  in  the  bottom  row  is  ptn?  /core.  The  sequences  are 
identical. 
120 3.4.22  Expression  ofHBcAg  from  pc)NA3.1/core  in  Eukaryotic  Cells 
As  expression  of  the  core  antigen  in  eukaryotic  cells  is  a  prerequisite  for  the 
vaccine  to  function,  it  was  necessary  to  determine  whether  the  newly  synthesised 
pCDNA3.1/core  plasmid  was  able  to  express  antigen  in  vita.  This  was 
demonstrated  by  transformation  of  COS-7  cells  with  pcDNA3.1/core  using 
lipofectamine  (see  Materials  and  Methods  section  2.4.3).  Initially,  cellular  samples 
were  subject  to  standard  PAGE  gel  and  Western  blot  analysis.  However,  these 
experiments  failed  to  reveal  any  expression  of  the  antigen.  To  improve  the 
sensitivity  of  the  assay,  lysed  cellular  debris  was  dotted  directly  onto  nitrocellulose 
membranes  and  a  chemiluminescent  secondary  antibody  used  in  the  staining 
procedure  (section  2.3.4).  Using  this  method,  the  sensitivity  could  be  improved 
from  a  lower  limit  of  approximately  500ng  using  standard  Western  blot  to  between 
1-10ng  using  the  dotblot.  Comparison  with  samples  of  the  commercial  HBcAg 
showed  that  cells  transfected  with  pcDNA3.1/core  were  able  to  express  around  5ng 
of  protein  per  104  transfected  COS-7  cells  (Figure  3-6). 
Confirmation  that  this  plasmid  could  direct  the  expression  of  antigen  in 
eukaryotic  cells  suggested  that  the  DNA  generated  could  function  as  an  effective 
DNA  vaccine.  Immune  responses  to  DNA  vaccination  via  two  routes  of 
immunisation  were  to  be  considered;  i.  m.  and  by  particle  bombardment  with  a  gene 
gun- 
3.4.2.3  Large  Scale  Preparation  ofDNA 
Large  quantities  of  pcDNA3.1/core  were  required  for  use  in  vaccination 
experiments.  Following  confirmation  of  eukaryotic  expression,  a  large-scale 
preparation  of  the  plasmid  was  undertaken.  Using  a  Qiagen  Megaprep  Kit  plasmid 
was  isolated  and  then  characterised  by  digestion  with  Hind  III  and  BamH  I  to 
121 confirm  the  presence  of  the  core  sequence.  The  DNA  isolated  quantified  by  UV 
spectrophotometry.  Table  3-3  shows  typical  values  recorded  for  the  purity  and 
concentration  of  the  DNA  sample  by  W  spectrophotometry.  From  a  culture  of 
500ml,  approximately  1-2mg  of  DNA  was  generated.  This  procedure  was  carried 
out  on  several  occasions  and  each  batch  was  characterised  as  described  above. 
3.4.24  Measurement  ofLPS  Contamination  ofDNA 
To  determine  the  level  of  LPS  present  in  the  purified  plasmid 
pcDNA3.1  /core,  LAL  assays  was  performed  on  each  batch  of  DNA  prepared  (see 
Materials  and  Methods  section  2.2.13).  Results  of  these  tests  showed  that  the 
plasmid  produced  was  clean  and  uncontaminated  (less  than  O.  lIU/100ug  of  DNA). 
3.4.25  Preparation  of  Gene  Gun  Cartridges 
In  brief,  purified  DNA  was  bound  to  l  pm-diameter  gold  particles,  which 
were  then  attached  to  the  inside  of  a  hollow  plastic  tube  (external  diameter 
approximately  2mm)  using  a  special  rotating  apparatus  to  ensure  an  even  coating  of 
particles.  Following  attachment,  the  tubing  was  cut  into  8mm-long  sections,  which 
could  then  be  used  as  cartridges  in  the  gene  gun.  The  method  is  more  fully 
described  in  Materials  and  Methods  section  2.2.1.1. 
The  DNA  attached  to  the  cartridges  was  quantified  by  soaking  the  prepared 
cartridges  in  Tris/HC1  overnight.  The  resultant  supernatant  was  analysed  by  UV 
spectrophotometry.  Typical  results  of  this  analysis  are  shown  in  Table  3-4  and 
confirm  that  approximately  1  µg  of  each  vector  was  bound  per  cartridge. 
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Figure  3-6:  Expression  of  HBcAg  in  COS  7  cells 
1,  'xpressi<on  of  antigen  in  cells  transfected  with  either  pclNA3.1/core  (sample  a), 
pclNA3.  l  (sample  b)  or  untransformed  cells  (sample  c).  I?  xpression  detected  by 
polyclonal  mouse  anti-  Ii  BcAg  and  rabbit  anti-mouse  HRP  detected  with  chemi- 
luminescent  substrate.  V  ach  sample  represents  _104  hosed  cells.  The  standard 
represents  different  quantities  of  commercial  I  IBcAg  dotted  onto  the  membrane. 
123 Sample  OD260  OD2so  OD2601280  Concentration 
(of  100x  dilution)  (of  100x  dilution)  of  neat  sample 
(mg/ml) 
pcDNA3.1  0.354  0.187  1.893  1.77 
pcDNA3.1/core  0.468  0.252  1.857  2.34 
Table  3-3:  Spectrophotometric  analysis  of  DNA  samples  prepared  by  Qiagen 
Megaprep 
Two  typical  examples  of  calculated  concentrations  of  DNA  purified  from  a  500ml 
overnight  culture  of  bacteria  are  given  here.  Values  were  calculated  using  the 
following  formula: 
Concentration  (ng)  =  5OxOD2. 
The  level  of  protein  contamination  of  the  sample  is  calculated  by:  OD,,  =  OD.  o. 
Protein  contamination  of  the  sample  leads  to  significantly  reduced  values  and 
renders  the  concentration  calculation  invalid.  A  value  of  1.8  in  a  DNA  sample  is 
considered  to  be  uncontaminated  (Sambrook  et  aL  1989).  This  shows  the  DNA 
produced  was  of  high  quality. 
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cartridge 
number 
OD260  ODsso  DNA 
recovered 
Group  mean 
(µg),  standard 
deviation 
pcDNA3.1/core  1  0.206  0.161  1.03  1.102,0.174 
2  0.297  0.126  0.985 
3  0.185  0.126  0.925 
4  0.266  0.171  1.33 
5  0.248  0.181  1.24 
pcDNA3.1  1  0.264  0.192  1.32  0.975,0.179 
2  0.222  0.174  1.11 
3  0.193  0.139  0.965 
4  0.220  0.166  1.1 
5  0.145  0.131  0.725 
Table  3-4:  Measurement  of  DNA  from  gene  gun  cartridges 
DNA  was  recovered  from  cartridges  by  overnight  treatment  with  Tris/HCL  DNA 
recovered  was  calculated  as  [ODo]x50  =  [DNA  concentration]  tg/mL  Samples 
were  1  O0µ1  volume. 
125 3.4.2.6  Attenuated  Salmonella  Vaccine  Expressing  HBcAg 
The  S.  typhimurium  strain  used  in  these  studies  contained  two  attenuating 
deletions  in  the  aroA  and  aroD  genes  (strain  designated  as  BRD509).  Expression  of 
HBcAg  was  driven  from  the  plasmid  pGA-1,  which  encodes  the  protein  under  the 
control  of  an  anaerobically  induced  promoter  (nirB).  As  pGA-1  was  provided  in  the 
first  instance  in  E.  coli,  the  first  part  of  this  work  involved  the  transfer  of  the 
plasmid  into  the  Salmonella  strain. 
3.4.2.7  Generation  of  the  Salmonella  typhhnurium  Vaccine  Strain 
Two  considerations  rendered  the  transformation  strategy  somewhat 
complex.  The  first  involved  the  need  to  avoid  degradation  of  the  plasmid  by  the 
Salmonella  due  to  inappropriate  methylation.  To  achieve  this,  the  plasmid  was 
initially  transformed  into  an  intermediate  strain;  S.  typhimurium  LB5010  (Bullas  and 
Ryu  1983),  a  recA"  strain  that  is  unable  to  degrade  the  plasmid,  but  is  able  to 
methylate  progeny  plasmids  appropriately  for  Salmonella.  This  has  been  described 
previously  as  a  successful  method  for  the  production  of  Salmonella  vaccine  strains 
(Londono  et  al.  1996).  This  transformation  was  achieved  by  heat-shock  of  S. 
pphimurium  LB5010,  followed  by  selection  of  the  transformed  strain  on  agar 
containing  ampicillin. 
The  second  problem  was  the  maintenance  of  the  LPS  phenotype  of  S. 
typhimurium  BRD509  during  transformation.  Straightforward  heat-shock 
transformation  can  occasionally  result  in  the  loss  of  the  O-antigen  region  of  the  LPS 
in  the  recipient  bacterial  strain.  This  gives  the  bacteria  a  `rough'  phenotype  and 
allows  antibodies  and  complement  to  bind  to  the  bacteria  enabling  rapid  clearance 
and  reduced  exposure  of  the  antigen,  rendering  the  vaccine  less  effective  (Ernst  et  al. 
2001;  Freudenberg  et  ah  2001).  Therefore  an  alternative  method  of  transformation 
126 was  employed;  the  Salmonella  specific  bacteriophage  P22  was  used  as  a  transfer 
vector  between  the  two  strains  (as  previously  described  by  (Miller  et  al.  1989). 
Transformed  S.  fy  imurium  LB  5010  were  infected  with  the  phage.  Due  to  the 
random  nature  of  the  packaging  of  DNA  into  virus  particles,  some  of  the  resultant 
phage  particles  contain  the  plasmid  instead  of  the  P22  genome.  The  packaged 
DNA  was  then  used  to  infect  BRD  509  and  any  infectious  particles  were  prevented 
from  replication  by  addition  of  EGTA  to  the  medium.  Those  bacteria  in  which 
plasmid  had  been  successfully  injected  were  then  identified  by  their  ability  to  grow 
on  plates  containing  ampicillin.  The  presence  of  the  plasmid  within  these  clones 
was  confirmed  by  PCR 
3.4.2.8  Characterisation  of  S.  typhimurium  BRD509  PGA-1 
To  verify  that  this  transformed  strain  (designated  BRD509  PGA-1)  was  able 
to  express  HBcAg,  the  recombinant  bacteria  were  grown  under  anaerobic 
conditions  and  antigen  expression  confirmed  by  Western  blot  (Figure  3-7).  The 
band  identified  by  HBcAg  specific  sera  was  approximately  28kDa  in  size.  This  is 
larger  than  previously  observed  HBcAg  from  P.  pastorir  (see  Figure  3-1)  and  reflects 
the  addition  of  a  number  of  amino  acids  upstream  of  the  start  codon  of  the  protein. 
These  codons  do  not  affect  particle  formation  but  have  been  shown  to  enhance  the 
level  of  expression  of  the  recombinant  protein  in  E.  coli  (D.  Rowlands,  personal 
communication). 
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Figure  3-7:  Expression  of  HBcAg  from  S.  typhimurium  BRD509  pGA-1 
Anaerobic  overnight  cultures  of  S.  lyphimuri»m  BRll509  pGA-1  were  grown  and  a 
volume  of  culture  that  would  give  an  ()D5  reading  of  0.5  was  centrifuged  and  the 
pellet  resuspended  in  protein  sample  buffer.  't'hese  samples  were  run  on  a  30°% 
acrylamide  gel,  transferred  to  nitrocellulose  and  visualised  using  polyclonal  mouse 
anti-H13cAg  antibody  and  II  RP-  conjugated  rabbit  anti-mouse  antibody.  Samples  1 
-5  are  S.  /yphimurinm  1381)5O9  pGA  1.  Sample  6  is  ß8D509  without  the  plasmid. 
128 To  ensure  that  the  LPS  profile  of  the  transformed  bacteria  was  intact,  the 
bacteria  were  treated  with  proteinase  K  to  remove  the  protein  component  and  the 
remaining  material  was  subject  to  SDS  PAGE.  The  resultant  gel  was  silver  stained 
and  the  results  shown  in  Figure  3-8.  This  figure  shows  the  banding  pattern 
associated  with  smooth  LPS  structure  of  S.  t)phimurium  with  typical  core  and  0 
antigen  sugars  visualised.  Comparison  of  the  market  lanes  (LPS  samples  lacking  0 
antigen)  with  lane  1  (the  original  vaccine  strain  BRD509)  illustrates  the  typical 
ladder  feature  associated  with  0  antigen  expression.  From  this  figure,  it  would 
appear  that  no  differences  exist  between  the  LPS  profiles  of  BRD509  and  LPS  from 
the  transformed  strain  BRD509  pGA-1  (lanes  2  and  3).  Therefore  S.  typhimurium 
BRD509  pGA-1  has  not  lost  the  0  antigen  and  has  maintained  the  smooth 
phenotype  of  BRD509. 
To  show  that  the  transformed  bacteria  were  still  able  to  invade  and  persist  in 
eukaryotic  cells,  an  invasion  assay  in  a  macrophage  cell  line,  J774,  was  conducted 
using  a  similar  protocol  to  that  described  previously  (Jones  et  al.  1993).  Over  a 
period  of  72  hours,  the  number  of  viable  bacteria  recovered  from  infected  J774 
macrophages  was  recorded.  These  data  are  shown  in  Figure  3-9  and  indicates  that 
the  presence  of  the  pGA-1  plasmid  within  the  Salmonella  strain  does  not  affect  the 
ability  to  both  invade  and  persist  in  this  cell  line.  Invasion  of  around  1%  of  the 
original  inoculum  occurs  with  both  strains  within  the  first  2  hours  (and  is  in  line 
with  similar  studies  using  this  strain  in  the  literature  (Carlson  et  al.  2000))  and  this 
level  was  maintained  during  the  remaining  72  hours. 
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Figure  3-8:  Silver-stained  polyacrylamide  gel  comparing  LPS  from  samples  of 
S.  typhimurium  BRD509  and  S.  typhimurium  BRD509  pGA-1 
This  gel  confirmed  that  the  I.  PS  profile  is  unchanged  in  V.  typhinrurium  BR1)509 
following  transformation  with  bacteriophage  P22  containing  the  plasmid  pGA-1. 
Lane  1  contains  ITS  from  BR1)509,  lanes  2  and  3  contain  BRD509  pGA-1  ITS.  NI 
arc  markers  containing  I,  PS  without  0  antigen. 
130 Figure  3-9:  Number  of  bacteria  recovered  from  infected  J774  cells  over  time. 
Following  infection  of  J774  cells  with  the  S.  typhimurium  BRD  509  strains,  non- 
infecting  bacteria  were  killed  with  the  addition  of  gentamycin.  At  2,24,48  and  72 
hours  after  infection,  cells  were  taken  and  lysed,  the  lysates  plated  out  after  serial 
dilution  to  give  the  number  of  infecting  bacteria.  0  represents  BRD509  and 
represents  BRD509  pGA-1. 
131 Characterisation  of  S.  typhimurium  BRD509  pGA-1  clearly  demonstrates  that 
the  bacteria  are  able  to  express  HBcAg  and  possesses  a  smooth  LPS  phenotype. 
The  vaccine  is  therefore  judged  as  being  suitable  for  in  vivo  vaccination  experiments. 
3.5  Summary 
The  work  described  in  this  chapter  describes  the  characterisation  of  each 
vaccine  type  in  vitro.  It  shows  that  each  vaccine  behaved  as  expected  and  could 
subsequently  be  used  with  some  confidence  for  in  vivo  experiments. 
132 4  RESULTS  -  ASSAY  DEVELOPMENT 
4.1  Chapter  Aims 
The  aim  of  the  work  described  in  this  chapter  was  to  develop 
immunological  assays  capable  of  measuring  both  humoral  and  cellular  immune 
responses  to  HBcAg  following  vaccination  of  mice.  Optimisation  of  the  procedures 
used  ensured  the  reproducibility  and  sensitivity  of  the  assays. 
4.2  Introduction 
As  the  overall  objective  of  this  thesis  was  to  determine  the  influence  of 
route  and  form  of  immunisation  on  the  magnitude  and  quality  of  the  immune 
response  induced,  it  was  necessary  from  the  outset  to  define  which  aspects  of  the 
immune  response  should  be  measured.  As  the  emphasis  was  on  vaccine  design,  it 
was  felt  that  such  measurements  be  limited  to  aspects  of  the  acquired  immune 
response,  in  particular,  to  aspects  of  both  the  cellular  and  humoral  response.  The 
work  outlined  in  this  chapter  describes  the  assays  chosen  for  measurement  of  these 
responses  and  the  modifications  made  in  order  to  maximise  the  sensitivity  and 
reproducibility  of  each  method. 
4.3  Humoral  Immune  Responses 
Antibodies  generated  by  B  cells  have  a  vital  role  in  combating  infection  and 
protecting  the  host,  through  a  number  of  functions  including  neutralisation  and 
opsonisation  of  pathogens,  activating  complement  and  inducing  NK-mediated 
133 killing  of  infected  cells.  Antibody  responses  are  important  in  the  control  of 
pathogens  and  toxins  in  the  extracellular  spaces  of  the  body,  including  the  mucosal 
surfaces,  but  through  NK-mediated  killing  can  also  attack  intracellular  pathogens 
(see  Introduction  section  1.4.3). 
One  of  the  oldest  and  simplest  forms  of  measuring  an  immune  response  is 
to  assay  the  quantity  of  serum  antibody  against  a  particular  antigen.  The  assay  used 
to  measure  serum  antibody  levels  was  an  ELISA. 
4.3.1  Development  of  an  HBcAg-Specific  ELISA 
The  sensitivity  and  reproducibility  of  an  antigen  specific  ELISA  can  be 
affected  by  a  number  of  factors,  which  were  considered  when  optimising  this  assay. 
These  include: 
a)  The  initial  concentration  of  coating  antigen  added  to  the  wells  of  the  assay 
plate.  Insufficient  antigen  bound  to  the  surface  of  the  well  will  reduce  the 
upper  detection  limit  of  the  assay,  even  when  the  quantity  of  antibody  in  the 
sample  is  still  increasing. 
b)  The  coating  buffer,  in  which  the  coating  antigen  is  suspended,  can  affect  the 
quantity  of  antigen  bound  to  the  plate;  some  antigens  fail  to  bind  effectively 
to  plastic  at  neutral  pH's,  binding  more  effectively  in  alkaline  conditions. 
c)  The  selection  of  blocking  agent.  This  prevents  the  non-specific  binding  of 
unrelated  antigens  to  the  surface  of  the  well.  An  inappropriate  choice  of 
blocking  buffer  can  allow  other  antigens  to  bind,  potentially  increasing  the 
background  levels  of  substrate  colour  change  and  decreasing  the  overall 
sensitivity  of  the  assay. 
134 d)  Concentration  of  horseradish  peroxidase  (HRP)  conjugated  secondary 
antibody.  HRP  is  the  enzyme  that  catalyses  the  change  of  colour  when  the 
reaction  substrate  (0-phenyl  diamine  -  OPD)  is  added.  Since  the  colour 
change  is  proportional  to  the  quantity  of  HRP  present,  it  is  essential  to  use 
sufficient  to  allow  full  detection  of  antigen-specific  antibody  bound  to  the 
wells. 
These  variables  were  examined  to  determine  the  optimal  conditions  that 
would  allow  clear  and  consistent  assessment  of  antibody  concentrations  in  different 
samples.  In  these  optimisation  experiments,  a  polyclonal  mouse  anti-HBcAg 
antibody  raised  by  i.  m.  vaccination  of  mice  with  HBc-Ag  in  alum  was  used.  This 
was  known  to  contain  a  high  concentration  of  antigen  specific  antibody  and  was 
therefore  easy  to  detect. 
For  all  experiments,  the  ELISA  was  performed  as  described  in  Materials  and 
Methods  section  3.5.1.1,  with  variations  outlined  below. 
4.3.1.1  Coating  Antigen  Concentration 
Wells  were  coated  with  a  range  from  0  to  1µg/ml  of  the  coating  antigen, 
HBcAg.  As  the  concentration  of  the  coating  antigen  bound  to  the  well  is  also 
dependent  on  the  buffer  in  which  the  antigen  is  added,  the  antigen  was  coated 
independently  into  different  plates,  the  first  using  carbonate  buffer  as  the  diluent 
and  the  second  using  PBS.  The  plates  were  blocked  in  10%  NCS  and  polyclonal 
mouse  anti-HBcAg  was  added  at  2µl/well.  After  incubation,  a  secondary  antibody 
(rabbit  anti-mouse  HRP  conjugated  antibody)  was  added  at  a  1:  1000  dilution. 
Following  addition  of  the  substrate,  colour  was  allowed  to  develop  before  the 
addition  of  acid  to  stop  the  enzyme  activity.  The  colour  change  in  the  wells  was 
then  measured  at  a  wavelength  of  490nm  and  the  absorbance  recorded. 
135 From  this  experiment,  it  appears  that  0.5µg  HBcAg  saturated  the  wells  of 
the  plate.  Figure  4-1  shows  the  effect  of  coating  the  wells  of  the  ELISA  plate  with 
different  concentrations  of  HBcAg.  Figure  4-1A  shows  the  absorbance  from  wells 
coated  with  antigen  in  carbonate  buffer  and  4-1B  shows  that  of  wells  coated  using 
PBS.  The  choice  of  buffer  had  a  small  impact  on  the  assay  sensitivity,  with  those 
wells  coated  with  HBcAg  in  carbonate  buffer  showing  a  higher  OD 
4.3.1.2  Selection  of  BlockingBui7er 
For  blocking  of  non-specific  binding  to  the  wells,  two  buffers  were 
considered;  Newborn  Calf  Serum  (NCS)  and  BSA.  Wells  were  coated  with  0. 
5  tg/ml  HBcAg  in  carbonate  buffer.  Two  plates  were  then  blocked;  one  with  10% 
NCS  and  one  with  1%  BSA,  for  1  hour  at  37°C.  The  results  are  shown  in  Figure  4- 
2A  (NCS)  and  4-2B  (BSA).  These  indicate  that  the  buffers  function  similarly  well. 
Since  the  NCS  was  relatively  inexpensive  compared  to  BSA,  10%  NCS  was  used  as 
the  blocking  agent  in  all  subsequent  work. 
4.3.1.3  Concentration  ofAnti  Mouse  HRP  Conjugated  Antibody 
To  determine  the  effect  of  varying  the  concentration  of  the  conjugated 
antibody,  various  concentrations  ranging  from  1:  250  to  1:  5000  were  used  to  detect 
the  mouse  antibody  bound  to  HBcAg  on  the  plates.  Over  the  range  of  dilutions 
examined,  a  dilution  of  1:  1000  was  shown  to  provide  greatest  sensitivity. 
136 Figure  4-1:  Impact  of  coating  antigen  concentration  and  buffer  on  HBcAg- 
specific  ELISA 
Wells  were  coated  with  different  concentrations  of  coating  antigen  (HBcAg)  in 
carbonate  buffer  (Figure  4-1A)  or  PBS  (Figure  4-1B)  and  blocked  with  NCS. 
HBcAg  was  bound  with  polyclonal  anti-HBcAg  sera  and  detected  with  a  1:  1000 
dilution  of  HRP  conjugated  secondary  antibody.  "  represent  ODs  from  reactions 
containing  secondary  antibody  at  a  1:  1000  dilution.  o  represent  ODs  from 
reactions  without  secondary  antibody. 
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Figure  4-2:  Impact  of  blocking  agent  on  HBcAg-specific  ELISA 
Wells  were  coated  with  different  concentrations  of  HBcAg  in  carbonate  buffer, 
blocked  with  10%  NCS  (Figure  4-2A)  or  1%  BSA  (Figure  4-2B).  HBcAg  was 
bound  with  polyclonal  anti-HBcAg  sera  and  detected  with  a  1:  1000  dilution  of 
HRP-conjugated  secondary  antibody.  Negative  control  values  (no  anti-HBcAg  sera 
added)  were  subtracted  from  the  values  shown.  "  represent  ODs  from  reactions 
containing  secondary  antibody  at  a  1:  1000  dilution.  o  represent  ODs  from 
reactions  without  secondary  antibody. 
138 4.3.1.4  Optimised  HBcAg-Specific  ELISA 
To  summarise,  the  final  ELISA  assay  consisted  of  plates  coated  with  50µ1  of 
0.5µg/ml  HBcAg  in  sodium  carbonate  buffer.  Plates  were  blocked  with  10%  NCS. 
After  the  test  antibody  samples  had  been  added,  secondary  antibody  was  added  to 
wells  at  a  dilution  of  1:  1000.  The  plates  were  developed  with  OPD  substrate  and 
the  OD  490  was  measured.  Between  each  step  plates  were  incubated  for  2  hours  at 
37°C  and  washed  thoroughly  in  PBST.  The  full  protocol  is  detailed  in  Materials  and 
Methods  section  2.5.1.  Data  were  analysed  using  Microsoft  Excel  and  variations 
between  separate  ELISA  plates  were  corrected  using  the  titres  of  a  standard  positive 
controL 
4.3.2  ELISA  Subtype  Assay 
The  method  for  measuring  titres  of  individual  IgG  subtypes  was  similar  to 
that  of  the  total  immunoglobulin  ELISA.  The  main  difference  was  the  use  of 
subtype-specific  secondary  antibodies:  anti-IgGl  and  anti-IgG2a.  These  antibodies 
were  biotinylated,  so  the  plates  were  additionally  incubated  with  1:  1000  dilution  of 
streptavadin-HRP  for  an  hour  at  37°C  prior  to  the  final  wash.  The  anti-isotype 
antibodies  were  added  to  wells  at  dilutions  of  1:  5000  for  IgG1,  and  1:  2500  for 
IgG2a,  as  these  antibodies  had  been  shown  in  previous  studies  performed  in  this 
laboratory  to  have  a  slightly  different  avidity  for  each  isotype.  The  dilutions  used 
have  been  calculated  as  capable  of  detecting  the  equivalent  amount  of  each  of  the 
respective  IgG  isotypes  in  a  mixed  population. 
139 4.3.3  Measurement  of  HBcAg-Specific  IgA 
Immunoglobulin  A  (IgA)  is  a  class  of  antibody  important  in  protecting 
against  infection  and  pathology  at  mucosal  surfaces,  as  described  in  the 
Introduction,  section  1.4.3.  In  order  to  develop  an  ELISA  that  could  be  used  to 
determine  the  IgA  levels  in  different  samples,  it  was  necessary  to  a)  employ  a 
method  that  would  discriminate  between  IgA  and  other  immunoglobulins  and  b) 
obtain  a  positive  control  IgA  sample  that  would  allow  comparison  between  ELISA 
plates.  In  order  to  generate  a  positive  control  for  IgA-specific  ELISAs,  mice  were 
immunised  in.  with  2µg  HBcAg  and  2µg  E.  coli  labile  toxin  (LT)  in  a  volume  of 
30µl  PBS.  They  received  an  identical  boost  10  days  later.  After  a  further  10  days, 
the  mice  were  sacrificed  and  washes  of  the  lungs  and  nasal  cavity  were  made,  using 
sterile  PBS  containing  1%  BSA.  These  mucosal  washings  were  pooled  and  used  as 
positive  control  for  these  assays.  The  IgA  ELISA  was  conducted  in  the  same  way  as 
that  described  for  total  antibody  (section  4.3.1.4),  except  for  the  use  of  IgA  specific 
secondary  antibody.  The  assay  is  described  in  full  in  Materials  and  Methods  sections 
2.5.1.2). 
4.4  T  Cell  Responses 
T  lymphocytes  (T  cells)  fall  into  two  main  functional  classes  that  can  be 
distinguished  by  their  cell-surface  markers;  cytotoxic  T  lymphocytes  (CTLs)  bear  a 
cell  surface  molecule  called  CD8+  and  helper  T  (Th)  cells  carry  the  CD4+  molecule. 
The  activation  of  these  cells  is  an  important  indicator  of  the  immune  response. 
140 4.4.1  Ex  Vivo  Measurement  of  HBcAg-Specific  CD4+  T  Cell 
Proliferation 
CD4+  Th  cells  enhance  antibody  function,  phagocytosis  by  macrophages 
and  CTL  activation  (see  Introduction  section  1.4.2.2).  The  presence  of  a  Th  cell 
population  able  to  proliferate  in  response  to  an  antigen  is  an  indicator  of  effective 
vaccination,  and  is  therefore  an  important  aspect  of  the  response  to  be  measured. 
Following  successful  vaccination,  antigen-specific  CD4+  T  cells  differentiate 
and  proliferate.  The  higher  the  number  of  these  cells  present  in  the  animal  tissue, 
the  greater  the  level  of  ex  vivo  proliferation  seen  upon  restimulation  of  cells  from  the 
lymphoid  tissue  with  antigen.  The  proliferation  of  cells  can  be  measured  by  the 
addition  of  radioactively  labelled  nucleotides  to  the  media.  These  molecules  are 
taken  up  by  cells  and  used  in  the  synthesis  of  DNA  when  they  divide,  therefore  the 
level  of  radioactive  uptake  is  proportional  to  the  level  of  proliferation  in  the  culture. 
The  level  of  uptake  is  measured  by  harvesting  the  cells,  washing  off  free  radioactive 
nucleotides  still  in  the  media  and  assaying  the  cells  for  (3-particle  emission.  This 
forms  the  basis  of  the  proliferation  assay.  The  sensitivity  of  the  assay  depends  on  a 
variety  of  factors  outlined  below. 
a)  Culture  media  selection,  specifically  foetal  calf  serum  (FCS).  FCS  is  an 
essential  component  of  tissue  culture  media  used  to  maintain  the  immune 
cells  during  the  course  of  the  proliferation  assay.  Different  batches  of  FCS 
can  contain  different  levels  of  mitogenic  components.  These  compounds 
can  cause  the  non-specific  proliferation  of  cells  in  the  culture.  Since  any  cell 
synthesising  DNA  will  take  up  radioactive  nucleotides,  regardless  of  the 
initial  stimulus  for  proliferation,  the  assay  does  not  differentiate  between 
specific  and  non-specific  proliferation.  Therefore  to  ensure  the  assay 
141 measures  antigen-specific  proliferation  only,  it  is  essential  to  select  a  batch  of 
FCS  with  minimal  mitogenicity. 
b)  Selection  of  restimulating  antigen.  A  complication  of  using  HBcAg  as  the 
model  antigen  in  these  experiments,  is  the  fact  that  it  can  act  as  aT  cell 
independent  B  cell  mitogen  (Nilich  and  McLachlan  1986).  This  can  be 
another  cause  of  non-specific  proliferation  of  B-cells  in  the  assay  culture, 
making  measurement  of  CD4+  antigen-specific  proliferation  impossible. 
One  way  around  this  problem  is  to  use  a  suitable  CD4+  peptide  on  the 
HBcAg  as  the  restimulating  antigen.  This  will  be  appropriate  for  the 
restimulation  of  existing  HBcAg  specific  CD4+  cells  without  causing  non- 
specific  proliferation  of  B-cells. 
c)  Cell  population  selection.  Another  means  of  avoiding  non-specific 
proliferation  of  B  cells  is  to  remove  these  cells  from  the  proliferation  culture. 
This  can  be  done  using  MACS  separation  (see  Materials  and  Methods 
section  2.5.3)  in  one  of  two  ways:  by  selectively  removing  the  B  cells  from 
the  population,  or  by  selecting  only  the  CD4+  cells  for  inclusion  in  the 
proliferation  assay.  The  second  choice  requires  the  addition  of  an  APC 
population  to  the  culture. 
The  aim  of  the  following  experiments  was  to  determine  the  impact  of  the 
factors  described  above  on  the  execution  of  an  antigen-specific  T  cell  proliferation 
assay.  The  results  were  used  to  develop  an  optimised  assay  that  would  be  able  to 
reproducibly  demonstrate  quantitative  differences  in  the  responses  generated  by  the 
different  vaccine  regimes  examined  later  in  this  thesis. 
142 4.4.1.1  Generation  of  Immune  Cells  for  Development  of  the  HBc.  Ag- 
Specific  CD4}  T  Cell  Proliferation  Assay 
To  generate  populations  of  HBcAg-specific  T  cells,  mice  were  immunised 
i.  m.  with  5µg  of  HBcAg  in  alum  or  s.  c.  with  3µg  of  HBcAg  in  CFA  (actual  doses 
and  adjuvants  are  described  in  each  figure  legend).  Ten  days  after  vaccination,  the 
spleens  of  immunised  animals  were  removed  and  single  cell  suspensions'  prepared 
(as  described  in  Materials  and  Methods  section  2.5.2).  The  cells  were  then  used 
either  directly  in  the  proliferation  assay  or  separated  by  MACS  (Materials  and 
Methods  section  2.5.3)  prior  to  inclusion  in  the  assay  cultures.  The  mouse  strain 
used  in  these  experiments  was  C57/B16. 
4.4.1.2  Media  Selection 
To  identify  an  appropriate  source  of  FCS  for  use  throughout  the  entire 
project,  two  batches  of  FCS,  obtained  from  different  companies  (Gibco 
LifeSciences  and  Harlan  Serolabs),  were  compared.  Media  was  prepared  containing 
10%  FCS  and  used  to  set  up  proliferation  assays  using  cells  taken  from  immunised 
and  naive  mice.  For  both  groups  of  animals  four  spleens  were  initially  pooled  and 
single  cell  suspensions  prepared.  As  purified  HBcAg  was  to  be  used  as  a 
restimulating  antigen  in  this  assay,  B-cells  were  removed  from  the  population  using 
the  MACS  system.  The  resultant  cell  suspension  was  divided  into  two  equal 
volumes  of  cells  and  the  assay  was  performed  in  parallel  using  media  containing  the 
different  batches  of  FCS.  Apart  from  the  media  used,  the  assay  was  performed  as 
described  (Materials  and  Methods  2.5.4). 
The  impact  of  using  different  batches  of  FCS  is  shown  in  Figure  4-3.  This 
figure  shows  the  proliferation  of  B  cell  depleted  spleen  cells  from  mice  immunised 
with  HBcAg  and  CFA  compared  to  non-immunised  controls.  For  these 
143 experiments  cells  were  resuspended  in  media  containing  Gibco  FCS  (Figure  4-3A) 
or  media  containing  Harlan  FCS  (Figure  4-3B).  This  shows  that  proliferation 
occurs  at  similar  levels  whichever  source  of  FCS  is  used  and  suggests  that  use  of 
one  particular  sera  does  not  provides  a  significant  advantage.  However,  when  the 
proliferation  from  non-immunised  animals  is  considered,  the  nonspecific  response 
is  seen  to  be  lower  and  less  varied  when  the  Harlan  FCS  was  used. 
Therefore,  to  minimise  the  level  of  non  antigen-specific  proliferation  in  the 
assay,  and  to  decrease  variation  within  groups,  a  large  batch  of  Harlan  FCS  was 
purchased  and  used  in  all  subsequent  experiments  described  in  this  thesis. 
4.4.1.3  Peptide  Versus  Protein  as  RestirnulatingAntigen 
To  determine  whether  HBcAg  or  a  small  CD4+  specific  peptide  from 
HBcAg  acts  as  a  more  effective  restimulation  antigen,  the  two  antigens  were 
compared  in  parallel.  For  this  assay,  the  splenocytes  from  immunised  and  non- 
immunised  animals  were  isolated  and  the  B  cells  removed  by  MACS  (Materials  and 
Methods  2.5.2).  The  cells  restimulated  with  titrating  concentrations  of  either  the 
whole  protein  or  a  previously  described  HBcAg  CD4+  peptide  for  H2-b  mice 
(Milich  et  al.  1987).  The  sequence  for  this  peptide  is  given  in  Materials  and  Methods 
Table  2-3.  The  cells  were  restimulated  with  concentrations  of  peptide  that  had 
previously  been  shown  to  be  effective  in  this  paper.  The  results  of  this  experiment 
are  shown  in  Figure  4-4. 
The  three  major  points  of  interest  about  these  data  are: 
1)  Both  the  HBcAg  and  CD4+  peptide  are  able  to  stimulate  antigen 
specific  T-cells  in  the  spleen  cell  population  to  proliferate  in  a 
concentration  dependent  manner. 
144 2)  The  thymidine  incorporation  is  approximately  3  fold  higher  in  the 
peptide-stimulated  cultures  than  in  the  equivalent  HBcAg  cultures, 
in  both  immunised  and  naive  groups. 
3)  The  immunised  cells  in  the  peptide  cultures  respond  much  more 
strongly  to  an  increase  in  antigen  concentration  than  the  cells  in  the 
equivalent  HBcAg  culture,  over  the  range  of  concentrations 
examined. 
From  initial  consideration  of  the  data,  it  is  not  obvious  whether  protein  or 
peptide  restimulation  better  provides  a  sensitive  and  consistent  proliferation  assay. 
In  terms  of  counts  measured,  the  ratio  of  immunised  to  naive  counts  was  the  same 
for  both  peptide  and  protein.  The  only  important  difference  between  the  two  was 
that  small  increases  in  the  peptide  concentration  had  a  greater  effect  on  the  level  of 
proliferation  than  the  equivalent  changes  in  HBcAg  concentration.  However,  in 
terms  of  practical  application,  use  of  the  peptide  has  another  advantage  in  that  it 
does  not  require  the  removal  of  B-cells. 
For  these  reasons,  it  was  decided  that  the  CD4+  peptide  is  a  more  effective 
restimulation  antigen  than  the  entire  HBcAg,  and  therefore  restimulation  using  this 
peptide  was  adopted  in  all  future  experiments. 
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Figure  4-3:  Impact  of  different  sources  of  FCS  on  the  proliferation  of  HBcAg- 
specific  T  cell  responses. 
C57/Bl6  mice  were  immunised  s.  c.  with  3µg  HBcAg  in  CFA.  The  proliferation  of  a 
pool  of  B  cell  depleted  spleen  cells  from  4  mice  was  measured  by  [3-emission  of 
cells  after  DNA  incorporation  of  ['H]  thymidine  over  16  hours  following  3  day 
restimulation  with  a  range  of  HBcAg  concentrations.  Mean  CPM  of  triplicate 
cultures  of  pooled  cells  are  shown  ±  1SD.  The  two  cultures  were  restimulated  with 
media  containing  HBcAg  with  FCS  sourced  from  Gibco  life  sciences  (Figure  4-3A) 
or  from  Harlan  serolabs  (Figure  4-3B).  CPM  from  cells  of  immunised  mice  are 
represented  by  ".  CPM  from  the  cells  of  naive  mice  are  represented  by  o. 
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Figure  4-4:  Impact  of  using  purified  protein  versus  HBcAg  p120-140  on 
proliferation  of  HBcAg  specific  T  cells 
9  C57/B16  mice  were  immunised  im.  with  5µg  HBcAg  in  alum  on  day  1  and  day  8. 
Mice  were  sacrificed  and  splenocytes  recovered  on  day  15.  Proliferation  of  spleen 
cells  from  pooled  mice  was  measured  by  ß-emission  from  cells  after  DNA 
incorporation  of  [3H]  thymidine  over  16  hours  following  3  day  restimulation  with  a 
range  of  antigen  concentrations.  Mean  CPM  from  triplicate  cultures  of  pooled  cells 
are  shown  ±  1SD.  Figure  4-4A  shows  cells  cultured  with  HBcAg  as  the 
restimulating  antigen,  whereas  Figure  4-5B  shows  cells  restimulated  with  peptide 
HBcAg  p120-140.  CPM  from  cells  of  immunised  mice  are  represented  by  ".  CPM 
from  cells  of  naive  mice  are  represented  by  o. 
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As  the  T  cell  proliferation  assay  measures  proliferation  of  all  cells  in  the 
culture,  irrespective  of  the  stimulus  or  cell  type,  it  is  vital  to  the  accuracy  of  the  assay 
to  prevent  both  non-specific  T  cell  proliferation,  and  proliferation  of  other  cell 
types. 
One  approach  employed  to  avoid  the  problem  of  B  cell  mitogenicity 
involves  the  removal  of  these  cells  from  the  rest  of  the  lymphocyte  population. 
This  can  be  accomplished  using  the  MACS  separation  system  (Materials  and 
Methods  section  2.5.3).  The  choice  of  antibody  used  in  the  system  determines 
which  cells  are  removed  and  which  remain  in  the  population.  Two  different 
methods  were  considered. 
In  the  first  method,  the  B  cells  alone  were  removed  using  a  magnetic  anti- 
CD19  antibody.  As  CD19  is  aB  cell  marker,  use  of  this  antibody  causes  B  cells  to 
become  stuck  to  the  magnetic  column  whilst  the  remaining  splenocyte  population  is 
able  to  pass  through  uninhibited.  The  advantage  of  this  method  is  that  it  does  not 
remove  the  majority  of  APCs  present  in  the  spleen  that  are  required  for  efficient 
presentation  of  the  antigen  ex  vivo. 
In  contrast,  a  second  method  makes  use  of  a  CD4+  specific  antibody 
attached  to  a  magnetic  bead,  which  binds  the  CD4+  T-cells  to  the  column.  The 
resulting,  highly  pure,  population  of  CD4+  T  cells  can  then  be  eluted  by  removal  of 
the  magnet  and  should  not  be  contaminated  with  B  cells.  However,  to  be  effective 
in  the  proliferation  assay,  the  HBcAg  specific  T  cells  require  presentation  of  the 
antigen  by  a  suitable  APC.  For  these  experiments,  3  different  types  of  APC  were 
considered.  These  were: 
1.  Irradiated  splenocytes.  Spleen  cells  were  taken  from  a  naive  mouse  and 
irradiated.  These  cells  are  still  able  to  take  up  and  present  antigen  but 
148 are  unable  to  proliferate  due  to  the  damage  caused  to  their  DNA  by 
irradiation.  Cells  were  used  at  a  ratio  of  1:  3  irradiated  splenocytes  :T 
cells  in  the  proliferation  assay. 
2.  Mitomycin  C  treated  splenocytes.  Mitomycin  C  treatment  causes  DNA 
alterations  to  the  cell  that  again  prevents  proliferation  without  inhibiting 
antigen  presentation.  Cells  were  treated  with  50µg  mitomycin  C  per  10' 
splenocytes  for  75  minutes  and  washed  thoroughly  to  remove  the 
mitomycin  C  before  being  added  to  cultures  at  a  ratio  of  1:  APCs  :T 
cells  (see  Materials  and  Methods  section  2.5.4.2). 
3.  Irradiated  naive  DCs.  DCs  are  potent  specialist  antigen  presenters,  and 
can  be  cultured  from  the  bone  marrow  cells  of  mice  stimulated  with 
granulocyte-monocyte  colony  stimulating  factor  (GM-CSF)  (Materials 
and  Methods  section  2.5.4.3).  The  process  of  irradiation  was  the  same 
as  that  used  for  splenocytes.  Cells  were  added  at  1:  3  APCs  :T  cells. 
To  find  the  optimal  cell  population  to  use  in  the  proliferation  assay,  C57b1/6 
mice  were  immunised  with  HBcAg  in  alum,  as  described  above  in  section  4.4.1.2. 
Cells  were  recovered  from  the  spleens  of  vaccinated  animals  and  split  into  four 
populations  of  equal  number.  One  volume  of  cells  was  depleted  of  B  cells  using 
anti-CD19  beads.  The  remaining  populations  were  treated  with  anti-CD4+  beads 
and  the  CD4'  cell  population  isolated.  These  were  then  used  to  set  up  three 
proliferation  assays,  each  provided  with  one  of  the  APC  types  described  above.  All 
four  cultures  were  then  restimulated  with  the  CD4+  peptide  as  the  restimulating 
antigen. 
The  results  of  these  experiments  are  shown  in  Figure  4-5.  In  all  cases, 
HBcAg  specific  CD4+  proliferation  was  induced  with  higher  counts  in  wells 
149 containing  cells  from  immunised  animals  than  those  from  naive  animals.  The 
proliferation  observed  was  also  shown  to  be  antigen-concentration  dependent. 
However,  the  greatest  proliferation  was  observed  when  only  the  B  cells  were 
depleted  from  the  cell  suspension;  Figure  4-5A.  This  is  despite  the  higher  level  of 
emission  from  naive  groups  in  this  experiment  compared  to  those  using  non- 
proliferating  splenocytes;  both  the  absolute  and  proportionate  increase  of  the 
immunised  group  over  the  naives  is  greater  than  in  any  other  group.  Also,  the 
immunised  B  cell  depleted  cultures  were  more  sensitive  to  increases  in  antigen 
concentration  than  any  other  group. 
One  factor  that  might  explain  the  high  level  of  proliferation  in  this  system 
may  be  that  the  APCs  in  the  B  cell  depleted  culture  (Figure  4-5A)  have  not  suffered 
significant  DNA  damage.  Irradiation  and  mitomycin  C  treatment  both  result  in 
significant  damage  to  chromosomal  DNA  and  prevent  the  cells  replicating.  Protein 
expression  from  damaged  genes  will  also  be  impaired,  and  although  the  cells  are 
able  to  survive  and  present  antigen,  this  may  be  less  efficient  than  in  non-treated 
cells  (Figure  4-5B  and  C). 
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Figure  4-5:  Comparison  of  proliferation  of  T  cells  with  different  APC 
populations. 
9  C57/B16  mice  were  immunised  i.  m.  with  5µg  HBcAg  in  alum.  The  proliferation  of 
a  pool  of  spleen  cells  from  9  mice  was  measured  by  n-emission  from  cells  after 
DNA  incorporation  of  ['H]  thymidine  over  16  hours  following  3  day  restimulation 
with  a  range  of  antigen  concentrations.  Mean  CPM  from  triplicate  cultures  of 
pooled  cells  are  shown  ±  1SD.  Figure  4-5A  shows  B  cell  depleted  splenocytes, 
while  B,  C  and  D  show  CD4+  T  cells  with  added  APCs.  Figure  4-5B  shows  T  cells 
plus  naive  irradiated  splenocytes,  Figure  4-5C  shows  T  cells  with  naive,  mitomycin 
C  treated  splenocytes  and  Figure  4-5D  shows  T  cells  with  naive,  mitomycin  treated 
DCs  as  APCs.  CPM  from  cells  of  immunised  mice  are  represented  by  ".  CPM 
from  cells  of  naive  mice  are  represented  by  o. 
151 After  the  B  cell  depleted  group,  the  next  highest  level  of  proliferation  was 
measured  in  wells  in  which  purified  CD4+  T  cells  had  been  admixed  with  irradiated 
DCs  (Figure  4-5D).  DCs  are  potent  APCs,  capable  of  efficiently  presenting  antigen 
to  T  cells,  which  probably  explains  their  success  when  compared  to  the  mixed 
populations  of  naive  non-proliferating  splenocytes  present  in  the  two  remaining 
cultures. 
A  problem  with  the  cultures  containing  DCs  as  APCs  is  the  high  level  of 
proliferation  seen  in  the  naive  group.  This  indicates  that  either  the  DCs  are  causing 
T  cells  to  proliferate  non-specifically,  or  that  the  DCs  were  insufficiently  treated 
with  Mitomycin  C  to  prevent  their  own  replication  during  the  proliferation  assay. 
Whichever  theory  is  correct,  it  means  that  these  cells  are  not  suitable  for  use  in  the 
proliferation  assay. 
As  a  result  of  these  data,  all  further  experiments  looldng  at  antigen  specific 
CD4+  T  cell  proliferation  were  performed  using  CD-19  B  cell  deleted  lymphocyte 
populations. 
4.4.1.5  Optimised  Assay  for  Measuring  HBcAg-Specific  CD4'Responses 
As  a  result  of  these  experiments,  CD4+  T-cell  responses  were  subsequently 
measured  by  isolation  of  a  splenocyte  population  whose  B-cells  were  removed  using 
CD19  beads.  To  each  well  of  a  microtitre  plate,  2x105  cells  were  added  and  were 
restimulated  with  the  HBcAg  CD4+  peptide  (HBcAg  p120-140).  All  RPMI  media 
used  in  culturing  of  these  cells  contained  FCS  sourced  from  Harlan  Serolabs. 
Cultures  were  incubated  for  72  hours  at  37°C,  5%  COZ,  then  pulsed  with  tritiated 
thymidine. 
152 4.4.2  CD8+  CTL  Responses 
CTLs  are  a  second  type  of  T  lymphocyte,  generally  characterised  by  the 
presence  of  CD8+  molecules  on  the  cell  surface,  rather  than  CD4+  as  on  T  helper 
cells.  Functionally,  they  are  quite  different  from  T  helper  cells.  Although  they  also 
recognise  antigen  in  a  specific  manner,  antigen  can  be  presented  to  CD8+  T  cells  by 
almost  any  cell  (not  just  specialist  APCs),  since  they  recognise  antigen  bound  to 
MHC  class  I  molecules,  expressed  by  nearly  every  cell  type  in  the  body.  On 
recognition  of  antigen  and  following  a  secondary  signal,  a  naive  CD8+  T  cell  is 
activated  and  differentiates  into  a  CTL  that  can  kill  cells  presenting  its  specific 
antigen  by  inducing  apoptosis.  This  mechanism  is  used  to  control  intracellular 
pathogens,  such  as  viruses  and  invasive  bacteria.  Activated  CTLs  also  secrete  IFN-y 
a  molecule  whose  functions  include  the  inhibition  of  virus  replication  within  cells 
and  the  activation  of  macrophages  (see  Introduction  section  1.4.2.1).  Both  CTL 
killing  and  IFN-y  secretion  have  been  assayed  for  as  part  of  this  project. 
4.4.21  CTL  KillingAssay 
In  order  to  determine  whether  different  formulations  of  vaccine  could 
stimulate  HBcAg-specific  CD8+  killing  responses,  a  chromium  release  assay  was 
developed.  This  CTL  killing  assay  is  based  on  the  ability  of  antigen  specific  CD8' 
cells  to  recognise  and  destroy  target  cells  which  express  the  HBcAg  specific  CD8+ 
peptide  on  their  surface.  The  assay  itself  involves  the  isolation  of  splenocytes  from 
vaccinated  animals,  which  are  incubated  with  the  target  cell  population  in  vitro  for  5 
days.  This  is  necessary  to  restimulate  and  amplify  the  number  of  specific  CTLs 
generated.  After  5  days,  the  amplified  cell  population  is  re-exposed  to  a  fresh  set  of 
target  cells  that  have  been  previously  incubated  with  radioactive  sodium  chromate 
153 [51Cr].  After  co-incubating  radioactive  cells  with  the  CTLs  for  4  hours,  the  culture 
supernatants  are  removed  and  measured  for  ß-emission.  As  target  cells  that  have 
been  destroyed  by  CTL  activity  release  [51Cr]  into  the  supernatant,  the  level  of 
radioactivity  in  the  supernatants  can  be  correlated  to  the  number  of  cells  destroyed. 
This  is  calculated  as  a  percentage  by  comparing  the  emission  to  populations  of 
target  cells  lysed  with  a  detergent,  triton  X,  which  gives  100%  lysis,  and  unlysed 
target  cells. 
Optimisation  of  [s'Cr]  Sodium  Chromate  Labelling  of  Target  Cells 
HBcAg  specific  target  cells,  P815/c  and  the  equivalent  P815  control  cells 
were  a  kind  gift  from  R  Schirmbeck,  University  of  Ulm,  Germany.  To  optimise  the 
assay  the  uptake  of  radioactive  sodium  chromate  [s'Cr]  by  these  cells  was  examined. 
Different  numbers  of  target  cells  were  incubated  for  different  lengths  of  time  with 
radioactivity.  To  quantify  the  absorbance  of  radioactivity,  cells  were  lysed  with 
triton  X  100  and  the  (3  emissions  of  the  supernatants  measured.  The  results  are 
shown  in  Figure  4-6.  The  data  shows  that  the  a-emission  increases  with  the 
number  of  cells  labelled,  but  is  not  directly  proportional,  with  a  greater  increase 
between  1x104  and  1x105  cells  than  between  1x103  and  1x104.  The  greatest  increase 
in  counts  due  to  incubation  time  was  between  30  minutes  and  1  hour,  with  a  longer 
incubation  period  giving  less  of  an  increase. 
154 Figure  4-6:  Effect  of  incubation  time  and  target  cell  number  on  CrS1 
absorbance 
The  amount  of  radioactivity  absorbed  by  either  P815  (hollow  symbols)  or  P815/c 
cells  (filled  symbols)  was  measured  by  lysis  of  these  cells  with  detergent  after  30 
minutes  (2),  60  minutes  (A)  or  120  minutes(*).  Mean  CPM  of  triplicate  cultures  are 
shown  ±1  SD. 
155 The  results  from  this  experiment  show  that  1x105  target  cells  generate  a 
strong  ß-emission  signal,  i.  e.  in  the  order  of  10,000cpm.  The  counts  were  directly 
proportional  to  the  number  of  cells  present,  and  both  target  (P815c)  and  control 
(P815)  cells  gave  similar  counts.  Therefore  it  was  considered  that  1x105  target  cells 
per  well  was  the  optimal  number  for  use  in  these  assays  and  cells  should  be  labelled 
for  a  minimum  of  1  hour  prior  to  use. 
Optimisation  of  the  Chromium  Release  Killing  Assay 
To  determine  whether  antigen  specific  CD8+  responses  could  be  measured 
in  vivo,  BALB/c  mice  were  vaccinated  with  100µg  pcDNA3.1/core  im.  and 
sacrificed  after  10  days.  Splenocytes  were  isolated  and  restimulated  with  target  cells 
for  5  days,  as  described  above.  They  were  then  incubated  for  4  hours  with  sodium 
[51Cr]  chromate  labelled  target  cells  and  the  ß  emission  measured. 
Figure  4-7  shows  the  percentage  of  specific  killing  by  cells  from  BALB/c 
mice  immunised  with  pcDNA3.1/core,  pcDNA3.1  and  in  untreated  animals. 
These  data  show  that  the  assay  is  able  to  measure  antigen-specific  killing,  which 
occurs  effectively  in  animals  immunised  with  the  pcDNA3.1/core  vaccine.  Such 
induction  is  in  agreement  with  similar  observations  in  the  literature  (Kuhrober  et  aL 
1996).  This  assay  appears  discriminatory  with  little  killing  observed  in  control 
groups.  It  was  therefore  decided  that  this  assay  was  sufficiently  sensitive  and 
discriminating  to  be  used  for  measuring  CTL  activity. 
156 Figure  4-7:  HBcAg-specific  CTL  killing  by  mice  immunised  with 
pcDNA3.1/core 
Percentage  of  specific  killing  of  target  cells  by  spleen  cells  restimulated  in  vitm  for  5 
days,  following  harvesting  from  BALB/c  mice  10  days  after  immunisation  with 
pcDNA3.1/core.  50:  1  effector  :  target  cell  ratio. 
157 4.4.2.2  Interferon-y  Release  -an  Indirect  Measurement  of  CTL  Activation 
One  feature  of  CTL  activation  that  can  be  used  as  an  indirect  measurement 
of  CTL  activity  is  secretion  of  IFN-y.  To  assess  whether  CTLs  could  be  quantified 
using  this  method,  5  BALB/c  mice  were  vaccinated  with  100µg  pcDNA3.1/core 
im.  and  sacrificed  after  10  days.  Using  the  protocol  described  in  the  materials  and 
methods  2.5.7,  adapted  from  (Culshaw  et  aL  1997),  no  spots  were  detectable  on  the 
filter,  suggesting  that  no  activated  CTLs  were  present.  However,  considering  that 
the  CTL  killing  described  in  section  4.4.2.1  was  so  high,  it  was  felt  that  the  HBcAg 
specific  CTLs  were  present,  but  that  assay  lacked  discrimination.  In  order  to 
emulate  the  method  and  level  of  response  indicated  by  the  killing  assay,  it  was 
decided  to  restimulate  the  isolated  T  cells  with  target  cells  prior  to  their  use  in  the 
ELISPOT  (see  above). 
Therefore  the  isolated  T  cells  were  restimulated  for  5  days  in  vitro  at  a  ratio 
of  10  :1  effector  :  target  cells.  Using  this  method  clear,  antigen  specific  IFN-'y 
production  was  observed.  The  numbers  of  Spot  Forming  Cells  (SFC)  are  shown  in 
Figure  4-8.  The  data  in  this  figure  confirms  that  immunisation  of  mice  with 
pcDNA3.1/core  results  in  the  generation  of  IFN-y  producing  T-cells.  Although  it 
is  likely  that  the  production  of  this  cytokine  is  from  antigen  specific  CD8+  cells 
(given  the  use  of  the  CD8;  specific  peptide),  this  could  have  been  further  confirmed 
by  intracellular  cytokine  staining  of  these  cells  and  measurement  by  FACSort 
analysis.  This  assay  appeared  to  be  discriminating  as  the  number  of  spots  generated 
following  vaccination  with  pcDNA3.1/core  was  approximately  twice  the  number 
observed  in  equivalent  control  wells. 
158 Figure  4-8:  Numbers  of  IFN-y  secreting  T  cells  following  i.  m. 
pcDNA3.1/core  vaccination 
The  number  of  spots  per  well  produced  by  IFN-y  secreting  T  cells  are  shown.  Cells 
from  BALB/c  mice  immunised  with  pcDNA3.1/core  (0),  pcDNA3.1  alone  (o)  and 
from  naive  animals  (C)  are  shown.  T  cells  were  recovered  10  days  after  vaccination 
and  restimulated  for  5  days  prior  to  the  ELISPOT  assay.  SFC  represent  the  mean 
number  of  spots  counted  in  duplicate  wells  containing  50µ/ml  HBcAg  peptide 
CD8+  p87-95. 
159 4.5  Conclusion 
As  a  result  of  work  described  in  this  chapter,  it  was  felt  that  appropriately 
sensitive  and  discriminating  methods  had  been  developed  for  studying  the  cellular 
and  humoral  immune  response  to  HBcAg.  These  assays  therefore  form  the 
foundation  for  subsequent  studies,  which  were  carried  out  to  compare  the  relative 
response  to  different  vaccination  strategies  described  in  the  remainder  of  this  thesis. 
160 5  RESULTS  -  GENERATION  OF  AN  IMMUNE  RESPONSE 
FOLLOWING  SYSTEMIC  DELIVERY  OF  A  DNA  VACCINE 
ENCODING  THE  HBcAG 
5.1  Chapter  Aims 
The  aim  of  this  chapter  was  to  examine  the  humoral  and  cellular  HBcAg- 
specific  responses  generated  following  vaccination  with  the  naked  plasmid  vaccine 
pcDNA3.1/core.  The  effects  of  delivering  this  vaccine  either  directly  into  the  skin 
using  a  gene  gun  or  into  the  muscle  by  injection  were  observed.  In  addition, 
consideration  is  given  to  the  subsequent  enhancement  of  these  responses  by  im. 
delivery  of  a  purified  protein  boost. 
5.2  Introduction 
It  has  previously  been  shown  that  the  route  of  immunisation  for  DNA 
vaccines  can  significantly  affect  the  magnitude  and  quality  of  the  immune  response 
generated  (see  Introduction  section  1.5.4.3).  In  general,  DNA  vaccines  delivered 
intramuscularly  (im.  )  require  high  amounts  of  DNA  to  stimulate  measurable 
antibody  and  cellular  responses.  In  the  literature,  these  appear  to  be  dominated  by 
the  stimulation  of  helper  CD4+  T  cells  of  the  Thl  phenotype.  In  contrast,  when 
DNA  is  given  intradermally  using  a  gene  gun,  relatively  low  doses  of  the  vaccine  are 
required  to  generate  equivalent  levels  of  immunity,  and  the  response  is  dominated 
by  CD4+  T  cells  of  the  Th2  phenotype.  However,  most  studies  to  date  have 
examined  soluble,  non-particulate  antigens.  This  chapter  describes  the  impact  of  a 
161 DNA  vaccine  based  on  a  large  particulate  antigen.  This  work  provides  a  strong 
foundation  on  which  the  subsequent  impact  of  additional  heterologous  boost 
vaccinations  can  be  considered. 
To  determine  the  effect  of  the  HBcAg-encoding  DNA  vaccine 
pcDNA3.1/core  in  stimulating  various  aspects  of  the  immune  response,  mice  were 
initially  given  2  doses  of  the  vaccine  either  by  intramuscular  (i.  m)  injection  or  via 
the  skin  using  a  gene  gun.  To  avoid  any  bias  of  the  inbred  mouse  strains  towards  a 
particular  type  of  immune  response,  experiments  were  carried  out  in  both  BALB/c 
and  C57/B16  mice.  The  subsequent  humoral  and  cellular  responses  that  were 
measured  are  described  below  and  are  considered  based  on  the  route  of 
immunisation,  with  immunity  to  im.  vaccination  examined  in  the  first  instance. 
5.3  Humoral  Responses  to  pcDNA3.1/core  Following 
Intramuscular  Vaccination 
In  these  experiments,  C57/B16  mice  (H2-b  MHC  haplotype)  were 
immunised  on  days  1  and  8  with  100µg  of  pcDNA3.1/core  im.  Control  animals 
were  similarly  immunised  with  100µg  of  pcDNA3.1  vector  alone  to  differentiate 
between  responses  due  to  the  expressed  vaccine  antigen  and  the  plasmid  backbone. 
A  third  group  of  mice  were  given  two  doses  of  1µg  HBcAg  protein  im.  at  the  same 
times,  to  act  as  a  positive  control  To  monitor  the  generation  of  HBcAg  specific 
antibodies,  sample  bleeds  were  taken  14  and  31  days  following  the  second 
vaccination  (see  Figure  5-1). 
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Figure  5-1:  Immunisation  regimen  for  mice  vaccinated  i.  m.  with  the  DNA 
and  protein  vaccine  formulations. 
This  figure  shows  the  timing  of  vaccine  delivery  to  the  mice  and  quantification  of 
anti-HBcAg  response  by  assessment  of  tail  sample  bleeds  taken  from  each  mouse. 
163 HBcAg  specific  humoral  responses  were  measured  by  ELISA  and  are 
shown  in  Figure  5-2.  In  brief,  this  figure  shows  that  although  no  detectable 
responses  were  observed  prior  to  immunisation  (Figure  5-2A),  14  days  after  the 
second  vaccination,  all  mice  immunised  with  pcDNA3.1  /core  had  developed  low 
but  detectable  antibody  responses  in  the  sera  (Figure  5-2B).  The  titres  generated  are 
approximately  ten  times  lower  than  those  observed  in  mice  immunised  with  the 
purified  protein.  These  data  indicate  the  strong  immunogenicity  of  the  HBcAg  and 
are  consistent  with  results  described  elsewhere  (Bohm  et  aL  1996).  These  responses 
do  not  appear  to  improve  with  time  as  calculated  titres  of  HBcAg  specific  antibody 
had  not  changed  significantly  in  any  group  by  39  days  following  immunisation 
(Figure  5-2C). 
To  confirm  that  the  MHC  haplotype  of  the  mice  does  not  affect  the 
humoral  response  generated,  the  experiments  were  repeated  in  BALB/c  mice  (H2-d 
haplotype).  The  results  from  these  experiments  are  given  in  Figure  5-3.  These 
confirmed  the  previous  data  generated  in  the  C57/B16  mice  and  show  that  low 
levels  of  HBcAg  specific  antibodies  are  detectable  in  all  mice  immunised  with 
pcDNA3.1/core  14  days  after  immunisation.  No  such  responses  are  observed  in 
animals  immunised  with  the  vector  alone.  These  responses  are  lower  than  those 
observed  in  mice  immunised  with  the  purified  HBcAg  material  and  do  not  improve 
over  time  (Figure  5-3C).  These  data  demonstrated  that  the  DNA  vaccine  construct 
was  able  to  stimulate  equivalent  humoral  HBcAg  specific  responses  in  two  mouse 
strains  of  different  MHC  haplotype. 
In  order  to  more  fully  define  the  nature  of  the  immune  response  generated 
by  the  DNA  vaccine,  the  pattern  of  antigen  specific  IgG  isotypes  in  the  sera  was 
also  analysed.  T  helper  cell  responses  can  be  broadly  divided  into  Thl  or  Th2, 
depending  on  the  cytokines  secreted  by  individual  11i  cells.  These  cytokines  drive 
164 the  production  of  specific  sub-types  of  immunoglobulin  G  (IgG),  therefore  the 
nature  of  the  T  helper  cell  response  can  be  determined  by  examining  the  levels  these 
subtypes.  In  mice,  IgG1  is  indicative  of  a  Th2  CD4*  response  and  IgG2a  indicates 
Thl  (Abbas  el  at  1996),  see  Introduction  section  1.4.2.2,  CD4+  T  cell  Responses). 
Figure  5-4  show  the  titres  of  HBcAg-specific  IgG  subtypes  in  the  sera  of  the 
two  mouse  strains  at  day  39,  after  immunisation  on  days  1  and  8  with 
pcDNA3.  l  /core,  control  DNA  or  1µg  purified  HBcAg.  Interestingly,  none  of  the 
mice  immunised  with  either  protein  or  pcDNA3.  l/core  show  any  specific  IgGl 
production,  instead  the  dominant  antibody  was  IgG2a,  although  the  titres  measured 
varied  considerably.  This  indicates  the  development  of  a'I'hl  response  to  HBcAg 
whether  vaccination  is  DNA  or  protein  based. 
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Figure  5-2:  i.  m.  DNA  vaccination  in  C57/B16  mice;  development  of  HBcAg- 
specific  serum  antibody 
Groups  of  5  C57/Bl6  mice  were  immunised  im.  with  either  100µg  DNA 
(pcDNA3.1/core  and  DNA  control  groups)  or  1pg  HBcAg  protein  alone  (HBcAg 
x2  group),  on  days  I  and  8  of  the  experiment.  Figure  S-2A  shows  the  titres  of 
HBcAg  specific  immunoglobulin  from  all  mice  prior  to  vaccination,  Figure  5-2B  at 
14  days  after  the  second  vaccination  and  Figure  5-2C  shows  titres  at  31  days  after 
vaccination.  HBcAg  specific  titres  are  represented  by  4,  groups  means  by 
horizontal  bars. 
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Figure  5-3:  i.  m.  DNA  vaccination  in  BALB/c  mice;  development  of  HBcAg- 
specific  serum  antibody 
Groups  of  5  BALB/c  mice  were  immunised  i.  m  with  either  100µg  DNA 
(pcDNA3.1/core  and  DNA  control  groups)  or  lpg  HBcAg  protein  alone  (HBcAg 
x2  group)  on  days  1  and  8  of  the  experiment.  Figure  5-3A  shows  the  titres  of 
HBcAg  specific  immunoglobulin  from  all  mice  prior  to  vaccination,  Figure  5-3B  at 
14  days  after  the  second  vaccination  and  Figure  5-3C  shows  titres  at  31  days  after 
vaccination.  HBcAg-specific  titres  are  represented  by  4,  groups  means  by 
horizontal  bars. 
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Figure  5-4:  Measurement  of  antibody  subtypes  in,  the  sera  of  mice  vaccinated 
with  pcDNA3.1/core  i.  m.  or  purified  HBcAg 
BALB/c  (Figure  5-4A)  and  C57/B16  (Figure  5-4B)  mice  were  immunised  with 
100µg  pcDNA3.1  /core  or  1µg  HBcAg  im.  on  day  1  and  day  8.  Immunoglobulin 
subtypes  were  examined  on  day  39.  Calculated  specific  anti-HBcAg  titres  are 
shown.  A  represent  IgGl  titres  for  individual  mice,  11  represent  IgG2a  titres. 
168 5.4  Cellular  Responses  to  pcDNA3.1/core  Following 
Intramuscular  Vaccination  of  C57/B16  mice 
5.4.1  CD4+  T  Cell  Responses 
To  determine  the  impact  of  vaccination  on  HBcAg  specific  CD4;  cells,  mice 
were  immunised  as  described  in  Figure  5-1  and  CD4f  T  cells  purified  from  spleens 
and  draining  lymph  nodes  (popliteal  and  inguinan  14  days  after  the  second  vaccine 
dose.  Proliferation  was  measured  by  ß-emission  of  these  cells  following 
incorporation  of'H-thymidine  in  culture  (Materials  and  Methods  section  2.5.4  - 
2.5.5).  Unfortunately,  despite  several  attempts  using  optimised  protocols  no 
HBcAg-specific  proliferation  could  be  measured  in  any  of  the  mice.  This  may  have 
been  due  to  a  genuine  lack  of  response  in  the  animals,  or  problems  with  sensitivity 
of  the  assay  (see  Chapter  4  for  details  of  the  assay  development).  Another 
possibility  was  that  there  were  only  low  numbers  of  primed  cells  at  the  time  point 
studied.  To  see  if  this  was  the  case,  CD4*  responses  were  measured  using  an 
alternative  vaccination  protocol  In  this  experiment,  mice  were  immunised  on  days 
1  and  28  and  T  cell  proliferation  examined  on  day  56  of  the  experiment.  It  was 
thought  that  the  greater  time  interval  between  immunisations  and  killing  would 
allow  a  longer  period  of  antigen  expression  by  the  cells  leading  to  stimulation  of  a 
greater  number  of  naive  T  cells. 
The  results  of  this  experiment  are  shown  in  Figure  5-5  and  confirm  that 
antigen-specific  T  cell  proliferation  can  be  observed  in  the  spleens  of  these  mice. 
These  responses  were  dramatically  higher  than  those  observed  in  cells  from  naüve 
mice.  In  contrast  no  detectable  response  was  observed  in  the  cells  taken  from  the 
popliteal  lymph  nodes  (Figure  5-5B).  This  suggests  that  the  antigen  specific  cells 
169 have  matured  and  trafficked  to  the  spleen  at  this  time  point  This  longer-term 
vaccination  regime  was  not  adopted  for  general  use  since  these  experiments  were 
conducted  toward  the  end  of  the  experimental  work  for  this  thesis  and  too  late  to 
be  incorporated  into  the  general  scheme  of  work. 
5.4.2  CD8+  T  Cell  Responses 
To  measure  HBcAg  specific  CD8ý  T  cell  responses,  mice  were  given  a  single 
dose  of  100µg  pcDNA3.1/core  and  killed  10  days  later.  Splenic  cells  from  these 
mice  were  isolated  and  restimulated  ex  vivo  for  5  days  with  P815/c  target  cells,  as 
described  in  Materials  and  Methods  section  2.5.6.  The  killing  capacity  of  these 
restimulated  cells  is  shown  in  Figure  5-6.  These  data  dearly  demonstrate  the 
induction  of  antigen-specific  CTZs  following  vaccination  with  a  single  100µg  im. 
dose  of  the  pcDNA3.1/core  vector.  At  effector  :  target  cell  ratios  of  50:  1  and  25:  1 
this  killing  response  is  approximately  25%  greater  than  that  observed  with  the 
equivalent  number  of  cells  taken  from  naive  animals  or  those  immunised  with  the 
vector  alone. 
An  alternative  method  of  evaluating  the  CIL  response  is  to  measure  the 
number  of  IFN-'y  secreting  cells  in  an  ELISPOT  assay  (Materials  and  Methods 
section  2.5.7).  Cells  taken  from  mice  immunised  twice  with  pcDNA3.1/core,  as 
before,  yielded  the  results  shown  in  Figure  5-7. 
The  number  of  spot  forming  cells  (SFC)  are  higher  in  the  pcDNA3.1/core 
group  than  the  DNA  control  and  naive  groups,  at  both  the  10:  1  and  5:  1  E  APC 
ratios,  irrespective  of  the  quantity  of  restimulation  antigen  used  in  the  assay  (the 
results  shown  are  from  cultures  stimulated  with  50µg/ml  HBcAg  peptide  (p93-100). 
This  confirms  that  vaccination  with  pcDNA3.1/core  activated  CD8+  T  cells  and 
170 shows  that  CD8*  T  cells  from  naive  animals  were  not  activated  to  produce  IFN-y 
during  the  assay. 
These  results  are  in  line  with  and  expand  upon  previous  findings  showing 
that  im.  DNA  vaccination  can  induce  an  anti-HBcAg  specific  CTL  killing 
(Kuhroben  et  aL  1996). 
5.5  Summary  of  Results 
From  these  initial  in  sire  experiments,  it  was  clear  that  the  plasmid 
pcDNA3.1/core  was  able  to  stimulate  humoral  and  cellular  immune  responses 
following  im.  administration.  The  results  shown  here  represent  typical  data  from 
several  experiments  and  did  not  appear  to  be  affected  by  the  haplotype  of  the 
mouse  strain  used.  Therefore  unless  stated,  all  later  experiments  were  carried  out  in 
C57/BI6  mice  only.  These  data  confirm  similar  observations  in  the  literature  that 
im.  DNA  immunisation  induces  strong  antigen  specific  CD8*  responses  and  low 
but  detectable  humoral  responses.  It  was  not  possible  to  detect  a  measurable 
antigen  specific  CD4*  response  without  increasing  the  time  between  immunisations 
and  the  measurement  of  proliferation.  This  may  be  due  to  the  limit  of  sensitivity  of 
the  assay  employed  or  an  only  gradual  activation  of  such  cells  because  of  long-term, 
low  level  antigen  expression. 
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Figure  5-5:  Measurement  of  CD4'  T  cell  proliferation  in  vitro  using  cells  from 
mice  immunised  i.  m.  with  pcDNA3.1/core 
C57/Bl6  mice  were  immunised  with  100µg  of  DNA  i.  m.  on  days  1  and  8  of  the 
experiment,  or  1µg  HBcAg  alone  on  day  8,  and  sacrificed  on  day  56.  Spleen  (Figure 
5-5A)  and  popliteal  and  inguinal  lymph  node  cells  (Figure  5-5B)  were  recovered 
from  mice  immunised  with  pcDNA3.1  /core  (0)  or  naive  mice  (0).  Control  mice 
received  only  the  1µg  dose  of  HBcAg  im.  (").  The  proliferation  of  cells  from 
pooled  mice  was  measured  by  ß-emission  from  cells  after  DNA  incorporation  of 
['H]  thymidine  over  16  hours  following  3  day  restimulation  with  a  range  of  peptide 
concentrations.  Assay  described  in  full  in  materials  and  methods  sections  2.5.2  - 
Z5.4.  Mean  CPM  from  triplicate  culture  wells are  shown  ±  ISD. 
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Figure  5-6:  Specific  killing  by  spleen  cells  of  DNA  immunised  mice 
Percentage  specific  killing  of  p815/c  target  cells  by  spleen  cells  of  C57/B16  mice 
immunised  im.  with  100µg  pcDNA3.1/core.  Groups  of  5  mice  were  immunised 
with  100µg  pcDNA3.1/core  (")  or  pcDNA3.1  (0)  or  were  left  unimmunised  (1k) 
and  were  sacrificed  10  days  after  the  final  vaccination.  The  spleen  cells  were 
restimulated  ex  vivo  for  5  days  with  p815c  target  cells  (5  target  cells  per  100 
splenocytes)  at  37°C,  5%  CO2.  The  cells  were  then  added  to  fresh,  "Cr  labelled 
target  cells  at  different  ratios  for  a4  hour  killing  assay,  as  described  in  full  in  section 
2.5.5. 
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Figure  5-7:  CD8*  T  cell  activation  in  DNA  vaccinated  mice  measured  by 
IFN-y  ELISPOT 
C57/B16  mice  were  immunised  on  day  1  and  8  with  100µg  of  pcDNA3.1/core  ("), 
pcDNA3.1  (o)  or  remained  naive  (Cfj,  and  sacrificed  on  day  15.  Cells  were 
incubated  in  a5  day  restimulation  assay  and  IFN-y  secreting  cells  quantified  by 
ELISPOT  at  different  effector  :  APC  ratios.  Cells  were  incubated  with  50µg/ml 
HBcAg  p93-100  peptide  during  the  assay.  Error  bars  represent  the  standard 
deviation  of  three  SFC  counts  for  each  well. 
174 5.6  Enhancement  of  Immunity  Through  Prime-Boost 
Vaccination  Strategies 
For  a  DNA  vaccine  candidate  to  be  of  maximal  potential  use,  strong  cellular 
and  humoral  responses  should  be  activated  following  immunisation.  Therefore  in 
an  attempt  to  augment  the  CD4+  and  antibody  responses  to  HBcAg  (and  to  provide 
both  types  of  response  simultaneously)  the  potential  for  combining 
pcDNA3.1  /core  vaccination  with  different  boosts  was  investigated.  The  remainder 
of  this  chapter  describes  the  investigations  into  whether  immunity  to  the  HBcAg 
generated  by  the  im.  DNA  vaccine  could  be  enhanced  by  boosting  with  a  small 
quantity  of  purified  HBcAg  protein,  also  administered  by  the  i.  m.  route.  Figure  5-8 
shows  the  revised  vaccination  schedule  and  the  timing  of  this  boost  immunisation. 
5.7  Humoral  Responses  Following  i.  m.  DNA  Prime  and 
Purified  i.  m.  HBcAg  Boost 
For  these  experiments,  animals  were  primed  with  pcDNA3.1  /core,  as 
described  previously,  on  days  1  and  8,  and  then  boosted  with  Ipg  HBcAg  on  day  40 
of  the  experiment  (Figure  5-8).  As  before,  to  determine  the  response  to  the  DNA 
vector  backbone,  control  mice  were  immunised  with  the  vector  alone  and  then 
boosted  with  purified  HBcAg  as  described  above.  To  allow  comparison  with  mice 
given  the  purified  protein  alone,  some  mice  were  injected  with  the  purified  protein 
rather  than  DNA  (HBcAg  x3),  at  the  same  timepoints.  Finally,  to  determine  the 
impact  of  the  boost  alone,  previously  naive  mice  were  given  a  single  lµg  dose  of 
HBcAg  (xl)  on  day  40.  To  confirm  no  differences  were  observed  using  mice  of 
175 different  haplotype,  these  experiments  were  performed  in  both  BALB/c  and 
C57/B16  mice. 
The  effect  of  the  boost  is  shown  in  Figure  5-9  (C57/B16  mice)  and  Figure  5- 
10  (BALB/c  mice).  In  both  strains,  those  animals  primed  with  pcDNA3.1/core 
show  a  greater  than  ten-fold  increase  in  mean  titres.  The  increase  in  the  BALB/c 
mice  pcDNA3.1/core  group  following  the  boost  is  significant  (Student's  t-test, 
p=0.042),  however  that  observed  in  the  equivalent  C57/B16  group  is  not  (p=0.079), 
although  it  is  consistent  between  experiments. 
It  is  clear  that  there  is  a  much  greater  increase  in  HBcAg-specific  antibody 
titres  in  these  groups  than  is  observed  in  either  the  mice  primed  with  the  vector 
alone  or  those  animals  receiving  the  boost  immunisation  alone.  In  contrast,  there 
was  little  change  in  the  antibody  titres  observed  in  mice  previously  immunised  with 
2  doses  of  HBcAg.  This  is  possibly  because  the  maximal  antibody  response  had 
already  been  achieved  in  these  animals.  Interestingly,  the  mean  titre  of  the  group 
immunised  with  pcDNA3.1/core  HBcAg  and  boosted  with  protein  was 
approximately  equivalent  to  that  observed  at  the  final  time-point  of  those  given  the 
purified  antigen  alone,  despite  low  titres  measured  prior  to  the  boost. 
5.7.1  Subtype  Responses 
To  determine  the  impact  of  the  boost  on  the  nature  of  the  CD4+  Th 
response  in  these  animals,  the  presence  of  different  IgG  isotypes  within  the  HBcAg- 
specific  serum  antibody  response  were  examined.  The  titres  are  shown  in  Figure  5- 
11.  On  boosting,  titres  of  IgG2a  increased  in  all  mice  primed  with 
pcDNA3.1  /core,  although  there  was  still  a  broad  range  of  titres  in  identically 
immunised  animals.  As  before,  in  C57/B16  mice,  there  was  no  measurable  IgG1 
176 production.  In  the  BALB/c  mice,  one  out  of  5  animals  showed  a  low  level  of  IgGI 
production,  whilst  the  others  showed  no  response.  This  combination  of  responses 
indicates  the  maintenance  of  the  Thl  dominated  response  seen  following  DNA 
vaccination  alone. 
5.8  Cellular  Responses  Following  i.  m.  DNA  Prime  and 
Purified  i.  m.  HBcAg  Boost  Vaccination 
5.8.1  CD4+  T  Cell  Proliferation 
Splenocytes  taken  from  mice  immunised  with  two  doses  of  pcDNA3.1  /core 
and  boosted  with  HBcAg  protein  were  cultured  in  proliferation  assays,  the  results  of 
which  are  shown  in  Figure  5-12.  In  contrast  to  earlier  experiments  when  no 
detectable  CD4+  responses  could  be  observed  in  animals  immunised  with 
pcDNA3.1/core  alone  (in  a  short-term  vaccination  regime),  animals  primed  with 
pcDNA3.1/core  and  boosted  with  purified  HBcAg  showed  strong  antigen  specific 
proliferation.  These  responses  were  equivalent  in  magnitude  to  those  observed  in 
animals  that  received  three  doses  of  the  protein.  Interestingly,  a  single  dose  of  the 
HBcAg  was  not  sufficient  to  cause  proliferation  in  previously  naive  mice,  but  did 
result  in  low  level  proliferation  in  control  DNA-primed  mice.  This  may  have  been 
due  to  the  non-specific  immuno-potentiating  activity  of  the  CpG  motifs  in  the 
control  DNA. 
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Figure  5-8:  Revised  vaccination  regime  for  pcDNA3.1/core  immunisation 
including  a  subsequent  heterologous  boost  with  i.  m.  recombinant  HBc.  Ag 
178 C57/B16  mice  were  immunised  as  described  in  Figure  5-8.  The  graph  shows  the 
mean  titres  of  HBcAg-specific  antibody  calculated  from  5  individual  animals. 
Sample  bleeds  were  taken  1  day  prior  to  the  boost  immunisation  (D)  or  10  days 
following  the  boost  (M).  Error  bars  represent  the  standard  deviation  from  the  mean 
titre  of  each  group. 
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Figure  5-9:  Impact  of  i.  m.  boost  with  purified  HBcAg  on  HBcAg-specific 
serum  antibody  titres Figure  5-10:  Impact  of  i.  m.  boost  with  purified  HBcAg  on  HBcAg-specific 
serum  antibody  titres 
BALB/c  mice  were  immunised  as  described  in  Figure  5-&  The  graph  shows  the 
mean  titres  of  HBcAg-specific  antibody  calculated  from  5  individual  animals. 
Sample  bleeds  were  taken  1  day  prior  to  the  boost  immunisation  (0)  or  10  days 
following  the  boost  (1).  Error  bars  represent  the  standard  deviation  from  the  mean 
titre  of  each  group.  *  indicates  a  significant  difference  between  titres  in  the 
pcDNA3.1  /core  group  following  the  HBcAg  boost. 
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Figure  5-11:  Measurement  of  antibody  subtypes  in  the  sera  of  mice 
vaccinated  with  pcDNA3.1/core  and  boosted  with  purified  HBcAg 
BALB/c  (Figure  5-11A)  and  C57/B16  (Figure  5-11B)  mice  were  immunised  with 
100µg  pcDNA3.1/core  or  control  DNA  on  days  1  and  8,  and  boosted  with  1µg 
HBcAg  im.  on  day  40  (as  described  in  Figure  5-8).  Immunoglobulin  subtypes  were 
examined  on  day  50.  Calculated  specific  anti-HBcAg  titres  are  shown.  A  represent 
IgGi  titres  for  individual  mice,  0  represent  IgG2a  titres. 
181 Figure  5-12:  Impact  of  i.  m.  boost  with  purified  HBcAg  on  specific 
proliferation  of  CD4;  T  cells  from  mice  primed  with  pcDNA3.1/core 
C57/B16  mice  were  immunised  according  to  the  schedule  described  in  Figure  5-8. 
100µg  pcDNA3.1  /core  (0)  or  control  DNA  (O)was  delivered  im.  on  days  I  and  8, 
and  mice  were  boosted  on  day  40  with  1µg  purified  HBcAg  im.  Control  groups 
were  given  three  doses  of  lpg  purified  HBcAg  at  the  same  timepoints  ()  or  a 
single  dose  on  day  40  A.  One  group  remained  untreated  (A).  All  mice  were 
sacrificed  and  splenocytes  recovered  on  day  50.  Pooled  splenic  populations  were 
stimulated  in  vitro  and  the  level  of  proliferation  measured  by  incorporation  of 
tritiated  thymidine.  The  counts  shown  are  the  mean  values  calculated  from 
triplicate  wells  of  pooled  cells  stimulated  with  different  concentration  of  protein. 
Error  bars  represent  the  standard  deviation  from  the  mean. 
182 5.8.2  CD8+  T  Cell  Responses 
CD8+  T  cell  activation  was  measured  by  ELISPOT  assay,  as  shown  in 
Figure  5-13.  As  with  DNA  vaccination  alone,  the  prime-boost  strategy  was  able  to 
activate  greater  numbers  of  cells  than  when  a  single  dose  of  HBcAg  was  given. 
5.9  Comparison  of  the  Route  of  Administration  of  the 
DNA  Vaccines  on  Immunity:  i.  m.  Vaccination 
Versus  Gene  Gun  Delivery 
Based  on  the  impressive  results  achieved  by  boosting  the  DNA  primed  mice 
with  purified  antigen,  we  looked  to  improve  the  overall  prime  boost  strategy 
employed.  As  i.  m.  vaccination  requires  very  high  amounts  of  DNA  per  dose,  it  is 
unlikely  to  be  ever  considered  as  suitable  for  use  in  humans.  Alternative  methods 
such  as  use  of  gene  gun  have  therefore  been  used  clinically.  However,  previous 
experiments  have  shown  that  the  use  of  gene  gun  can  alter  significantly  the  type  of 
immune  response  primed.  The  impact  of  priming  animals  with  DNA  by  gene  gun 
on  subsequent  responses  following  boosting  with  purified  protein  was  therefore 
considered. 
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Figure  5-13:  Measurement  of  CD8+  T  cell  activation  in  DNA  primed,  purified 
HBcAg  boosted  mice  by  IFN-y  ELISPOT 
Mice  were  immunised  twice  with  100µg  of  pcDNA3.1  /core  (.  )  or  psDNA3.1  alone 
(/)  and  boosted  with  1µg  HBcAg  im.  before  sacrifice  10  days  later.  One  group 
remained  untreated  (Q.  Cells  were  incubated  in  a5  day  restimulation  assay  and 
IFN-y  secreting  cells  quantified  by  ELISPOT  at  different  effector  :  target  cell  ratios. 
Cells  were  incubated  with  200pg/ml  HBcAg  p93-100. 
184 5.9.1  Humoral  Responses 
DNA  vaccination  using  a  gene  gun  is  fully  described  in  the  Introduction 
(section  1.5.4). 
For  these  experiments,  animals  were  again  immunised  using  the  schedule 
shown  in  Figure  5-8.  Animals  given  im.  immunisations  were  given  100µg  of  DNA 
per  dose  whilst  in  parallel,  animals  immunised  using  the  gene  gun  were  given  with 
between  1-2µg  per  dose  (Figure  5-14).  Despite  the  lower  dosage,  the  anti-HBcAg 
antibody  titres  calculated  were  not  significantly  different  to  those  observed  in 
animals  immunised  im.  with  pcDNA3.1  /core  (Figure  5.14B,  C).  Control  DNA  did 
not  elicit  an  antibody  response  by  either  route. 
5.9.2  Impact  of  Purified  Protein  Boost  on  Gene  Gun-Primed 
Mice  Compared  to  i.  m.  -Primed  Mice 
5.9.2.1  Impact  ofBoost  on  Humoral  Responses 
Following  boosting  of  these  primed  animals  with  purified  protein,  titres  of 
antibodies  were  again  enhanced  to  an  approximately  equivalent  level  (Figure  5-15). 
In  contrast,  the  mice  immunised  with  the  control  vector  im.  and  the  naive  animals 
failed  to  respond  to  the  antigen  alone.  Interestingly,  the  mice  given  the  vector  alone 
by  gene  gun  and  then  boosted  showed  a  low  but  measurable  response  to  the 
antigen.  It  is  unclear  why  this  occurred  but  may  reflect  the  sensitivity  of  the 
immune  system  to  CpG  motifs  delivered  using  the  intradermal  route.  Indeed,  this 
may  also  explain  why  slightly  stronger  responses  were  observed  in  the  gene  gun 
group  compared  to  i.  m.  vaccinated  DNA  control  mice,  (although  not  statistically 
significant).  Interestingly,  animals  vaccinated  with  the  gene  gun  responded  more 
185 consistently;  with  less  variation  between  individual  titres  observed  in  this  group. 
For  this  reason  the  increase  in  titres  following  the  boost  are  highly  statistically 
significant  (p<0.001)  and  the  more  varied  titres  in  the  im.  group  following 
vaccination  do  not  constitute  a  significant  increase,  although  the  observation  of  an 
increase  was  consistent  between  experiments. 
The  titres  of  IgG  subtypes  1  and  2a  in  the  serum  of  mice  on  day  50  are 
shown  in  Figure  5-16.  Both  gene  gun  and  im.  immunisation  led  to  the 
development  of  HBcAg-specific  IgG2a  titres.  As  before,  the  i.  m.  DNA 
immunisation  followed  by  purified  HBcAg  boost  resulted  in  an  IgG2a  dominated 
response,  as  was  the  case  with  animals  given  control  DNA  by  either  gene  gun  or 
im.  routes  followed  by  the  im.  protein  boost.  In  contrast,  as  well  as  strong  IgG2a 
titres,  immunisation  with  the  gene  gun  resulted  in  strong  IgG1  titres  in  most  mice. 
This  is  indicative  of  a  more  Th2-like  immune  response  (Abbas  et  aL  1996)  and  is 
consistent  with  other  observations  that  have  indicated  that  immunisation  with  gene 
gun  induces  a  greater  Th2  response. 
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Figure  5-14:  Development  of  antibody  titres  following  DNA  vaccination  by 
gene  gun  or  i.  m.  injection 
Groups  of  C57/Bl6  mice  were  immunised  either  i.  m.  with  100µg  pcDNA3.1  /core 
or  by  gene  gun  (10  mice  by  gene  gun,  5  in  all  others)  with  1µg  of  the  same  plasmid, 
on  days  1  and  8  of  the  experiment.  Anti-HBcAg  specific  antibodies  were  measured 
in  blood  samples  taken  prior  to  the  first  immunisation  (Figure  5-14A),  14  days  after 
the  second  vaccination  (Figure  5-14B)  or  31  days  after  the  second  vaccination 
(Figure  5-14C).  Titres  of  individual  mice  are  represented  as  f,  the  mean  value  of 
each  group  as  horizontal  bars  and  the  threshold  of  sensitivity  of  the  assay  by  the 
horizontal  line. 
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Figure  5-15:  effect  of  boost  on  anti-HBcAg  titres  in  gene  gun  and  i.  m.  DNA 
vaccinated  C57/B16  mice 
Mice  were  immunised  as  described  in  Figure  5-8,  with  either  100µg  DNA  i.  m.  or 
1µg  DNA  delivered  by  gene  gun,  on  days  1  and  8.  In  addition,  they  were 
subsequently  boosted  with  1µg  recombinant  HBcAg  protein  im.  on  day  40  of  the 
experiment,  and  the  final  sample  taken  on  day  50.  Sample  bleeds  were  taken  1  day 
prior  to  the  boost  immunisation  (0)  or  10  days  following  the  boost  ( ).  mean 
titres  of  groups  of  5  mice  (excepting  pcDNA3.1/core  gene  gun  group,  which 
consisted  of  10  mice)  ±1  standard  deviation.  *  indicates  a  highly  significant 
difference  (p>0.9999)  between  titres  in  the  gene  gun  group  following  the  HBcAg 
boost. 
188 5.9.2.2  CD  e  proliferation  in  Gene  Gun  Primed  and  HBcAg  Boosted  Mice 
To  compare  the  effect  of  gene  gun  priming  on  T  cell  responses,  splenic 
CD4+  cells  from  mice  vaccinated  with  pcDNA3.1/core  and  boosted  with  protein. 
Again  in  contrast  to  the  DNA  alone  experiments  described  at  the  start  of  this 
chapter,  measurable  proliferative  responses  were  observed  in  cells  from  animals 
boosted  with  purified  protein  (Figure  5-17).  The  level  of  proliferation  was 
considerably  greater  in  the  group  primed  with  pcDNA3.1  /core  than  that  observed 
in  either  the  naive  or  vector  alone  control  mice.  Interestingly,  although  the  highest 
specific  responses  were  observed  in  inguinal  lymph  nodes  from  animals  primed  with 
pcDNA3.1  /core  (Figure  5-17B),  the  highest  responses  in  the  spleen  were  observed 
in  animals  immunised  with  the  purified  antigen  alone.  This  may  indicate  a 
difference  in  the  rate  of  trafficking  of  DNA-  or  protein-primed  activated  CD4+  T 
cells  to  the  spleen.  As  only  one  time  point  was  considered  in  these  experiments  it  is 
unclear  whether  the  results  reflect  differences  in  timing  or  efficiency  of  trafficking 
to  the  spleens  of  these  animals. 
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Figure  5-16:  Antibody  subtype  titres  following  i.  m.  and  gene  gun  vaccination. 
C57/B16  mice  were  immunised  with  100µg  pcDNA3.1/core  or  control  DNA  on 
days  1  and  8,  and  boosted  with  1  µg  HBcAg  im.  on  day  40  (as  described  in  Figure  5- 
8).  Immunoglobulin  subtypes  were  examined  on  day  50.  Calculated  specific  anti- 
HBcAg  titres  are  shown.  A  represent  IgGI  titres  for  individual  mice,  O  represent 
IgG2a  titres. 
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Figure  5-17:  Gene  gun  DNA  immunisation;  spleen  and  lymph  node  CD4*  T 
cell  proliferation 
C57/B16  mice  were  immunised  on  days  1  and  8  with  1-2ig  pcDNA3.1/core  (A)  or 
control  DNA  (A)  by  gene  gun  vaccination.  One  group  was  given  1  Vg  purified 
HBcAg  in  alum  im.  on  days  1  and  8  as  a  positive  control  (0).  All  three  of  these 
groups  were  given  a  boost  of  lµg  of  purified  HBcAg  on  day  34.  One  group 
remained  untreated  (0).  Mice  were  sacrificed,  splenocytes  and  draining  lymph  node 
cells  recovered  on  day  45.  The  proliferation  of  spleen  (Figure  5-17A)  and  lymph 
node  (Figure  5-17B)  cells  from  pooled  mice  was  measured  by  ß-emission  from  cells 
after  DNA  incorporation  of  ('H]  thymidine  over  16  hours  following  3  day 
restimulation  with  a  range  of  peptide  concentrations.  Assay  described  in  full  in 
materials  and  methods  sections  2.5.2  -  25.4.  Mean  CPM  from  triplicate  cultures  of 
pooled  cells  are  shown  ±  1SD.  Note  the  difference  in  scale  between  spleen  and 
lymph  node  graphs. 
191 5.10  Summary  of  Responses  to  DNA  Prime,  Protein  Boost 
Vaccination 
5.10.1  Humoral  Responses 
The  experiments  described  in  this  chapter  show  that  pcDNA3.1/core  is  able 
to  induce  an  antibody  response  in  both  C57  b1/6  and  BALB/c  mice,  when  delivered 
by  im.  or  gene  gun  vaccination.  This  response  can  be  significantly  enhanced 
following  boosting  with  the  purified  antigen.  This  shows  that  vaccinated  animals 
have  seen  sufficient  antigen  as  a  result  of  the  DNA  vaccine  to  be  specifically  primed 
against  this  antigen.  Responses  to  pcDNA3.1/core  with  an  im.  HBcAg  boost 
appear  equivalent  and  are  unaffected  by  the  route  of  delivery,  despite  50  to  100  fold 
less  plasmid  delivered  when  the  gene  gun  method  is  employed.  These  results  show 
that  both  im.  and  gene  gun  DNA  vaccination  are  effective  at  inducing  HBcAg- 
specific  humoral  responses,  especially  when  coupled  with  a  purified  protein  boost. 
However,  despite  the  similarity  in  magnitude  of  the  antibody  response,  im. 
DNA  vaccination  leads  to  an  IgG2a  dominated  response,  whilst  gene  gun 
immunisation  results  in  a  more  mixed  IgGl/IgG2a  response.  It  has  been  shown 
that  the  structural  nature  of  HBcAg  is  crucial  to  the  nature  of  the  T  helper  response 
developed:  mice  injected  with  purified  HBcAg  developed  IgG2a  but  no  IgG1  anti- 
HBcAg  antibodies.  In  contrast,  mice  immunised  with  HBeAg,  (an  HBV  protein 
with  near  identical  sequence  but  which  does  not  polymerise  into  a  particulate  form) 
exhibited  a  response  dominated  by  IgG1  (Milich  et  aL  1997).  This  suggests  that  Th 
cells  with  the  same  specificity  can  develop  into  different  Th  subsets  depending  on 
the  structural  nature  of  the  antigen. 
192 The  work  in  this  chapter  echoes  these  findings,  with  particulate  antigen 
stimulating  IgG2a  production.  Immunisation  im.  with  the  plasmid  also  stimulates  a 
IgG2a  dominated  response  suggesting  that  sufficient  levels  of  antigen  are  being 
produced  to  form  a  particle.  In  contrast,  gene  gun  vaccination  results  in  a  mixed 
response  including  both  subtypes.  It  is  unclear  from  these  data  whether  the  route 
of  immunisation  or  the  structure  of  the  protein  generated  by  the  transfected  cells  at 
each  location  is  responsible  for  this  difference.  However,  previous  work  conducted 
in  this  laboratory  showing  a  similar  pattern  of  results  when  comparing  im.  and  gene 
gun  delivered  DNA  vaccines  expressing  a  soluble,  non-particulate  antigen  (Tetanus 
toxin  fragment  G)  (Zlei  2002),  suggesting  the  route  of  immunisation  has  a  greater 
role  to  play  in  this  phenomenon. 
5.10.2  Cellular  Responses 
In  summary,  these  results  show  that  im.  DNA  vaccination  with 
pcDNA3.1/core  is  capable  of  eliciting  CD4+  and  CD8+  T  cell  responses.  The 
strong  T  helper  proliferative  response  demonstrates  that  many  helper  cells  had  been 
exposed  to  and  responded  to  the  HBcAg  expressed  by  the  DNA  vaccine.  These 
CD4+  T  helper  cells  are  important  in  co-ordinating  the  immune  response,  increasing 
the  efficacy  of  specific  humoral  and  mechanisms  as  well  as  encouraging  non-specific 
innate  immune  functions. 
The  vaccine  has  also  been  shown  to  induce  C  IL  killing  of  target  cells 
bearing  HBcAg  epitopes.  This  is  of  interest  because  conventional  vaccination 
strategies  fail  to  induce  C  TL  responses  to  HBcAg.  This  is  thought  to  be  due  to  the 
difficulty  of  processing  large,  particulate  antigen  in  the  MHC  class  I  antigen- 
processing  pathway.  Demonstration  of  the  CTL  response  in  mice  immunised  with 
193 pcDNA3.1  /core  confirms  that  the  antigen  is  being  expressed  within  eukaryotic  cells 
where  it  can  readily  gain  access  to  the  class  1  pathway  (see  Introduction  section 
1.4.1.1).  Unfortunately  time  did  not  permit  similar  analysis  of  antigen  specific  CD8* 
cells  following  immunisation  with  the  gene  gun. 
This  chapter  shows  that  the  DNA  construct  pcDNA3.1/core  effectively 
generates  specific  cellular  and  humoral  responses  against  the  HBcAg.  This  is  true  of 
delivery  by  either  the  im.  route  or  using  a  gene  gun,  and  is  especially  promising 
when  the  effect  of  the  combined  prime-boost  strategy  is  considered.  The  success  of 
the  prime/boost  vaccination  strategy,  together  with  the  knowledge  that  weak 
responses  can  be  effectively  increased  by  a  heterologous  boost  encouraged  the 
investigation  of  other  strategies  through  which  HBcAg-specific  responses  could  be 
boosted.  These  alternative  strategies  are  described  in  chapters  6  and  7. 
194 6  RESULTS  -  DNA  PRIME  VACCINATION  AND  MUCOSAL 
BOOSTING  WITH  ATTENUATED  SALMONELLA 
TYPHIMURIUM 
6.1  Chapter  Aims 
The  aim  of  the  work  described  in  this  chapter  was  to  examine  the  specific 
humoral  and  cellular  immune  responses  generated  when  mice  primed  systemically 
with  DNA  encoding  HBcAg  were  boosted  mucosally  by  administration  of  an 
attenuated  strain  of  S.  fpbimurium  expressing  the  same  antigen. 
6.2  Introduction 
Mucosal  vaccine  delivery  has  many  advantages  including  the  fact  that  oral 
immunisation  can  induce  immune  responses  at  mucosal  surfaces  as  well  as 
systemically,  thus  providing  protection  at  the  site  of  initial  entry  into  the  body  for 
many  pathogens.  A  full  description  of  mucosal  vaccination  is  given  in  section  1.5.3. 
S.  typbimurium  is  much  studied  as  a  vehicle  for  delivering  heterologous 
antigens  in  mucosal  vaccination.  It  is  relatively  simple  to  manipulate  genetically, 
resulting  in  the  production  of  a  range  of  deletion  mutants,  many  of  which  have  been 
demonstrated  to  show  an  appropriate  level  of  attenuation  and  immunogenicity  (see 
Introduction  sections  1.532  and  1.5.3.4  and  Bumann  et  al  or  Darji  et  al  for  review 
(Bumann  et  aL  2000;  Darji  et  aL  2000)).  The  strain  used  in  these  experiments,  S. 
typfnmm  um  BRD509,  is  also  described  in  the  Introduction  (section  1.53.3). 
195 6.3  Responses  to  pcDNA3.1/core,  S.  typhrmurium 
BRD509  pGA-1  Vaccination 
Following  the  successful  boosting  of  primed  responses  with  systemically 
administered  recombinant  HBcAg,  we  wished  to  consider  whether  similar  levels  of 
enhancement  could  be  achieved  when  different  boost  vaccination  strategies  were 
employed.  One  such  approach  made  use  of  the  attenuated  Salmonella  strain 
described  above;  S.  typbimurium  BRD509  pGA-1.  In  these  studies  animals  were 
primed  systemically  as  described  previously  and  then  the  effects  of  a  subsequent 
boost  of  Salmonella  expressing  the  HBcAg  were  observed 
6.3.1  Preparation  of  Bacteria  for  Intragastric  Immunisation. 
To  ensure  that  the  primed  animals  were  boosted  with  an  appropriate 
number  of  viable  bacteria,  a  trial  run  of  the  inoculum  preparation  was  undertaken. 
Bacteria  were  grown  for  12-16  hours  in  anaerobic  conditions  at  37°C.  The  bacteria 
were  harvested  by  centrifugation  and  resuspended  in  LB  broth.  As  it  is  impossible 
to  estimate  the  number  of  viable  bacteria  prior  to  the  inoculation  of  the  animals,  a 
curve  was  generated  that  made  use  of  the  correlation  between  optical  density  at 
650nm  (ODd  of  the  culture  and  viability.  This  was  achieved  by  preparing  the 
bacteria  at  various  values  of  OD  and  performing  viable  counts  (see  Material  and 
Methods  section  2.1.6).  The  resultant  graph  is  shown  in  Figure  6-1  and  was  used  in 
the  preparation  of  the  inoculum  for  boosting  the  primed  animals. 
196 Figure  6-1:  Standard  curve  to  establish  the  relationship  between  viable 
numbers  of  Salmonella  and  optical  density  of  cultures 
The  symbol  f  represents  the  relationship  between  OD  and  viability  of  S. 
(  biwunr  im  BRD509  pGA-1,  whilst  the  symbol  O  represents  S.  typhimurium  BRD509 
alone.  Values  were  calculated  from  colony  counts  from  serial  dilution  samples 
cultured  on  agar  as  described  in  section  21.6. 
197 6.3.2  Immunisation  of  Mice 
Mice  were  primed  im.  with  either  10Oµg  of  the  HBcAg  expression  vector 
(pcDNA3.1/core)  or  the  empty  vector  on  days  I  and  8  of  the  experiment  (as 
described  previously).  Sample  bleeds  taken  at  day  21  confirmed  the  previous 
observation  that  those  animals  immunised  with  the  pcDNA3.1/core  plasmid  had 
generated  specific  anti-HBcAg  antibodies.  These  were  absent  in  mice  immunised 
with  the  vector  alone  and  naive  animals  (Figure  6-2).  Following  DNA  priming,  the 
ten  mice  in  each  group  (pcDNA3.1/core,  pcDNA3.1  alone  and  naive  mice)  were 
randomly  divided  into  two  groups  of  5  animals.  The  first  group  were  immunised 
intragastrically  ii.  )  using  a  gavage  needle  with  BRD509  pGA-1,  whilst  the  second 
group  were  immunised  with  BRD509  alone  (for  vaccination  schedule  see  Figure  6- 
3).  The  approximate  number  of  viable  bacteria  administered  in  each  case,  is  given 
in  Table  6-1.  This  shows  that  despite  efforts  to  correlate  OD  with  viability,  animals 
immunised  with  Salmonella  alone  were  exposed  to  approximately  3  times  the  number 
of  bacteria  than  those  given  Salmonella  expressing  the  HBcAg.  The  impact  of  this 
on  the  results  observed  will  be  discussed  later  (see  section  6.4).  In  addition,  in  an 
attempt  to  study  the  impact  of  the  Salmonella  immunisation  alone,  naive  animals 
were  also  inoculated  with  the  Salmonella  strain. 
Mice  were  sacrificed  28  days  after  the  i.  g.  boost  and  spleens  and  draining 
lymph  nodes  recovered.  The  extended  time  period  between  the  boost  and  sacrifice 
(compared  to  the  10  day  period  for  other  experiments  in  this  thesis)  was  intended  to 
allow  the  bacteria  to  be  cleared  by  the  mice  prior  to  assessment  of  immunity  and 
thus  prevent  any  bacterial  infection  of  in  vitro  restimulation  cultures. 
198 BRD509  +  pGA-1  BRD  509  alone 
Calculated  number  of  bacteria  per  dose  2.5x101°  8.1x10'0 
Mean  anti-LPS  titre  1393  3003 
Table  6-1:  The  relationship  between  bacteria  administered  and  mean  anti- 
LPS  titre 
The  number  of  bacteria  administered  per  dose  is  shown,  calculated  from  cultures  of 
serial  dilutions  made  from  the  bacterial  suspension  administered  to  mice.  Also 
shown  is  the  calculated  mean  anti-LPS  specific  titre  in  the  sera  of  animals  28  days 
after  administration  of  bacteria. 
199 Figure  6-2:  Titres  of  HBcAg-specific  antibody  in  the  sera  of  mice  immunised 
with  DNA  alone 
Titres  of  serum  antibodies  from  individual  mice  (")  were  measured  14  days  after 
the  second  of  two  100µg  doses  of  DNA  given  im.  The  mean  calculated  titre  of 
each  group  of  5  mice  is  indicated  as  is  the  threshold  of  sensitivity  of  the  assay 
(1:  100,  represented  by  horizontal  line). 
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Figure  6-3:  Vaccination  regime 
This  figure  shows  the  timing  of  vaccine  delivery  to  the  mice  and  of  sample  bleeding 
to  assess  the  quantity  of  the  anti-HBcAg  generated  by  each  mouse. 
201 6.3.3  Humoral  Responses  to  i.  m.  DNA  Prime  Vaccination 
Followed  by  i.  g.  Boosting  with  Salmonella  Expressing 
HBcAg 
Results  in  Figure  6-4  show  the  titres  of  antibodies  in  the  sera  of  mice 
immunised  im.  with  DNA  and  boosted  with  Salmonella.  These  data  indicate  that 
animals  primed  with  pcDNA3.1/core  and  boosted  with  BRD509  pGA-1  show  a 
mean  antibody  response  more  than  10  fold  higher  than  those  primed  with 
pcDNA3.1/core  and  boosted  with  the  control  Salmonella  However,  due  to  the  high 
variability  of  individual  titres  within  this  group  the  results  are  not  statistically 
significant. 
Surprisingly,  in  contrast  to  the  literature,  no  immune  response  was  detected 
in  animals  given  Salmonella  expressing  the  HBcAg  without  DNA  priming.  However, 
these  responses  were  measured  following  a  single  dose  of  Salmonella  and  may  well 
have  increased  over  time  or  following  administration  of  a  second  dose  of  the 
bacteria  (as  was  used  in  the  described  paper)  (London  tt  aL  1996). 
Of  the  un-primed  mice  and  mice  primed  with  control  DNA,  only  the  group 
primed  with  control  DNA  exhibited  a  specific  anti-HBcAg  antibody  response 
following  immunisation  with  the  HBcAg-expressing  bacteria.  The  mean  titre  in  this 
group  was  approximately  half  that  of  mice  immunised  with  pcDNA3.1/core  and 
boosted  with  control  Salmonella  Since  no  response  was  observed  in  un-primed 
mice,  it  appears  that  once  again,  the  DNA  alone  is  responsible  for  some  non- 
specific  immunostimulatory  effects.  This  is  especially  impressive  given  the  length  of 
time  between  the  second  DNA  vaccination  and  the  Salmonella  inoculation,  and  the 
physical  separation  of  the  sites  of  administration  (i.  e.  peripherally  with  the  im. 
vaccination  versus  the  mucosal  boost). 
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In  contrast  to  the  result  observed  in  the  im.  primed  animals,  boosting  of 
animals  with  Salmonella  in  mice  primed  with  DNA  using  the  gene  gun  failed  to 
enhance  the  antibody  response  generated,  with  no  significant  difference  between  the 
titres  before  and  after  the  boost  (Figure  6-5).  The  lack  of  synergy  between  the  two 
vaccinations  may  be  due  to  the  different  quality  of  the  immune  responses  generated. 
As  noted  previously  (see  Chapter  5),  the  gene  gun  vaccination  elicits  a  more  h2- 
like  immune  response,  whereas  im.  vaccination  gives  an  IgG2a  only,  Thl  response. 
Oral  Salmonella  immunisation  has  been  described  as  stimulating  a  Thl  response 
similar  to  that  achieved  by  priming  with  DNA  im.  (Dunstan  et  at  1998)  In  this 
case,  production  of  pro-Thl  cytokines  by  Thl  cells  activated  during  the  boost  might 
enhance  the  activity  of  antigen  specific  Thl  cells  generated  in  response  to  the 
priming  vaccination.  This  mechanism  may  be  less  successful  in  gene  gun  vaccinated 
animals,  since  Th2  cells  from  the  DNA  prime  would  not  respond  to  cytoldnes 
produced  by  Thl  cells  activated  by  the  Salmonella. 
203 Groups  of  5  C57/B16  mice  were  immunised  im.  with  100µg  of  either 
pcDNA3.1/core  or  control  DNA.  This  was  repeated  on  day  8  of  the  experiment. 
Mice  were  boosted  with  10'0  S.  typbimmium  BRD  509  with  or  without  the  pGA-1 
plasmid  (Salmonella  HBcAg  and  Salmonella  control)  on  day  35.  Mean  titres  at  day  34 
(prior  to  boost;  q  and  day  63  (post  boost,  r  are  shown.  Error  bars  represent  I 
standard  deviation. 
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Figure  6-4:  Titres  of  HBcAg-specific  antibody  in  the  sera  of  C57/B16  mice 
immunised  with  DNA  i.  m.  and  boosted  with  Salmonella 10000 
1000 
100 
pcDNA3.1/core  pcDNA3.1/core  DNA  control  DNA  control  Salmonella  Salmonella  naive 
Salmonella  Salmonella  Salmonella  Salmonella  HBCAg  control 
HBcAg  control  HBCAg  control 
Figure  6-5:  Titres  of  HBcAg-specific  antibody  in  the  sera  of  C57/B16  mice 
inununised  with  DNA  by  gene  gun  and  boosted  with  Salmonella 
Groups  of  5  C57/B16  mice  were  immunised  by  gene  gun  with  1-2µg  of  either 
pcDNA3.1/core  or  control  DNA.  This  was  repeated  on  day  8  of  the  experiment. 
Mice  were  boosted  with  10'0  S.  tyßhimmium  BRD  509  with  or  without  the  pGA-1 
plasmid  on  day  35.  Mean  titres  at  day  34  (prior  to  boost;  Cl}  and  day  63  (post  boost, 
0)  are  shown.  Error  bars  represent  I  standard  deviation  from  the  mean  titre 
calculated  from  5  mice. 
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An  obvious  advantage  of  combining  a  systemic  and  mucosal  vaccination 
strategy  would  be  the  induction  of  mucosal  as  well  as  systemic  immune  responses. 
To  determine  whether  the  prime  boost  strategies  used  above  could  stimulate  the 
production  of  HBcAg  specific  mucosal  IgA,  ELISAs  were  performed  on  faecal 
samples  and  intestinal  washes  taken  from  the  mice  of  both  gene  gun  and  i.  m.  prime 
experiments  on  day  63.  Unfortunately,  none  of  the  samples  showed  the  presence  of 
any  HBcAg  specific  IgA.  This  was  disappointing;  especially  in  the  groups  given 
Salmonella  expressing  the  antigen  alone,  which  according  to  the  literature  should 
have  generated  these  detectable  responses.  The  implication  of  this  poor  response 
will  be  discussed  in  greater  detail  later  in  the  chapter. 
6.3.6  Anti-Salmonella  Responses 
6.3.6.1  Anti-Salmonella  Serum  Antibodies 
Serum  samples  taken  at  the  end  of  the  experiment  were  examined  for  the 
presence  of  anti-S.  typbimurium  LPS  antibodies  by  ELISA  (described  in  section 
2.5.1.3).  The  results  of  this  assay  (shown  in  Figure  6-6)  show  that  the  mice 
immunised  with  either  strain  of  Salmonella  develop  a  low  but  specific  anti-LPS 
response.  In  addition  there  is  a  good  correlation  between  the  calculated  bacterial 
dose  and  the  mean  anti-LPS  titre  with  animals  immunised,  with  3  times  more 
Salmonella  showing  approximately  3  times  higher  titres  of  antibodies  to  LPS  in  the 
sera  (see  Table  6-1).  These  titres  indicate  that  the  BRD509  strain  is  immunogenic 
with  or  without  the  plasmid  pGA-1,  and  that  the  bacteria  persist  for  sufficient  time 
for  a  serum  antibody  response  to  develop. 
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Figure  6-6:  Anti-S.  typhimurium  LPS  titres  in  serum  28  days  after 
administration 
Mice  were  immunised  with  S.  typbimurium  BRD509  pGA-1  (n=13),  S.  typhimurium 
BRD509  alone  (n=12),  or  remained  naive  (n=5).  The  calculated  inoculation  doses 
are  shown  in  'f'able  6-1.  Titres  of  LPS-specific  antibodies  in  the  sera  of  individual 
mice  (")  and  calculated  mean  titres  (horizontal  bars)  are  shown. 
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Figure  6-7  shows  the  and  S.  typhimurium  LPS  titres  of  individual  mice 
measured  from  intestinal  washes  (P  and  faecal  pellets  (FP).  In  the  intestinal  wash 
samples,  the  majority  of  mice  from  both  groups  (those  immunised  with  BRD509 
pGA-1  and  those  with  the  control  bacteria)  display  LPS  specific  IgA  responses. 
These  responses  are  about  three  times  stronger  in  the  control  group  (Salmonella 
alone)  than  the  group  immunised  with  Salmonella  expressing  the  HBcAg.  This  result 
is  in  agreement  with  that  observed  in  the  serum  titres  (Figure  6-6)  and  probably 
reflects  differences  in  the  number  of  bacteria  initially  administered  (see  Table  6-1). 
This  result  indicates  that  the  Salmonella  strains  used  are  capable  of  generating  both  a 
mucosal  and  serum  immune  response  even  if  this  response  is  limited  the  carrier. 
6.3.7  Cellular  Responses  to  HBcAg  in  DNA-Primed  Animals 
Following  Mucosal  Boosting  with  Salmonella. 
To  measure  the  cellular  responses  following  vaccination,  tissues  from  all 
groups  of  mice  were  isolated  and  single  cell  suspensions  prepared.  These  were 
either  used  to  measure  CD4+  responses  using  the  optimised  method  described 
(Materials  and  Methods  section  2.5.5)  or  cultured  with  RBL5  target  cells  for  the 
CD8+  IFN-y  ELISPOT  assay  (Materials  and  Methods  section  2.5.7).  Unfortunately, 
despite  the  presence  of  antibiotics  in  the  tissue  culture  medium  in  both  assays, 
contamination  was  observed  in  the  cultures  of  cells  taken  from  mice  immunised 
with  the  Salmonella  expressing  the  HBcAg  protein.  This  contamination  prevented 
any  measurement  of  the  cellular  responses.  Interestingly,  bacterial  growth  was 
restricted  to  cultures  taken  from  those  mice  immunised  with  BRD509  pGA-1.  In 
order  to  determine  whether  the  contaminants  were  the  Salmonella  used  for 
208 vaccination  persisting  in  the  tissues,  an  HBcAg-sequence  specific  PCR  was 
conducted.  This  confirmed  the  presence  of  the  HBcAg  gene  in  the  contaminating 
bacteria,  suggesting  that  the  contamination  due  to  the  presence  of  the  vaccine  strain, 
which  was  able  to  persist  in  vivo  for  at  least  28  days  following  immunisation. 
Although  many  experiments  using  Salmonella  as  a  delivery  system  have  been 
performed  successfully  at  28  days  following  vaccination,  the  study  which  most 
closely  resembles  this  one  (Londono  et  aL  1996)  studied  cellular  responses  42  days 
after  vaccination.  It  is  likely  that  by  this  time  point  the  bacteria  would  be  cleared 
from  the  organs,  allowing  measurement  of  cellular  responses. 
6.4  Study  of  Tissue  Colonisation  by  BRD509 
The  anti-HBcAg  titres  generated  following  im.  and  gene  gun  vaccination 
were  generally  disappointing,  especially  as  this  approach  has  been  apparently 
successful  previously  (Londono  et  aL  1996).  However,  on  further  consideration  of 
the  literature,  it  became  clear  that  most  of  the  studies  described  used  BALB/c  (H2- 
d)  (Schodel  et  aL  1994);  (Huang  et  aL  2001)  rather  than  C57/B16  mice  (H2-b). 
Although  am  mutants  of  S.  tt  phinrurium  have  been  observed  to  be  attenuated  in  this 
strain  of  mice  (Khan  et  aL  2003),  it  has  also  been  shown  that  inbred  mouse  strains 
display  varying  levels  of  natural  resistance  to  Salmonella  infection  (Hormaeche  1979). 
It  was  therefore  unclear  whether  the  lack  of  response  reflected  differences  in  the 
ability  of  the  two  strains  of  mice  to  dear  the  bacteria. 
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Specific  antibody  titres  from  individual  mice  (")  were  determined  as  the  reciprocal 
of  the  highest  serum  dilution  which  gave  a  value  of  0.4  above  the  background.  The 
mean  calculated  titre  of  groups  of  mice  is  indicated  as  is  the  threshold  of  sensitivity 
of  the  assay  (1:  100  -  represented  by  the  horizontal  line). 
210 In  an  attempt  to  determine  whether  colonisation  of  organs  varied  in 
BALB/c  and  C57/B16  mice,  parallel  experiments  were  performed  in  which  mice  of 
both  haplotypes  were  immunised  with  the  two  Salmonella  strains  used  in  this 
experiment.  Twenty  four  days  after  immunisation,  animals  were  culled  and  Peyer's 
patches,  mesenteric  lymph  nodes,  livers  and  spleens  were  removed.  These  tissues 
were  homogenised  and  viable  bacterial  counts  prepared  on  L-agar  plates  with  and 
without  ampicillin.  Results  of  the  experiment  are  shown  in  Figures  6-8  and  6-9. 
Figure  6-8  shows  the  number  of  viable  bacteria  (CFU/tissue)  recovered 
from  various  tissues  and  grown  on  1-agar  plates  containing  no  antibiotics.  These 
data  dearly  show  that  more  bacteria  (from  animals  immunised  with  bacteria  both 
with  and  without  pGA-1)  could  be  recovered  from  C57/B16  mice  than  from  the 
BALB/c  strain.  This  suggests  that  the  Salmonella  strains  were  being  more  readily 
cleared  from  the  organs  of  the  BALB/c  animals.  This  may  explain  why,  in  contrast 
to  the  literature,  our  cultures  were  contaminated  with  bacteria  28  days  post 
vaccination.  Interestingly,  when  plated  on  agar  in  the  absence  of  antibiotic,  the  total 
number  of  bacteria  from  animals  immunised  with  Salmonella  or  Salmonella  containing 
the  plasmid  did  not  appear  to  vary  significantly  within  each  mouse  strain.  This 
suggests  that  the  presence  of  the  plasmid  does  not  result  in  any  additional  metabolic 
burden  on  the  strain.  However,  if  the  number  of  viable,  ampicillin-resistant  bacteria 
recovered  from  the  same  animals  are  calculated  (Figure  6-9),  it  is  clear  that  the 
presence  of  the  plasmid  has  some  effect,  as  a  high  percentage  of  the  total  bacteria 
have  managed  to  effectively  lose  this  construct.  This  means  the  number  of  bacteria 
capable  of  re-stimulating  the  DNA  primed  response  to  HBcAg  will  be  fairly  low. 
This  lack  of  stability  is  surprising,  given  the  previous  use  of  the  plasmid  in  Salmonella 
inoculation  studies  that  resulted  in  the  development  of  specific  anti-HBcAg  titres 
(Londono  et  aL  1996).  The  explanation  could  be  expression  of  the  antigen  occurs 
211 over  an  initial  period  shortly  after  administration  of  the  bacteria,  and  although  the 
plasmid  was  lost  at  some  stage,  expression  up  to  that  point  was  sufficient  to 
enhance  the  existing  systemic  antibody  response  to  HBcAg. 
Interestingly,  the  majority  of  bacteria  were  recovered  from  the  Peyer's 
patches  and  mesenteric  lymph  nodes  in  both  strains  of  mice.  This  result  probably 
reflects  the  relatively  low  numbers  of  bacteria  that  survive  and  are  able  to  traffic  to 
deeper  tissues,  compared  to  much  larger  numbers  able  to  colonise  the  epithelium 
and  M  cells  of  the  Pet'er's  patches.  The  high  counts  in  the  mesenterics  may  indicate 
the  presence  of  macrophages  recently  infected  via  the  nearby  GALT  but  which  have 
not  yet  migrated  to  other  sites. 
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Figure  6-8:  Number  of  viable  Salmonella  recovered  from  various  tissues  of 
BALB/c  and  C57/B16  mice  24  days  after  i.  g.  vaccination 
BALB/c  and  C57/B16  mice  were  immunised  i.  g.  with  2.3x101°  S.  tjphimurium  BRD 
509  with  or  without  the  pGA-1  plasmid.  Mice  were  sacrificed  and  Peyer's  patches, 
mesenteric  lymph  nodes  (MIN),  spleens  and  livers  were  recovered.  Tissues  were 
homogenised  and  serial  dilutions  made  in  PBS.  Dilutions  were  plated  on  LB  agar 
and  incubated  overnight  at  37°C.  CFU  per  organ  were  calculated  from  colony 
counts.  Figures  6-8A  -D  show  the  number  of  bacteria  recovered  from  C57/B16 
mice  whilst  Figures  6-8E  -H  show  the  number  recovered  from  BALB/c  mice.  A 
and  E  are  counts  from  the  Peyer's  patches,  B  and  F  from  the  mesenteric  lymph 
nodes,  C  and  G  from  the  spleen  and  D  and  H  from  the  liver. 
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Figure  6-9:  Number  of  viable,  ampicillin  resistant  bacteria  recovered  form 
the  tissues  of  BALB/c  and  C57/B16  mice  24  days  after  i.  g.  vaccination 
Samples  from  the  same  mice  as  described  in  Figure  6-8  were  cultured  on  LB  plates 
containing  ampicillin.  This  allows  growth  of  only  S.  typhimurium  BRD509  carrying 
the  pGA-1  plasmid.  A  shows  counts  from  the  Peyer's  patches,  B  from  the 
mesenteric  lymph  nodes,  C  from  the  spleen  and  D  from  the  liver. 
214 6.5  Summary  of  Results 
In  these  experiments,  priming  of  a  humoral  response  was  only  boosted  by 
ig.  vaccination  with  S.  typhimurium  BRD509  pGA-1  when  DNA  was  delivered  im. 
Such  an  enhancement  was  not  observed  when  the  animals  were  primed 
intradermally  using  the  gene  gun  (Figure  6-4). 
Obviously  the  efficacy  of  the  prime-boost  strategies  described  in  this 
chapter  cannot  be  fully  assessed  without  consideration  of  the  T  helper  cell  and  CTL 
activation.  This  could  be  addressed  by  extending  the  period  between  Salmonella 
vaccination  and  harvesting  cells  for  T  cell  assays  to  42  days  (Londono  et  at  1996). 
Alternatively,  different  antibiotics  could  be  used  in  the  in  vitm  cultures  that  would 
more  effectively  prevent  bacterial  growth.  CD4+  T  cell  proliferation  data  would 
give  a  much  dearer  understanding  of  the  role  of  the  mechanisms  driving  the  anti- 
HBcAg  antibody  response,  as  well  as  clarifying  the  presence  and  magnitude  of  a 
CD8+  T  cell  response. 
215 7  RESULTS  -  SYSTEMIC  DNA  AND  INTRANASAL  PROTEIN 
VACCINATION 
7.1  Chapter  aims 
The  aim  of  the  work  described  in  this  chapter  was  to  determine  the  impact 
of  mucosal  boosting  with  purified  protein  on  the  magnitude  and  type  of  immune 
response  generated  in  mice  that  had  been  previously  vaccinated  systemically  with 
pcDNA3.1  /core. 
7.2  Introduction 
Work  described  in  Chapter  5  examined  the  effect  of  systemic  boosting, 
using  purified  protein,  on  the  immune  response  generated  following  systemic 
priming  of  the  animals  with  the  DNA  vaccine  pcDNA3.1/core.  In  this  chapter, 
experiments  were  designed  to  determine  to  what  extent  mucosal  boosting  using 
purified  protein  could  affect  the  nature  and  magnitude  of  the  primed  responses 
generated. 
These  experiments  aimed  to  answer  the  following  questions: 
1.  Is  the  HBcAg  particle  an  effective  mucosal  antigen,  or  does  it  require 
the  presence  of  a  mucosal  adjuvant  to  trigger  the  mucosal  response? 
For  a  description  of  the  mucosal  adjuvants  used  in  this  project,  see 
sections  1.3.1  and  1.5.4.3. 
2.  Does  priming  with  systemic  DNA  vaccination  prior  to  mucosal 
boosting  with  the  particulate  HBcAg  enhance  the  subsequent  immune 
216 response?  If  so,  what  effect  does  the  route  (that  is,  im.  or  id)  of  the 
priming  vaccination  have  on  the  final  immunological  readout? 
7.3  Efficacy  of  HBcAg  as  a  Mucosal  Immunogen 
7.3.1  Humoral  Responses  to  i.  n.  Delivered  Purified  HBcAg 
In  initial  experiments  mice  were  immunised  intranasally  with  purified 
HBcAg  in  the  presence  or  absence  of  the  mucosal  adjuvant  LT.  In  addition,  as  a 
positive  control,  a  third  group  of  animals  were  immunised  im  with  1µg  of  HBcAg, 
without  adjuvant.  Ten  days  later  the  HBcAg  specific  serum  antibody  response  was 
measured  by  ELISA.  The  data  shown  in  Figure  7-1  indicates  that  even  after  this 
relatively  short  period  of  time,  mice  that  received  HBcAg  in.  with  LT  developed  a 
low  but  detectable  anti-HBcAg  response  in  the  sera.  These  responses  were  of  a 
similar  order  of  magnitude  to  those  observed  when  the  same  amount  of  protein  was 
delivered  parenterally  without  adjuvant.  In  contrast,  mice  immunised  with  the  same 
dose  of  HBcAg  in.  in  the  absence  of  an  adjuvant,  only  a  very  low  antigen  specific 
response  was  observed.  Therefore  the  immunogenicity  of  the  protein  is  dependent 
on  the  route  of  delivery.  Nose  and  lung  washes  were  also  examined  for  the 
presence  of  anti-HBcAg  antibody,  but  no  specific  responses  were  observed  in  any 
of  the  samples  tested. 
7.3.2  CD4+  T  Cell Proliferation 
In  addition  to  humoral  responses,  proliferation  of  HBcAg  specific  CD4+  T 
was  also  measured  in  these  mice.  For  these  experiments  cells  were  isolated  from  the 
217 spleens  and  cervical  lymph  nodes  (CLN)  and  restimulated  in  in  with  HBcAg 
specific  peptide  (Materials  and  Methods  section  2.5.2  -  2.5.5). 
The  results  of  these  experiments  are  shown  in  Figure  7-2.  Following  in. 
delivery  of  HBcAg  with  IT,  strong  proliferation  of  antigen  specific  CD4*  T  cells 
can  be  observed  in  both  the  spleens  and  CLN.  Interestingly,  the  proliferation 
appears  greater  in  the  local  draining  lymph  nodes  than  the  spleen,  with  the  average 
count  at  the  highest  concentration  of  restimulating  antigen  more  than  20,000  higher 
than  that  in  the  spleen.  In  contrast,  when  the  antigen  was  delivered  without  LT, 
there  was  no  detectable  response  in  the  lymph  nodes  and  only  a  moderate  response 
in  the  spleen.  This  demonstrated  that  the  presence  of  the  LT  adjuvant  is  very 
effective  at  stimulating  a  long-lasting  antigen  specific  CD4*  response  in  the  local 
tissues. 
The  CD4;  proliferation  in  response  to  HBcAg  delivered  im.  also  appears  to 
be  different  from  the  situation  with  LT  as  in  this  case,  like  the  antigen  alone 
mucosally,  low  responses  are  seen  in  spleens  but  not  in  the  local  draining  lymph 
nodes  (popliteal  and  inguinal),  as  shown  in  Figure  5-5,  for  example.  This 
demonstrates  that  the  localisation  and  magnitude  of  immune  responses  may  be 
dependent  on  both  the  route  of  immunisation  and  the  adjuvant  used  to  enhance  this 
response. 
218 Figure  7-1  Serum  anti-HBcAg  titres  following  in.  or  i.  m.  HBcAg  vaccination 
in  C57/B16  mice 
Groups  of  10  C57/B16  mice  were  immunised  in.  with  1µg  HBcAg  with  or  without 
LT,  or  with  1  µg  of  HBcAg  im.  The  mean  serum  anti-HBcAg  titres  are  shown  prior 
to  immunisation  Q  or  10  days  post  immunisation  (W,  ±  1S.  D.  Results  are 
representative  of  two  experiments. 
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Figure  7-2:  i.  n.  HBcAg  vaccination;  effect  of  LT  adjuvant  on  CD4+ 
proliferation 
Groups  of  5  C57/B16  mice  were  immunised  with  1Etg  of  HBcAg  in  with  (0)  or 
without  LT  (ti).  One  group  remained  untreatedol.  Ten  days  later  mice  were 
sacrificed  and  the  proliferation  of  pools  of  B  cell  depleted  cervical  lymph  node 
(Figure  7-2A)  or  spleen  (Figure  7-2B)  cells  was  measured  by  [i-emission  of  cells 
after  DNA  incorporation  of  [  l1]  thymidine  over  16  hours  following  3  day 
restimulation  with  a  range  of  HBcAg  peptide  [aa  120-1401  concentrations.  Mean 
CPM  of  triplicate  cultures  of  pooled  cells  are  shown  ±  1SD. 
220 7.4  Intramuscular  DNA  Prime,  Intranasal  HBcAg  Boost 
Vaccination 
In  line  with  the  previous  chapters,  we  aimed  to  determine  the  effect  on 
DNA  primed  animals  of  boosting  these  same  animals  mucosally  with  purified 
HBcAg  delivered  in.  An  outline  of  the  timings  for  the  vaccination  protocol  is 
outlined  in  Figure  7-3. 
7.4.1  HBcAg-Specific  Humoral  Responses 
As  observed  previously,  i.  m.  immunisation  with  pcDNA3.1  /core  induced  a 
low  but  measurable  response  to  the  HBcAg  in  the  sera  of  vaccinated  mice  (Figure  7- 
4).  However,  following  in.  boosting,  this  response  was  improved  by  approximately 
five-fold.  This  increase  was  found  to  be  statistically  significant  and  in  contrast  to 
the  previous  data,  appeared  to  be  independent  of  whether  or  not  LT  was  included 
as  a  mucosal  adjuvant  (p>0.95  for  both  groups).  In  light  of  these  data  it  is  not  clear 
whether  the  protein  boost  is  responsible  for  the  measured  increase  in  titres 
observed  or  whether  these  increases  are  the  result  of  continued  expression  from  the 
pcDNA3.1/core  vector.  Although  time  did  not  allow  completion  of  these 
experiments,  it  would  be  relatively  easy  to  determine  whether  this  was  the  case  by 
examination  of  HBcAg  titres  from  animals  primed  with  pcDNA3.1  /core  only. 
In  contrast,  animals  primed  with  the  vector  alone  showed  only  very  modest 
levels  of  anti-HBcAg  in  the  serum  (in  line  with  those  responses  described  in  7.3.1). 
Disappointingly,  no  antigen  specific  antibodies  against  HBcAg  or  LT  could  be 
detected  in  any  of  the  mucosal  washes  tested. 
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Figure  7-3:  Vaccination  regime  for  DNA  prime,  i.  n.  boost  experiments 
The  timing  and  nature  of  vaccinations  and  sampling  in  the  experiments  described  in 
this  chapter. 
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Figure  7-4:  HBcAg-specific  titres  in  the  sera  of  DNA-primed  mice  pre-  and 
post-boost  vaccination 
Groups  of  10  C57/B16  mice  were  immunised  im.  with  100µg  DNA 
(pcDNA3.1/core  and  DNA  control  groups),  on  days  1  and  8  of  the  experiment.  5 
mice  from  each  group  were  boosted  with  lµg  HBcAg  with  LT,  5  with  HBcAg  alone 
on  day  35.  The  mean  serum  anti-HBcAg  titres  are  shown  on  day  34  (CI)  and  day  45 
(r),  ±1  SD. 
223 7.4.2  CD4+  T  Cell  Proliferation 
In  addition  to  humoral  responses,  CD4i  proliferative  responses  were  also 
measured  in  the  local  lymph  nodes  and  spleens  of  the  im.  vaccinated  mice.  Figure 
7-5  shows  the  responses  observed  in  the  CLN  of  DNA-primed  animals  boosted 
with  purified  protein  in  the  presence  or  absence  of  LT  as  an  adjuvant.  The 
responses  in  spleen  cells  are  shown  in  Figure  7-6. 
In  contrast  to  expectations,  in  both  local  lymph  nodes  and  splenic  tissue, 
pre-immunisation  with  the  pcDNA3.1/core  vector  appears  to  reduce  the  capacity 
of  the  mucosal  adjuvant  LT  to  stimulate  CD4;  specific  T  cells  as  responses  in  these 
animals  were  shown  to  be  lower  than  those  observed  in  animals  that  were 
immunised  with  vector  alone.  In  these  animals,  CD4+  cells  from  both  local  lymph 
nodes  and  spleens  showed  a  very  strong  proliferative  response  following 
immunisation  with  LT  and  HBcAg  (similar  to  that  seen  on  immunisation  with 
I-IBcAg  and  LT  without  any  DNA  prime,  Figure  7-2).  In  addition,  there  is  a 
consistency  in  the  data  with  that  observed  previously  in  that  proliferation  was  seen 
in  lymph  nodes  when  an  HBcAg  boost  was  given  with  IT,  whilst  in  the  spleens, 
proliferative  responses  were  generated  whether  HBcAg  was  given  alone  or  with  LT. 
The  magnitude  of  the  humoral  response  generated  does  not  appear  to  be 
significantly  different  between  the  two  groups.  This  would  suggest  one  of  two 
possible  explanations.  Either  the  humoral  response  is  unaffected  by  the  mucosal 
boost  (antibodies  measured  are  generated  by  DNA  alone),  or  the  key  location  for 
interaction  between  primed  T  -cells  for  enhancement  of  the  immune  response  is  the 
spleen. 
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Figure  7-5:  Measurement  of  HBcAg  specific  CD4+  responses  in  the  CLN  of 
DNA-primed  mice  boosted  in.  with  purified  HBcAg 
Groups  of  5  C57/B16  mice  were  immunised  as  described  in  Figure  7-4:  i.  m.  with 
100µg  DNA  (pcDNA3.1/core  and  DNA  control  groups),  on  days  1  and  8  of  the 
experiment.  All  groups  were  boosted  with  1µg  HBcAg,  either  with  or  without  LT, 
on  day  35.  Ten  days  later  mice  were  sacrificed  and  the  proliferation  of  pools  of  B 
cell  depleted  lymph  node  cells  was  measured  by  [3-emission  of  cells  after  DNA 
incorporation  of  ['H]  thymidine  over  16  hours  following  3  day  restimulation  with  a 
range  of  HBcAg  peptide  [aa  120-1401  concentrations.  Mean  CPM  of  triplicate 
cultures  of  pooled  cells  are  shown  ±  1SD.  Figure  7-5A  shows  mice  primed  with 
pcDNA3.1  /core  and  boosted  in.  with  HBcAg  and  LT  (+)  or  HBcAg  alone  (O). 
Figure  7-5B  shows  mice  primed  with  control  DNA  and  boosted  in.  with  HBcAg 
and  LT  U  or  HBcAg  alone  (0). 
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Figure  7-6:  Measurement  of  HBcAg  specific  CD4+  responses  in  the  spleens 
of  DNA-primed  mice  boosted  i.  n.  with  purified  HBcAg 
Mice  were  vaccinated  and  spleen  cell  proliferation  measured  in  the  same  way  as  for 
lymph  nodes  (Figure  7-5).  Figure  7-6A  shows  mice  primed  with  pcDNA3.1/core 
and  boosted  in.  with  HBcAg  and  LT  (")  or  HBcAg  alone  (O).  Figure  7-6B  shows 
mice  primed  with  control  DNA  and  boosted  in.  with  HBcAg  and  LT  (1)  or  HBcAg 
alone  P. 
226 7.5  Gene  Gun  DNA-Prime,  intranasal  HBcAg  Boost 
Vaccination 
7.5.1  HBcAg-specific  Humoral  Responses 
As  described  previously,  in  response  to  the  gene  gun  vaccination  with 
pcDNA3.1/core  a  specific  and  detectable  response  to  HBcAg  was  observed  prior 
to  boosting,  as  shown  in  Figure  7-7.  On  mucosal  boosting  with  the  purified  protein 
and  LT,  the  magnitude  of  this  response  was  significantly  enhanced  over  that 
observed  prior  to  the  boost  (p=0.00722).  There  was  also  an  increase  in  the  group 
boosted  with  HBcAg  alone,  but  this  was  increase  was  not  statistically  significant  due 
to  variation  in  individual  titres  within  the  group.  As  with  the  i.  m.  prime  and 
boosted  experiment,  the  inclusion  of  LT  as  the  adjuvant  did  enhance  the  humoral 
response  over  that  observed  when  the  antigen  was  used  alone.  Once  again,  no  IgA 
specific  responses  to  HBcAg  or  LT  could  be  detected  in  nasal  or  pulmonary  washes. 
7.5.2  CD4+  T  Cell  Proliferation 
The  HBcAg-specific  proliferations  measured  in  response  to  this  prime  boost 
regimen  are  shown  in  Figure  7-8  (CLN)  and  Figure  7-9  (spleen)  respectively.  In  the 
local  lymph  nodes,  gene  gun  administration  of  pcDNA3.1  /core  followed  by  an  in. 
boost  of  HBcAg  alone  resulted  in  proliferation  of  the  same  level  as  that  induced  by 
vaccination  with  control  DNA  boosted  by  HBcAg  with  LT.  When  animals  were 
primed  with  pcDNA3.1  /core  and  boosted  with  HBcAg  with  LT  the  response  was 
higher  still.  This  situation  is  the  reverse  of  the  observed  following  im.  vaccination, 
where  priming  the  animals  with  pcDNA3.1/core  and  boosting  with  LT  +  HBcAg 
appeared  to  reduce  the  proliferative  response.  Once  more,  the  magnitude  of  spIcnic 
227 responses  did  not  appear  to  be  affected  by  the  inclusion  of  LT  as  a  mucosal 
adjuvant 
These  data  are  of  particular  interest  in  that  the  pattern  of  the  response  being 
enhanced  at  the  local  (lymph  node)  rather  than  the  systemic  (spleen)  level  following 
gene  gun  vaccination  corresponds  to  that  observed  following  systemic  boosting  of 
DNA  primed  animals  as  shown  in  Chapter  5. 
7.6  Comparison  of  IgG  Subtype  Titres 
Figure  7-10  shows  a  comparison  of  the  IgGl  and  IgG2a  titres  measured  in 
response  to  the  prime-boost  vaccination  regime  with  and  without  LT.  In  line  with 
the  total  IgG  titres,  the  IgG2a  titres  are  higher  in  the  im.  group  than  the  gene  gun 
group.  As  previously  noted  in  chapter  5,  gene  gun,  but  not  im.  vaccination, 
induced  low  levels  of  IgG1  antibody,  indicating  a  more  Th2  like  response  in  the 
gene  gun  group.  Inclusion  of  LT  as  a  mucosal  adjuvant  in  these  experiments  did 
not  appear  to  influence  the  IgG1:  IgG2a  generated. 
228 Groups  of  10  C57/B16  mice  were  immunised  by  gene  gun  with  100µg  DNA 
(pcDNA3.1/core  and  DNA  control  groups),  on  days  1  and  8  of  the  experiment.  5 
mice  from  each  group  were  boosted  with  lµg  HBcAg  with  LT,  5  with  HBcAg  alone 
on  day  35.  The  mean  serum  anti-HBcAg  titres  are  shown  on  day  34  (q  and  day  45 
(0),  ±  1S.  D. 
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Figure  7-7:  HBcAg-specific  titres  in  the  sera  of  gene  gun  DNA-primed  mice 
pre-  and  post-i.  n.  HBcAg  boost  vaccination Groups  of  5  C57/B16  mice  were  immunised  as  described  in  Figure  7-4:  by  gene  gun 
with  100µg  DNA  (pcDNA3.1/core  and  DNA  control  groups),  on  days  1  and  8  of 
the  experiment.  All  groups  were  boosted  with  1µg  HBcAg,  either  with  or  without 
LT,  on  day  35.  Ten  days  later  mice  were  sacrificed  and  the  proliferation  of  pools  of 
B  cell  depleted  cervical  lymph  node  cells  was  measured  by  n-emission  of  cells  after 
DNA  incorporation  of  ['H]  thymidine  over  16  hours  following  3  day  restimulation 
with  a  range  of  HBcAg  peptide  [aa  120-140]  concentrations.  Mean  CPM  of 
triplicate  cultures  of  pooled  cells  are  shown  ±  1SD.  Figure  7-8A  shows  mice  primed 
with  pcDNA3.1/core  and  boosted  in.  with  HBcAg  and  LT  (/)  or  HBcAg  alone 
(0).  Figure  7-8B  shows  mice  primed  with  control  DNA  and  boosted  i.  n.  with 
HBcAg  and  LT  (")  or  HBcAg  alone  (O). 
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Figure  7-8:  Measurement  of  HBcAg  specific  CD4*  responses  in  the  CLN  of 
gene  gun  DNA-primed  mice  boosted  i.  n.  with  purified  HBcAg Figure  7-9  A  Figure  7-9 
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Figure  7-9:  Measurement  of  HBcAg  specific  CD4+  responses  in  the  spleens 
of  gene  gun  DNA-primed  mice  boosted  i.  n.  with  purified  HBcAg 
Groups  of  5  C57/B16  mice  were  immunised  as  described  in  Figure  7-4:  by  gene  gun 
with  100µg  DNA  (pcDNA3.1  /core  and  DNA  control  groups),  on  days  1  and  8  of 
the  experiment.  All  groups  were  boosted  with  1µg  HBcAg,  either  with  or  without 
LT,  on  day  35.  Ten  days  later  mice  were  sacrificed  and  the  proliferation  of  pools  of 
B  cell  depleted  spleen  cells  was  measured  by  ß-emission  of  cells  after  DNA 
incorporation  of  ['H]  thymidine  over  16  hours  following  3  day  restimulation  with  a 
range  of  HBcAg  peptide  [aa  120-140]  concentrations.  Mean  CPM  of  triplicate 
cultures  of  pooled  cells  are  shown  ±  1SD.  Figure  7-9A  shows  mice  primed  with 
pcDNA3.1/core  and  boosted  in.  with  HBcAg  and  LT  (0)  or  HBcAg  alone  (1). 
Figure  7-9B  shows  mice  primed  with  control  DNA  and  boosted  in.  with  HBcAg 
and  LT  (+)  or  HBcAg  alone  (O). 
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Figure  7-10:  Antibody  subtype  titres  following  i.  m.  and  gene  gun  vaccination. 
C57/B16  mice  were  immunised  with  100µg  pcDNA3.1  /core  or  control  DNA  on 
days  1  and  8,  either  im.  (Figure  7-10A)  or  by  gene  gun  (Figure  7-10B).  Animals 
were  boosted  with  1µg  HBcAg  in.,  with  or  without  LT  on  day  35. 
Immunglobulin  subtypes  were  examined  on  day  45.  Calculated  specific  anti- 
HBcAg  titres  are  shown.  A  represent  IgG1  titres  for  individual  mice,  11  represent 
IgG2a  titres. 
232 7.7  Mucosal  Antibody  Production 
Given  the  strong  CD4+  proliferation  observed  in  these  experiments  in  local 
lymph  nodes,  it  was  hoped  that  a  mucosal  antibody  response  would  develop. 
However,  this  promise  was  not  borne  out  by  ELISAs  using  nasal  and  pulmonary 
washes;  no  HBcAg  specific  IgA  responses  could  be  detected  in  any  samples.  To 
determine  if  a  secretory  antibody  response  had  developed  against  the  adjuvant,  LT- 
specific  ELISAs  of  these  samples  were  also  conducted,  but  again,  no  specific 
responses  could  be  detected. 
This  was  disappointing,  and  upon  reflection,  it  may  be  that  either  a  greater 
length  of  time  is  required  between  the  delivery  of  the  protein  boost  and  the 
examination  of  the  mucosal  tissues,  or  that  multiple  doses  of  LT  and  HBcAg  are 
required  to  maximise  this  response.  In  previous  studies,  antigen  specific  IgA  has 
been  observed  in  nasal  and  lung  washes  following  at  least  three  immunisations  with 
a  similar  toxin  (Douce  et  aL  1997). 
7.8  Summary  of  Results 
7.8.1  Humoral  Responses 
Overall,  the  magnitude  of  the  humoral  responses  generated  when  animals 
are  primed  im.  or  by  gene  gun  and  boosted  mucosally  are  remarkably  similar.  Final 
titres,  after  the  boost,  are  slightly  higher  in  the  gene  gun  experiments  when 
equivalent  groups  are  examined,  but  these  differences  are  small  and  not  statistically 
significant.  Disappointingly,  neither  vaccination  strategy  resulted  in  measurable  IgA 
specific  antibodies  against  either  HBcAg  or  against  LT. 
233 7.8.2  CD4+  T  Cell  Responses 
The  experiments  described  in  this  chapter  demonstrate  that  there  are 
differences  in  the  localisation  of  CD4'  specific  T  -cells  following  priming  with  DNA 
either  by  im.  or  gene  gun  delivery.  As  seen  before  in  Chapter  5,  following  boosting 
of  gene  gun  immunised  animals,  the  majority  of  proliferation  occurs  in  the  lymph 
nodes,  whilst  in  animals  vaccinated  im.,  the  greater  responses  were  found  in  the 
spleen  following  the  boost.  However,  the  use  of  LT  appears  to  introduce  a  second 
location-specific  response.  Since  it  is  a  mucosal  adjuvant,  it  is  unsurprising  that  the 
toxin  enhanced  the  responses  observed  in  the  CLN,  however,  more  interesting  is 
the  fact  that  these  responses  were  enhanced  in  these  lymph  nodes  if  the  animals 
were  primed  using  pcDNA3.1/core  using  the  gene  gun.  In  contrast  use  of  LT  in 
mice  primed  using  the  im.  route  generated  less  proliferation  in  the  local  lymph 
nodes  than  those  immunised  with  the  vector  backbone.  The  implications  for  these 
observations  on  use  of  prime  boost  strategies  are  given  in  the  Discussion. 
234 8  DISCUSSION 
Although  there  has  been  a  large  volume  of  work  conducted  on  the  efficacy 
of  DNA  vaccination,  there  have  been  few  studies  systematically  comparing  the 
delivery  of  one  antigen  by  different  vaccination  strategies.  Likewise,  although 
prime-boost  vaccination  has  been  studied  in  depth,  parallel  studies  comparing 
delivery  of  a  particulate  antigen  by  different  prime-boost  vaccination  strategies  have 
rarely  been  conducted,  in  fact,  only  one  study  (based  on  a  regime  of  DNA-prime, 
protein  boost  (Schirmbeck  and  Reimann  2001)),  could  be  found.  The  results 
presented  in  this  thesis  directly  compare  the  immune  response  to  im.  and  gene  gun 
HBcAg  DNA  vaccination  in  three  prime-boost  vaccination  strategies.  The 
strategies  studied  were:  systemic  DNA  vaccination  boosted  either  systemically  with 
(Lm.  )  recombinant  protein,  or  mucosally  using  purified  protein  or  attenuated 
Salmonella  strain  as  a  delivery  vehicle. 
8.1  Intramuscular  DNA  Vaccination 
In  order  to  examine  the  impact  of  vaccinating  with  the  DNA  vaccine 
pcDNA3.1/core  alone,  the  response  to  im.  delivery  of  the  plasmid  was  studied  in 
isolation.  These  experiments  are  described  in  Chapter  5.  Several  experiments 
consistently  showed  the  ability  of  the  plasmid  to  induce  a  limited  humoral  response. 
The  magnitude  of  this  response  was  found  to  be  independent  of  whether  DNA  was 
delivered  im.  or  by  gene  gun.  The  generally  low  level  of  antibody  produced  by 
DNA  vaccination  when  unaccompanied  by  a  heterologous  boost  is  probably  a 
consequence  of  too  low  a  concentration  of  protein  in  the  extracellular  environment 
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described  in  the  literature  describing  variable  humoral  responses  to  DNA 
vaccination  (Davis  and  McCluskie  1999). 
CD4'  T  cell  proliferation  was  not  observed  over  the  short  time-scale  initially 
examined,  when  DNA  was  given  on  days  1  and  8  and  cells  recovered  on  day  21. 
However,  an  alternate  protocol  in  which  mice  were  immunised  with  two  doses  of 
DNA  on  days  1  and  28,  and  cells  were  examined  on  day  56,  revealed  strong 
proliferation.  This  shows  the  importance  of  selecting  the  most  appropriate  time- 
scale  for  vaccination  and  examination  of  responses. 
In  contrast,  a  strong  CD8'  response  could  be  measured  relatively  quickly 
(10  days)  after  a  single  vaccination.  These  could  be  restimulated  in  vitm  with  an 
HBcAg  specific  peptide  to  secrete  IFN-y  and  were  also  shown  to  be  capable  of 
killing  target  cells  expressing  an  HBcAg  epitope  in  an  antigen-specific  manner. 
These  results  are  in  agreement  with  a  body  of  work  in  the  literature,  regarding 
activation  of  CD8''  T  cells  following  DNA  vaccination,  as  measured  by  IFN-y 
secretion  (Sedegah  et  aL  1998),  (not  previously  shown  for  HBcAg),  and  antigen- 
specific  cytotoxicity  in  the  same  cells  (which  has  been  shown  in  HBcAg  studies: 
(Bohm  et  aL  1996;  Kuhrober  et  aL  1996).  The  relatively  early  time  point  at  which 
these  can  be  measured  suggests  that  expression  of  antigen  in  the  context  of  MHC 
class  I  occurs  more  rapidly  than  in  the  context  of  MHC  class  II. 
Although  vaccination  with  pcDNA3.1  /core  alone  demonstrated  that  this 
vaccine  has  the  potential  to  induce  powerful  cellular  responses,  the  low  humoral 
response  generated  reduces  the  applicability  of  these  type  of  vaccines  over  a  greater 
number  of  diseases  in  which  both  cellular  and  humoral  responses  are  important. 
Therefore  the  challenge  remained  of  strengthening  humoral  responses  and  perhaps 
of  enhancing  the  existing  cellular  responses.  The  experiments  discussed  below  (and 
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heterologous  prime-boost  strategies  that  were  studied  in  order  to  achieve  these 
aims. 
8.2  DNA  Prime,  Recombinant  Protein  Boost  Vaccination 
Animals  that  had  been  primed  with  the  pcDNA3.2/core  construct  were 
boosted  with  small  amounts  of  purified  antigen  alone  (as  outlined  in  the  latter  part 
of  Chapter  5).  These  experiments  consistently  showed  that  the  humoral  responses 
primed  by  pcDNA3.1  /core  could  be  enhanced  by  boosting  the  animals  with 
purified  protein.  These  responses  were  significantly  higher  than  those  titres 
observed  in  animals  which  were  only  given  the  purified  protein  boost  or  were  pre- 
immunised  with  the  vector  backbone  alone.  In  addition,  cellular  responses  did  not 
appear  to  be  affected  following  im.  boosting  with  recombinant  protein.  The  CD4+ 
Th  proliferations  induced  were  equivalent  to  those  seen  following  multiple 
vaccinations  with  the  protein,  in  line  with  observations  in  the  literature  (Böcher  et  aL 
2001). 
Unfortunately,  results  from  later  experiments,  in  which  DNA  alone  was 
administered  and  responses  were  measured  after  a  longer  time  period,  did  not 
determine  whether  the  strong  CD4'  response  measured  following  prime-boost 
vaccination  results  from  the  boost  effect.  It  could  also  be  due  to  continual  exposure 
of  the  antigen  from  the  DNA  vaccine  over  a  long  period  of  time,  as  seen  in  the 
extended  time-scale  DNA  alone  experiment.  It  seems  likely,  though,  that  both  the 
prime  and  booster  vaccinations  contribute  to  the  CD4t  response,  since  the  purified 
HBcAg  protein  has  been  shown  to  elicit  such  responses  following  im.  injection  of 
the  purified  antigen  alone  (Milich  and  McLachlan  1986). 
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similar,  but  two  main  differences  were  observed.  These  were:  firstly,  the  localisation 
of  the  CD4*  cells  that  exhibited  the  strongest  HBcAg-specific  proliferation  and 
secondly,  the  pattern  of  antigen-specific  IgG  subtype  production.  Intramuscular 
vaccination  with  DNA  and  recombinant  protein  induced  strong  CD4+  proliferative 
responses  in  cells  isolated  from  the  spleen,  but  weaker  responses  in  draining  lymph 
nodes  close  to  the  site  of  vaccination,  at  the  time-point  examined.  Interestingly,  this 
observation  is  reversed  with  epidermal  gene  gun  vaccination;  higher  CD4+ 
proliferation  was  observed  in  the  lymph  nodes  than  in  the  spleen.  This  may  be 
linked  to  the  timing  of  the  experiments;  it  has  been  shown  that  T  cell  responses 
initiate  in  draining  lymph  nodes  and  are  not  observed  until  later  in  the  spleen 
(Akbari  tt  aL  1999).  Alternatively  it  may  suggest  that  less  antigen  is  being  generated 
using  this  route  of  immunisation  and  may  reflect  the  lower  dose  of  DNA  used  for 
this  form  of  vaccination. 
It  has  been  suggested  that  activation  of  native  CD4+  cells  depends  solely 
upon  antigen  presentation  by  DCs  (Akbari  et  aL  1999;  Jenkins  et  aL  2001).  In  the 
case  of  gene  gun  vaccination,  the  main  group  of  cells  involved  would  be  LCs,  a 
subset  of  DCs  that  form  an  almost  continuous  layer  in  the  dermis,  and  which  are 
directly  transfected  during  gene  gun  vaccination  (Tighe  et  aL  1998).  These  cells 
become  migratory  due  to  inflammatory  signals  caused  by  tissue  damage  associated 
with  vaccination  and  express  chemokines,  which  direct  migration  to  the  secondary 
lymphoid  tissues.  Within  these  tissues  they  are  able  to  activate  CD4'  T  cells 
following  specific  recognition  of  the  presented  antigen  by  the  TCR  (see 
Introduction  section  1.4.1.2).  The  occurrence  of  a  stronger  CD4;  proliferation  in 
the  lymph  nodes  following  gene  gun  vaccination  could  therefore  also  be  due  to  the 
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nodes  prior  to  the  spleen  Qenkins  et  aL  2001). 
Following  im.  DNA  vaccination,  on  the  other  hand,  myeloid  DCs  (from 
other  sites  within  the  body)  rather  than  DCs  will  be  involved  in  the  processing  and 
presentation  of  antigen  to  CD4+  cells.  These  DCs  will  be  attracted  to  the  site  of 
vaccination  due  to  inflammation  caused  by  tissue  damage.  They  could  process  and 
present  HBcAg  epitopes  as  MHC  class  II-peptide  complexes  by  one  of  two 
mechanisms.  Firstly  by  taking  up  HBcAg,  expressed  by  myocytes,  as  exogenous 
antigen  (which  is  the  same  mechanism  by  which  purified  HBcAg  from  the  boost 
vaccination  is  processed  and  presented).  A  perhaps  less  likely  mechanism,  would  be 
that  the  DCs  internalise  the  pcDNA3.1/core  plasmid  and  express  the  HBcAg 
themselves.  As  well  as  the  MHC  class  I  presentation  that  would  follow  expression, 
it  is  possible  that  some  peptide  would  be  presented  by  MHC  class  II  through  cross- 
priming  mechanisms  (see  Introduction  section  1.4.1.3).  Whichever  mechanism  is 
responsible,  the  DCs  may  then  migrate  directly  to  the  spleen  rather  than  to 
peripheral  draining  lymph  nodes,  which  could  explain  the  higher  CD4'  proliferation 
observed  in  the  spleen  following  im.  DNA  immunisation  (Akbari  et  aL  1999; 
Bajenoff  and  Guerder  2003).  Further  details  of  the  localisation  of  the  T  cell 
response  are  discussed  below  in  section  8.6. 
Another  difference  between  the  responses  following  im.  and  gene  gun 
vaccination  is  nature  of  the  humoral  response.  These  results  indicate  that  both  im. 
DNA  vaccination  with  a  plasmid  encoding  HBcAg  and  vaccination  with  purified 
protein,  generate  a  strong  IgG2a  response,  with  little  or  no  IgGI.  In  contrast,  gene 
gun  vaccination  results  in  response  that  includes  both  subtypes  of  antibody.  This 
mixed  response  is  in  contrast  to  previous  work  conducted  in  this  laboratory  and 
elsewhere  (Zlei  2002;  Zhou  et  aL  2003),  showing  a  more  definitive  shift  to  a  Th2 
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fragment  C)  are  delivered  by  gene  gun.  It  is  therefore  possible  that  the  differences 
observed  reflect  the  impact  of  the  structure  of  the  particle  on  the  response  induced. 
For  example,  it  has  previously  been  shown  that  the  HBcAg  preferentially  induces 
Thl  responses  when  delivered  im.,  as  indicated  by  the  presence  of  IgG2a,  but  no 
IgG1  anti-HBcAg  antibodies.  This  response  is  believed  to  reflect  the  particulate 
nature  of  the  antigen,  as  mice  immunised  with  HBeAg,  (an  HBV  protein  with  near 
identical  sequence  but  which  does  not  polymerise  into  a  particulate  form)  exhibited 
a  response  dominated  by  IgGl  (Milich  et  aL  1997). 
This  result  suggests  that  the  antigen  is  being  expressed  following  im. 
vaccination  that  it  is  being  generated  in  sufficient  quantities  to  generate  particulate 
structures,  (although  there  is  no  direct  evidence  of  this).  In  contrast,  the  mixed 
response  observed  following  gene  gun  vaccination  (which  usually  induces  Th2 
responses  (Zhu  et  aL  2004)  suggest  that  that  some  particle  structure  is  also  being 
generated.  However,  due  to  the  relatively  low  amount  of  DNA  delivered  and 
therefore  protein  expressed,  the  concentration  maybe  insufficient  for  generation  of 
high  numbers  of  complete  particles  leading  to  the  mixed  response  observed. 
Therefore,  gene  gun  delivery  of  pcDNA3.1  /core  may  still  have  potential  for 
immunomodulation  of  existing  Th2  responses  to  Thi,  unlike  delivery  of  other 
antigens  by  gene  gun  (see  Introduction  section  1.5.4.3)  and  section  8.6  on 
therapeutic  vaccination,  below. 
Trans-dermal  protein  vaccination,  like  gene  gun  vaccination,  induces  Th2 
biased  responses,  as  determined  by  cytokine  production  and  antibody  subtype 
analysis  (Strid  et  aL  2004),  whereas  im.  DNA  vaccination  gives  Ill  responses 
(Fcltquate  et  aL  1997).  This  suggests  that  it  is  the  route  of  vaccination  that  results  in 
the  induction  of  112  cells  rather  than  the  nature  of  the  vaccine  (DNA  or  protein). 
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responses  in  these  cases,  given  the  presence  of  large  numbers  of  LCs  in  the  dermis. 
Myeloid  derived  DCs  (MDC)  in  mice  express  TLR-9  and  can  therefore  their  antigen 
presenting  and  T  cell  activating  capabilities  can  be  enhanced  by  CpG  motifs  (Cella  et 
aL  1999;  Krug  et  aL  2001).  Most  MDCs,  such  as  those  derived  from  peripheral 
blood  monocytes,  preferentially  induce  CD4'  differentiation  into  Thi  cells  (Rissoan 
et  aL  1999).  However,  the  LCs  that  reside  in  the  dermis,  although  derived  from  the 
same  lineage,  have  been  shown  to  differ  in  several  aspects  from  other  MDC, 
including  a  lack  in  IL-12  production  (a  pro-Thi  cytokine)  following  stimulation 
(Peiser  ct  aL  2004).  Since  vaccine  antigen  is  more  likely  to  encounter  other  MDCs 
capable  of  producing  IL-12,  this  could  explain  the  resultant  Th2  bias  of  gene  gun 
vaccination  compared  to  im.  vaccination. 
Another  potential  factor  in  the  bias  of  the  CD4+  response  is  the  level  of 
CpG  motifs  present  in  the  two  forms  of  vaccination.  Although  both  methods 
produce  sufficient  antigen  to  stimulate  cellular  and  humoral  responses,  im. 
vaccination  uses  greater  quantities  of  DNA,  and  therefore  contains  more  CpG 
motifs.  Since  these  motifs  preferentially  generate  Thl  immunity  (see  Introduction 
section  1.5.4.3)  this  provides  a  simple  potential  explanation  for  the  results,  backed 
up  by  observations  that  addition  of  CpGs  to  gene  gun  delivered  DNA  overcomes 
the  usual  Th2  bias  of  this  strategy  (Schirmbeck  and  Reimann  2001;  Zhou  et  al 
2003). 
8.3  DNA  Prime,  Oral  Salmonella  Boost  Vaccination 
Several  prime-boost  studies  involving  delivery  of  attenuated  Salmonella 
expressing  vaccine  antigens  have  been  performed  to  date.  In  one  such  experiment 
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injection  to  animals  that  had  been  primed  by  gene  gun  with  DNA  expressing  the 
same  antigen  (Mollenkopf  et  al  2001).  Interestingly,  whilst  the  Salmonella  expressing 
the  antigen  offered  some  protection  against  M.  tuberculosis  challenge,  the  animals 
which  had  been  primed  with  DNA  did  not  experience  enhanced  protection. 
Unfortunately  this  study  failed  to  characterise  specific  immunological  readouts  and 
it  is  therefore  unclear  why  the  DNA  prime  appeared  ineffective.  Other  prime-boost 
vaccine  strategies  involving  Salmonella  have  in  general  used  the  bacteria  as  the  prime 
immunisation  (Devico  et  aL  2002;  Londono-Arcila  et  aL  2002).  In  these  studies, 
Salmonella  prime  was  followed  by  a  heterologous  boost  using  purified  protein.  As 
such  it  is  difficult  to  directly  compare  the  results  with  the  work  in  this  thesis, 
although  these  experiments  show  that  the  prime-boost  strategies  offer  improved 
immune  responses  over  single  vaccinations. 
One  recent  study  found  that  boosting  gene  gun  primed  BALB/c  mice  with 
Salmonella  gave  a  much  more  Thl-like  response  than  mice  given  the  gene  gun  prime 
alone  (Lange  et  aL  2004).  This  provides  some  evidence  that  gene  gun  delivery  might 
not  preclude  the  use  of  a  strategy  as  a  therapeutic  vaccine  designed  to  initiate  a  type 
1  response.  However,  it  was  not  clear  from  this  study  whether  this  response  would 
have  been  further  enhanced  if  the  mice  had  been  initially  primed  using  the  im. 
route  of  immunisation. 
The  work  presented  in  Chapter  6  explores  the  impact  of  priming  the 
immune  system  using  pcDNA3.1  /core,  by  either  im.  injection  or  gene  gun  delivery 
and  boosting  with  subsequent  oral  delivery  of  Salmonella  expressing  the  same 
antigen. 
The  success  of  prime-boost  strategies  is  dependent  on  both  forms  of 
vaccination  being  efficacious  and  synergistic.  In  these  experiments,  BRD509  pGA- 
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DNA.  This  indicates  that  there  is  at  least  some  degree  of  positive  interaction 
between  the  responses  to  two  vaccines.  This  could  take  the  form  of  restimulation 
of  memory  T  cells  from  the  DNA  vaccination  by  Salmonella-expressed  HBcAg 
presented  by  APCs  either  at  the  mucosa  or  elsewhere. 
Interestingly,  although  a  strong  increase  in  antibody  titres  was  observed 
following  the  Salmonella  boost  in  the  im.  experiment,  this  increase  was  not  observed 
when  the  DNA  vaccine-prime  was  delivered  by  gene  gun.  A  possible  explanation 
for  the  observed  difference  involves  the  restimulation  of  memory  CD4*  T  cells  that 
had  been  activated  in  response  to  the  initial  DNA  vaccination.  For  this 
restimulation  to  occur,  HBcAg  must  be  transported  (free,  expressed  by  Salmonella  or 
carried  by  APCs)  from  the  mucosa  to  locations  where  primed  lb  cells  will  be  found 
(e.  g.  the  spleen  or  peripheral  lymph  nodes).  Evidence  discussed  elsewhere  in  this 
thesis  suggests  a  localisation  of  the  Th  response  in  the  spleen  following  im.  DNA 
vaccination.  If  the  Salmonella  response  was  likewise  directed  to  the  spleen,  this  could 
enhance  the  existing  response.  However,  in  the  case  of  a  gene  gun  prime,  the 
responses  to  the  prime  and  boost  would  occur  in  separate  locations  and  might  not 
enhance  antibody  production.  It  is  also  possible  that  by  using  the  different  routes 
of  DNA  priming  that  antagonistic  immune  responses  are  produced.  For  example  it 
is  possible  that  the  M2  cells  activated  by  the  gene  gun  prime  immunisation  (Creusot 
et  aL  2001)  down-regulate  responses  to  HBcAg  expressed  by  Salmonella,  which  is 
known  to  generate  a  more  Thl-like  response  (Medina  and  Guzman  2000). 
Another  interesting  observation  in  the  im.  experiment  was  the  complete 
lack  of  antibody  response  when  previously  naive  mice  were  immunised  with 
BRD509  pGA-1,  compared  to  a  response  in  the  group  of  mice  primed  with  the 
control  plasmid  before  boosting  with  the  same  bacteria.  This  result  may  reflect  the 
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with  pcDNA3.1  may  have  activated  the  immune  system  via  interaction  with  cells 
bearing  TLR-9,  resulting  in  the  upregulation  of  co-stimulatory  molecules  by  APCs 
and  providing  the  secondary  signal  needed  in  addition  to  specific  antigen- 
recognition  for  the  activation  of  naive  lymphocytes  (see  Introduction  section  1.4.1). 
The  plasmid  expressing  HBcAg  also  contains  these  motifs  and  therefore  should 
help  stimulate  a  specific  antibody  response  following  BRD509  pGA-1  vaccination 
in  the  same  way  as  the  control  plasmid.  In  the  parallel  experiments  using  the  gene 
gun,  there  was  no  significant  difference  in  titres  following  the  boost,  whether 
animals  were  primed  with  control  DNA  or  pcDNA3.1  /core  (Figure  6-5).  This  lack 
of  response  could  reflect  the  failure  of  HBcAg-specific  memory  T  cells  and  CpG- 
stimulated  APCs  to  migrate  to  areas  in  which  Salmonella  expressing  HBcAg  are 
present.  This  theory  is  supported  by  the  previous  data  that  showed  that  im.  DNA 
vaccination  induced  strong  proliferative  responses  by  cells  from  the  spleen,  whilst  in 
contrast  following  gene  gun  immunisation  proliferation  was  stronger  in  the  lymph 
nodes  than  the  spleen.  In  addition,  gene  gun  delivery  requires  substantially  lower 
amounts  of  DNA  to  prime  a  response,  therefore  there  is  less  CpG  DNA  available 
for  stimulation  of  Toll  receptors.  The  impact  of  these  motifs  on  the  boost  response 
could  be  further  elucidated  by  the  comparison  of  experiments  in  normal  and  TLR-9 
knock-out  mice.  It  is  unclear  at  this  stage  the  failure  of  gene  gun  control  DNA  to 
enhance  future  responses  could  be  overcome  by  more  appropriate  timing  of  the 
delivery  of  the  prime  and  boost  or  whether  one  of  the  limitations  of  DNA 
vaccination  using  the  gene  gun  is  lack  of  non-specific  immuno-potentiation  due  to 
relatively  small  quantities  of  CpG  motifs. 
The  inability  to  measure  cellular  responses  from  the  vaccination  experiments 
due  to  bacterial  growth  in  ex  tim  cultures  was  frustrating,  given  the  added  insight 
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As  well  as  the  information  on  CD4+  proliferation  that  would  have  helped  to  shed 
light  on  the  development  of  the  humoral  responses,  it  would  have  been  of  interest 
to  know  the  level  of  CD8+  T  cell  activation. 
The  attenuated  strain  used  in  these  experiments,  S.  typhimuiizum  BRD509  has 
been  studied  previously  with  the  same  plasmid  expressing  an  altered  form  of 
HBcAg  (Londono  el  at  1996).  In  these  experiments,  and  in  contrast  to  ours, 
bacteria  were  given  twice,  on  days  1  and  56,  without  any  prior  DNA  immunisation. 
This  group  also  found  that  specific  serum-antibody  titres  were  observed  against 
Salmonella  and  low  responses  were  also  detected  to  the  HBcAg.  It  is  therefore 
surprising  that  serum  anti-HBcAg  antibodies  could  not  be  measured  following 
vaccination  with  S.  tyßhimarium  BRD509  pGA-1  alone.  However,  this  experiment 
varied  in  two  aspects;  the  first  being  the  fact  that  two  doses  of  Salmonella  were  used 
prior  to  measurement  of  any  immunological  parameter,  the  second  being  the  fact 
that  these  experiments  were  originally  carried  out  in  BALB/c  mice,  an  inbred  strain 
which  is  particularly  sensitive  to  Salmonella  infection.  In  contrast,  our  experiments 
were  carried  out  in  C57/BI6  mice  to  allow  direct  comparison  with  other 
experiments  outlined  in  this  thesis.  Experiments  subsequently  carried  out  in  both 
these  mice  strains  indicated  that  although  the  Salmonella  were  maintained  in  higher 
numbers  in  the  C57/B16  mice,  the  anti-LPS  and  anti-HBcAg  titres  were  higher  in 
the  BALB/c  animals.  Therefore  the  development  of  the  immune  response-  is  not 
solely  dependent  on  longevity  of  the  bacteria  in  vivo,  but  may  also  reflect  the  ability 
of  the  mouse  strains  to  effectively  process  the  bacterial  antigens.  In  addition,  these 
experiments  showed  that  few  bacteria  recovered  from  tissues  were  expressing  the 
HBcAg.  A  consequence  of  this  result  is  the  limitation  placed  on  the  potential  of  the 
Salmonella  to  boost  any  response  primed  by  the  DNA  vaccination. 
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vaccination  was  also  disappointing,  although  anti-S.  tyßbimurium  titres  were  detected. 
Again,  an  extended  time-scale  or  repeat  vaccinations  might  be  of  benefit  under 
these  circumstances. 
Maximal  synergy  of  the  prime  and  boost  vaccinations  depends  on  the 
enhancement  of  APCs  and  lymphocytes  specifically  activated  by  the  DNA  vaccine 
being  stimulated  in  the  boost  vaccination.  This  may  include  upregulation  of 
activation  signals  in  previously  naive  cells,  and  the  restimulation  of  memory  T  and  B 
cells.  One  way  of  enhancing  these  effects  would  be  to  physically  bring  these  cells 
into  closer  proximity.  The  simplest  way  this  could  be  achieved  would  be  to  alter  the 
sites  of  immunisation  selected.  Intra-peritoneal  vaccination  with  DNA  might  result 
in  stimulation  of  cells  loser  to  the  intestinal  mucosa,  however,  this  route  has  been 
shown  not  to  generate  antibody  and  C  TL  responses  with  viral  antigens  (Bohm  et  aL 
1998).  Similarly,  Salmonella  can  be  delivered  by  other  routes  of  immunisation,  for 
example  intravenously.  However,  immunisation  using  this  route  completely  ablates 
the  potential  induction  of  a  mucosal  response. 
Despite  the  apparently  better  qualities  of  nirB,  as  a  promoter  in  attenuated 
intracellular  bacteria  described  in  the  literature  (see  Introduction  section  1.5.3.5) 
both  htrA  (Roberts  et  at  1998)  and  pagC  (Dunstan  et  aL  1999)  have  been  shown,  in 
direct  comparisons  with  nirB,  to  give  higher  antibody  titres  in  mvo.  Therefore, 
despite  in  vitro  and  even  some  in  vivo,  evidence,  switching  promoters  to  either  btrA 
or  pagC  may  have  yielded  improved  immune  responses. 
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Previous  studies  have  shown  that  parenteral  protein  immunisation  can 
prime  mucosal  immune  responses,  despite  the  fact  that  the  sites  of  vaccination  are 
in  two  separate  immunological  compartments  (McCluskie  et  at  2002).  The 
experiments  in  Chapter  7  describe  a  similar  approach  in  which  the  prime  consists  of 
a  DNA  vaccine  followed  by  an  intranasal  protein  boost  either  with  or  without  the 
mucosal  adjuvant  LT. 
The  humoral  responses  of  gene  gun  and  im.  DNA  primed  animals  to 
mucosal  boosting  with  purified  antigen  were  found  to  be  remarkably  similar  in  these 
experiments.  Although  final  antibody  titres  were  slightly  higher  in  gene  gun 
experiments,  these  differences  are  small  and  not  statistically  significant.  The 
important  difference  in  the  humoral  response  is  the  antibody  subtype  pattern,  which 
shows  a  more  MI-Eke  pattern  (no  IgGI  production)  in  the  im.  immunised  mice,  as 
previously  observed  in  Chapter  5. 
One  of  the  aims  of  using  a  mucosal  boost  was  the  potential  to  additionally 
induce  the  production  of  antigen-specific  secretory  IgA  that  could  be  measured  in 
nasal  or  pulmonary  washes.  However,  none  of  the  strategies  using  in.  delivery  of 
protein  resulted  in  measurable  titres.  This  was  disappointing,  but  perhaps  not 
surprising  given  the  low  systemic  antibody  response.  Repeated  vaccination  or 
increased  doses  of  HBcAg  might  give  rise  to  production  of  sIgA.  Interestingly 
there  was  no  antibody  response  to  LT  in  mucosal  washes,  despite  its  known  efficacy 
as  a  mucosal  adjuvant  and  the  impact  it  was  observed  to  have  on  CD4'  responses. 
It  is  unclear  why  this  occurred  and  may  reflect  the  fact  that  most  previous  studies 
have  looked  for  these  responses  following  more  than  one  dose  of  the  toxin. 
247 In  terms  of  CD4;  proliferation,  inclusion  of  LT,  led  to  very  strong 
responses  in  the  CLN,  which  were  absent  when  HBcAg  was  given  alone.  In 
contrast,  responses  to  HBcAg  were  observed  in  the  spleen  and  inclusion  of  LT 
enhanced  this  response.  This  suggests  that  HBcAg  delivered  in.  is  not  normally 
processed  by  APCs  and  T  cells  in  the  CLN  without  the  presence  of  the  LT. 
When  mice  were  primed  with  DNA  prior  to  the  in.  administration  of 
HBcAg,  the  pattern  changes.  The  results  shown  in  Chapter  5  and  7  indicate  that,  at 
least  at  the  time-points  examined,  CD4+  proliferation  following  gene  gun 
vaccination  occurs  largely  in  the  lymph  nodes  whilst  following  im.  DNA 
vaccination  it  is  mainly  restricted  to  the  spleen.  A  proliferative  response  occurs  in 
the  CLN  following  gene  gun  vaccination  and  in.  boosting,  which  is interesting  since 
the  lymph  nodes  here  are  not  physically  close  to  the  site  of  initial  vaccination.  This 
suggests  a  migration  of  HBcAg  presenting  APCs  to  distant  (as  well  as  local)  lymph 
nodes  following  gene  gun  vaccination,  or  more  likely,  the  trafficking  of  activated 
HBcAg-specific  CD4+  T  cells  through  different  lymph  nodes.  A  slightly  lower 
response  was  observed  in  the  spleen,  this  may  reflect  the  enhancement  of  an  initial 
low  level  response  to  the  gene  gun  vaccination  by  the  in.  boost. 
This  localisation  had  an  interesting  effect  on  the  responses  of  mice  to  a 
boost  containing  LT.  When  mice  primed  by  gene  gun  vaccination  were  boosted  in. 
with  HBcAg  and  LT,  the  CLN  response  was  increased  and  spleen  responses  were 
unaffected,  as  might  be  expected  from  a  mucosally  active  adjuvant.  The  most 
interesting  effect,  however,  was  the  nature  of  the  response  generated  when  an  im. 
DNA  prime  was  used  in  conjunction  with  the  HBcAg  and  LT  boost.  As  noted 
above,  im.  DNA  vaccination  appears  to  induce  strong  splenic  CD4+  T  cell 
proliferation.  The  presence  of  LT  in  the  boost  had  no  effect  on  the  splenic 
proliferation,  but  did  result  in  a  measurable  response  in  the  CLN  (compared  to  no 
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mice  primed  with  control  DNA  were  much  higher.  It  appears  that  priming  the 
mice  with  pcDNA3.1  /core  by  the  im.  route  reduced  the  ability  of  mice  to  respond 
to  a  boost  containing  LT. 
One  possible  explanation  for  this  is  that  HBcAg-specific  T  cells  migrate  to 
(or  are  maintained  in)  the  spleen  following  im.  vaccination.  These  activated  cells, 
would  not  respond  to  chemokine  signals  attracting  naive  T  cells  to  the  site  of  action 
of  LT,  thus  preventing  the  development  of  a  CLN  response  (Sallusto  et  aL  2004). 
Alternatively,  hyper-stimulation  of  previously  activated  T  cells  could  result  in 
apoptosis  of  a  proportion  of  the  HBcAg-specific  population.  Whatever  the 
explanation,  immunisation  by  gene  gun  is  dearly  the  more  appropriate  method  for 
priming  immunity  when  an  intranasal  boost  containing  LT  -  and  possibly  other 
mucosal  adjuvants  -  is  considered. 
It  was  interesting  that  strong,  if  localised  CD4+  T  cell  proliferation  was 
accompanied  by  only  poor  antibody  responses.  These  observations  could  be 
reconciled  by  considering  the  time-scale  over  which  responses  develop  following 
vaccination.  Following  the  first  exposure  to  an  antigen,  an  antibody  response  takes 
approximately  7  days  to  initiate,  and  then  increases  until  it  reaches  its  maximum 
level  at  about  21  days  post  immunisation,  unless  subsequently  boosted.  Therefore 
at  10  days  after  immunisation  the  response  will  be  far  from  its  maximum  level.  On 
the  other  hand,  CD4t  T  cell  proliferation  in  response  to  an  antigen  is  at  its 
maximum  between  9  and  15  days  after  immunisation.  Given  the  strength  of  the 
CD4'  response  and  the  timing  of  the  experiment,  it  is  likely  that  the  antibody 
response  would  continue  to  increase  with  time. 
The  poor  mucosal  immunogenicity  of  the  purified  protein  alone  may  reflect 
several  factors  that  control  the  responses  at  mucosal  surfaces.  Many  antigens  do 
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inducing  a  state  of  tolerance  (Eriksson  and  Holmgren  2002).  However,  particulate 
antigens  have  been  shown  to  be  effective  mucosal  adjuvants,  therefore  repeated  or 
increased  doses  of  HBcAg  may  have  led  to  stronger  humoral  responses.  In  fact,  it 
has  been  shown  that  a  chimeric  HBcAg  particle  expressing  a  heterologous  influenza 
virus  peptide  inserted  into  the  cl  loop  was  able  to  generate  antibody-mediated 
protection  against  challenge  with  a  lethal  dose  of  influenza  virus  following  in. 
immunisation  (Neirynck  et  aL  1999). 
The  vaccination  strategy  of  im.  pcDNA3.1/core  coupled  with  an  in.  boost 
of  purified  HBcAg  and  LT  as  an  adjuvant  was  successful  in  enhancing  the  humoral 
and  cellular  immune  responses  generated  by  the  pcDNA3.1/core  alone.  In 
agreement  with  previous  experiments  in  this  thesis  the  specific  antibody  response 
indicated  that  the  majority  of  CD4'  T  -cell  help  was  from  cells  of  the  Thl 
phenotype. 
8.5  Mechanisms  for  Localisation  and  Biasing  of  Cellular 
Immune  Responses 
The  results  shown  in  Chapters  5  and  7  indicate  that  CD4+  T  cell  responses 
are  at  least  partially  localised  to  either  the  spleen  or  local  lymph  nodes  following, 
respectively,  im.  or  gene  gun  DNA  vaccination.  Whilst  accepting  that  this  may 
reflect  timing  of  the  experiments  undertaken  and  the  influence  of  the  route  of  both 
priming  and  boosting  vaccinations,  these  observations  may  have  practical 
implications  for  the  selection  of  prime  boost  combinations  that  are  able  to 
synergise.  For  example,  it  is  clear  that  gene  gun  and  in.  vaccination  with  HBcAg 
and  LT  as  an  adjuvant  maximise  the  CD4+  response  generated.  Conversely,  the 
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in  the  local  lymph  nodes. 
The  localisation  of  responses  observed  could  be  could  be  due  to  timing.  It 
may  be,  for  example,  that  the  response  progresses  more  rapidly  following  i.  m.  DNA 
vaccination  than  by  gene  gun,  and  at  a  later  point  after  gene  gun  vaccination  the 
lymph  node  T  cells  would  also  have  migrated  to  the  spleen.  This  could  easily  be 
investigated  by  a  series  of  time  course  experiments. 
It  is  also  possible  that  the  different  responses  observed  are  due  to  the 
dominance  of  different  populations  of  T  cells  in  the  mice  at  the  time  at  which 
responses  were  examined.  It  is  known  that  native  T  cells  migrate  through  lymphoid 
tissues  but  memory  T  cells  are  able  to  recirculate  through  non-lymphoid  tissues 
such  as  the  mucosa  and  skin  (Dutton  et  aL  1998;  Mackay  and  von  Andrian  2001). 
There  are  two  distinct  subsets  of  these  memory  T  cells  following  vaccination  or 
infection;  T  central  memory  (Tan)  and  T  effector  memory  cells  (rem).  Tcrn  are 
characterised  by  the  ability  to  proliferate  readily  in  response  to  antigen  recognition, 
whereas  Tern  are  more  rapidly  stimulated  to  effector  function  (Sallusto  et  aL  2004). 
As  well  as  different  functional  capabilities,  these  populations  are  maintained  in 
distinct  areas.  Tem,  which  are  more  short  lived,  are  present  in  the  non-lymphoid 
tissues  to  a  greater  extent,  whereas  the  Tcm,  which  provide  longer  term  memory, 
are  found  largely  in  the  lymphoid  tissues  (Reinhardt  and  Jenkins  2003;  Sallusto  et  aL 
2004).  It  could  be  that  Tan  and  Tern  are  dominant  in  different  tissues  at  the  time 
point  examined,  and  their  relative  ability  to  proliferate  on  restimulation  gave  rise  to 
the  results  observed.  The  nature  of  the  T  cells  involved  could  be  evaluated  in  this 
context  by  FACS  analysis  of  cell  surface  markers  peculiar  to  each  subset. 
The  above  ideas  may  explain  the  situation  in  terms  of  the  recent  literature. 
However,  perhaps  a  more  obvious  theory  is  that  although  activated  T  cells  migrate 
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1999),  the  lymphoid  tissues  to  which  they  home  are  restricted  to  those  where  they 
were  first  activated.  This  would  make  sense  for  protection  against  disease,  since  the 
locus  of  infection  is  likely  to  be  dose  to  where  antigen  is  encountered,  and  in  the 
longer  term,  re-infection  is  also  likely  to  occur  at  the  same  location.  Such  localised 
T  cells  might  be  a  subset  of  the  Tan  or  Tern  population. 
There  is  some  evidence  for  this  in  the  literature;  memory  T  cells  isolated 
from  the  gut  were  found  to  migrate  preferentially  back  to  the  gut  following 
activation  and  trafficked  poorly  through  the  skin  (Mackay  et  aL  1992).  However, 
little  other  work  to  date  has  focussed  on  localisation  other  than  lymphoid/non- 
lymphoid.  The  migration  of  antigen-specific  T  cells  could  be  investigated  through 
the  use  of  peptide-MHC  tetrameters  bound  to  fluorescent  markers.  These  can  bind 
to  peptide-specific  T  cells  via  the  TCR  and  thus  be  used  to  track  cells  (Reinhardt 
and  Jenkins  2003). 
8.6  Prophylactic  and  Therapeutic  Vaccination 
The  heterologous  vaccine  strategies  examined  in  this  thesis  show  some 
promise  for  further  development  as  vaccines  to  prevent  or  treat  infectious  disease. 
Although  this  body  of  work  has  concentrated  on  HBcAg,  this  as  been  used  as  a 
model  antigen,  and  many  interesting  observations  on  the  dynamics  of  DNA  delivery 
and  in  particular  prime-boost  vaccination  regimes  could  offer  protection  against  a 
wide  range  of  infectious  disease  or  life  threatening  illnesses. 
In  humans  and  animal  models,  chronic  HBV  infection  requires  a  powerful 
and  broad  Thl  immune  response,  incorporating  strong  cellular  and  humoral 
responses,  in  order  to  dear  the  virus.  Therapeutic  agents  such  as  ribavirin  and 
252 recombinant  IFN  are  believed  to  function  by  inducing  Thi  responses  (Hultgren  et 
at  1998),  but  they  are  of  limited  efficacy.  Therapeutic  vaccination  provides  another 
potential  method  of  inducing  the  immune  response  required  (Michel  et  aL  2001).  At 
this  stage  it  is  difficult  to  assess  which  of  the  vaccination  strategies  examined  in  this 
thesis  would  be  most  suitable  to  take  forward  into  the  clinic  in  terms  of  potential 
success.  Intramuscular  DNA  vaccination  followed  by  an  intramuscular  protein 
boost  would  probably  be  the  most  appropriate  without  making  alterations  to  the 
vaccination  regime;  this  strategy  gave  CD4+  and  CD8'  T  cell  responses  together 
with  an  antibody  response  indicative  of  Thl  immunity  and  the  magnitude  of 
responses  was  enhanced  following  a  heterologous  boost.  Ian.  DNA  vaccination 
followed  by  a  heterologous  boost,  such  as  im.  protein,  may  therefore  act  as  a 
potentially  effective  therapeutic  vaccine.  However,  the  problems  associated  with 
intramuscular  delivery  of  a  vaccine  candidate  (even  DNA),  as  outlined  in  the 
Introduction  (section  *),  such  as  dangers  of  contamination  of  hypodermic  needles 
and  failure  of  uptake  in  the  population,  would  still  be  present. 
A  possible  solution  to  some  of  these  problems  would  be  the  use  of  the 
novel  gene  gun  technologies  with  intradermal  delivery  of  DNA  on  gold  particles.  It 
has  been  shown  in  the  past  that  gene  gun  vaccination  results  in  strongly  polarised 
T12  responses,  and  as  such  would  not  be  suitable  for  a  vaccine  designed  to  elicit 
Thl  immunity.  However,  results  in  this  thesis  suggest  that  the  Th2  response  is  not 
as  strongly  biased  when  using  a  particulate  antigen  as  in  previous  work  with  non- 
particulate  antigen  (see  Chapter  5,  Discussion  section  8.2).  This,  coupled  with  other 
strategies  for  inducing  Thl  cells  by  gene  gun  vaccination,  such  as  co-delivery  of 
CpG  DNA  (Schirmbeck  and  Reimann  2001;  Zhou  tt  at  2003),  could  therefore  also 
provide  the  basis  for  a  therapeutic  vaccine.  There  may  also  be  potential  in  gene  gun 
DNA  vaccination  followed  by  an  intranasal  boost.  Although  this  strategy  was  not 
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since  the  infection  is  already  established.  Antibody  responses  were  also  low,  but 
using  higher  doses  of  antigen  or  adjuvant  may  give  higher  responses. 
As  the  majority  of  pathogens  invade  over  mucosal  surfaces,  both  im.  and 
gene  gun  delivered  DNA  followed  by  a  parenteral  boost  with  HBcAg  protein  will 
not  be  able  to  generate  the  kind  of  mucosal  immune  responses  required  for 
protection.  The  introduction  of  a  mucosal  boost  within  the  immunisation  regime 
might  produce  such  responses.  This  raises  an  additional  problem;  in  the  mucosal 
boosted  experiments  undertaken  in  this  thesis,  the  mucosal  adjuvant  LT  was  used. 
Although  LT  is  a  potent  mucosal  adjuvant,  it  is  highly  toxic  in  humans  and 
therefore  cannot  be  licensed  as  an  adjuvant.  However,  it  may  be  possible  that 
detoxified  versions  of  the  protein  will  be  effective  and  safe  (Pizza  et  ai  2001).  Other 
strategies  to  incorporate  a  mucosal  delivery  of  a  boost  in  a  prime-boost  regime  may 
offer  a  solution  to  this  dilemma,  such  as  the  use  of  the  live  attenuated  Salmonella 
delivering  antigen  utilised  in  this  study.  The  Salmonella  boost  regime  helped  raise 
strong  systemic  antibody  titres,  which  may  indicate  the  presence  of  an  effective 
CD4'  T  helper  response.  Mucosal  responses  were  poor,  and  modifications  to  the 
vaccination  regime  would  have  to  be  made  before  this  strategy  could  be  used  to 
provide  protection  at  the  mucosal  surfaces.  However,  the  antibody  response  in  this 
case  again  indicated  the  dominance  of  a  Th  1  phenotype  after  boosting,  and  since 
DNA  vaccination  alone  can  induce  C  TL  responses,  this  strategy  might  also  be 
effective  clinically  as  a  therapeutic  vaccine. 
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